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Abstract  
 
 Tumour Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) is a known 
anti-cancer agent which exhibits cancer cell specificity.  Its efficacy in breast cancer is 
limited, however, as illustrated by the resistance demonstrated in a number of cell 
lines.  Cellular FLICE-Like Inhibitory Protein (c-FLIP) has been demonstrated to play a key 
role in TRAIL resistance in these cell line models, through its competitive interference 
with caspase-8 recruitment to the death inducing signalling complex (DISC).  Our lab has 
demonstrated that breast cancer 'stem cells', the cells proposed to be responsible for 
disease recurrence and metastasis, can be eliminated by combination of c-FLIP 
suppression, by siRNA, and TRAIL treatment.  While it has been proposed that 
suppression of c-FLIP could improve TRAIL efficacy in breast cancer, there are no 
pharmacological c-FLIP specific inhibitors available.  
 The purpose of this study therefore was to design and validate novel 
pharmacological inhibitors of c-FLIP and to determine their tumour efficacy in models of 
breast cancer.  Using in silico modelling, we have modelled the structure of c-FLIP and 
associated proteins, and, using virtual pharmacophore screening, we have identified 19 
potential small molecule c-FLIP inhibitors.  In vitro cell viability assays demonstrated 3 of 
these inhibitors to sensitise TRAIL resistant MCF-7 and BT474 breast cancer cell lines to 
TRAIL (p<0.05) at micromolar concentrations, with several additional compounds 
showing a partial ability to sensitise to TRAIL. Each of the three lead inhibitors were 
shown to be acting via caspase-8 and therefore in a TRAIL specific manner.  Two of the 
lead compounds in combination with TRAIL significantly reduced tumoursphere forming 
potential in an in vitro assay which represents breast cancer stem cell like traits.  The 
ability of our primary compound to target cells with breast CSC-like traits was further 
supported using a colony forming assay, which demonstrated a significant reduction in 
the potential for clonal expansion of breast cancer cells following treatment with the 
novel agent in combination with TRAIL.   
 Acceptor-photobleaching FRET was successfully utilised to show the mechanism 
of action of our lead inhibitors to indeed be based on interfering with the c-FLIP FADD 
interaction.  TALEN-mediated targeting of c-FLIP is being optimised to allow for further 
evaluation of these agents in addition to performing mutagenesis studies in a c-FLIP null 
background to further delineate the role and mechanism of c-FLIP in the sensitization of 
breast cancer stem cells to TRAIL.   
 Here we have identified several small molecule c-FLIP inhibitors which are able 
to specifically sensitise resistant breast cancer cells to TRAIL induced apoptosis via 
interfering with c-FLIP FADD interaction at the DISC, and thus allowing caspase-8 
mediated apoptosis to occur.  These early results show promise for our lead compounds 
as potential therapeutics in breast cancer, via sensitisation to TRAIL. 
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Chapter 1: General Introduction  
1.1 Breast Cancer 
 
1.1.1 Introduction  
 Cancer is one of the leading causes of mortality worldwide, accounting for 
around 8.2 million deaths in 2012 (WHO Statistics Ferlay et al., 2012).  Lung, liver, 
stomach, colorectal and breast cancer are the five cancers which contribute most to this 
statistic, although the occurrence of these cancers differs between males and females 
(WHO Statistics: Bray et al., 2013).  Breast cancer, despite almost exclusively affecting 
women, is the most common cancer in the UK and the second most common cancer 
worldwide (Hutchinson, 2010).  The disease, in fact the most prevalent cancer in 
women, is diagnosed in around 50,000 people each year in the UK alone (NCIN, 2011) 
and resulted in over 500,000 deaths worldwide in 2012; 130,000 of these being 
European cases (CRUK Statistics, Accessed October 2014).  Despite these statistics, 
improved options for therapy over the past 40 years has resulted in an increases of 
around 15, 35 and 40% in net survival over 1, 5 and 10 years respectively (Figure 1.1) 
(CRUK Statistics, Accessed October 2014).  
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Figure 1.1: Net Breast Cancer Survival rates for Women in Wales and England from 
1971-2011. 
1, 5 and 10 year survival rates of breast cancer patients in Wales and England over several 
diagnosis periods spanning 40 years (Figure adapted from CRUK Stats, 2014, Accessed 30 
November 2014). 
 
 
 Although statistics for breast cancer survival are improving, with a 10 year 
survival of approximately 80% (Rachet et al., 2009), drug resistance and disease relapse 
remain problematic for breast cancer treatment.  Further research into breast cancer 
including focussing on new therapeutics to target cancer cells specifically and to prevent 
the spread and relapse of the disease, is imperative in order to continue to improve on 
these statistics. 
 
1.1.2 Risk Factors and Causes of Breast Cancer 
 The exact initial cause of the cancer is often difficult to identify and one may be 
able to elucidate several plausible features of a patient’s lifestyle or genetics which have 
had large contributions in the development of breast cancer. 
 One of the greatest risk factors in breast cancer is increasing age and indeed 
around 80% of those diagnosed are women over the age of 50 (McPherson et al., 2000).  
The strong trend seen with increasing age and risk of breast cancer is likely to be due a 
link with hormonal status as the levels of sex hormones, including oestrogen, 
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progesterone and testosterone alters with age, with the biggest changes occurring post-
menopause.  The observed increase around age 50 may also be partly due to the fact 
that this is the age around which women are invited to attend breast cancer screening 
clinics, and thus more cases may be detected (McPherson et al., 2000). 
 As with the vast majority of cancers there are many lifestyle and environmental 
factors which can increase the risk of developing breast cancer although the correlation 
is not as strong as, for example, perhaps the most well-known example of lung cancer 
and smoking.  Excessive alcohol consumption, for example, is thought to slightly 
increase risk through mechanisms such as decreasing the efficiency of DNA repair 
(Vogel, 2000).  A similar, relatively modest link to increase in risk, has been identified 
with smoking tobacco (Terry and Rohan, 2002).  Other environmental factors include a 
person’s weight and height, and thus, their body mass index (BMI): post-menopausal 
women who are overweight have a higher than average risk of breast cancer 
(McPherson et al., 2000). 
 Genetics can play a large part in the risk of developing breast cancer, with 
susceptibility of an individual significantly increased if a first degree relative has had the 
disease.  Furthermore, genetically inherited cancer genes exist which are well-
documented to significantly increase risk of developing breast cancer. Perhaps the most 
well-known genetically inherited breast cancer genes are the breast cancer 1 and 2 
(BRCA) genes.  The BRCA genes, BRCA1 and BRCA2, are important for producing tumour 
suppressor proteins which are involved the repair of in double-stranded DNA breaks, 
thus, mutations in these genes can cause cells to grow abnormally (O'Donovan and 
Livingston, 2010).  The lifetime risk of breast cancer can be as much as 80% in families 
with BRCA1 mutations, although slightly lower at 45% for BRCA2 mutations (Milne and 
Antoniou, 2011).  Additional gene mutations which can be inherited and thus increase 
risk of breast cancer include ATM, TP53, PTEN and CHEK2, amongst several others, 
although these are much less common than the BRCA mutations (Ripperger et al., 
2009).   
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1.1.3 Tumorigenesis: Breast Cancer Development and Progression 
 The development of all cancers essentially results from the aberrant, 
uncontrolled proliferation of cells which have obtained mutations in genes important 
for cell growth and survival.  The acquisition of such mutations gives these cells certain 
properties, or ‘hallmarks’ which deem them to be cancerous.  Initially, six hallmarks of 
cancer were defined which are thought to be exhibited by most of all cancers.  These 
properties included: resistance to programmed cell death (PCD); self-sufficiency in 
growth signals; anti-growth signal evasion, ability to invade tissue and metastasise; 
unlimited replicative potential; and sustained angiogenesis (Hanahan and Weinberg, 
2000).  More recently, however, these cancer-common properties have been expanded 
to include four additional features: dysregulation of cellular energetics; genomic 
instability and mutation; tumour-promoting inflammation; and evasion of immune 
destruction (Hanahan and Weinberg, 2011).   
 Breast cancer, as with other cancers, develops as a result of a multistep process 
involving the acquisition of mutations in genes representing the key hallmarks of 
cancer, enabling the implicated cells to evade the body’s innate anti-cancer 
mechanisms.  In order to fully understand the process of breast cancer tumorigenesis, it 
is useful to have basic knowledge of the normal mammary gland structure. 
 
1.1.3.1 Mammary Gland Structure 
 The mammary gland is a complex secretory organ which is made up of a 
multitude of cell types all coordinating to facilitate the secretion of milk.  Epithelial cells 
grow out from the nipple into an adipocyte formed fat pad, which is infiltrated by 
several cell types including vascular endothelial cells, fibroblasts and various immune 
cells.  The mammary epithelium is comprised of basal and luminal cells.  Cells of the 
basal epithelium, i.e. the outer layer of the gland, consist primarily of myoepithelial cells 
and a smaller quantity of stem cells, present to generate the different cell types.  Ducts 
and secretory alveoli are formed from the luminal epithelium which is comprised of 
cells expressing different hormone receptors.  The myoepithelium and luminal 
epithelium combine to effectively generate a structure able to synthesize, secrete and 
deliver milk during lactation (Macias and Hinck, 2012).   
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1.1.3.2 Tumorigenesis of the Mammary Gland 
 Over 80% of adult cancers originate from the transformation of epithelial cells, 
which have over-proliferated to form an adenoma, to malignant cancerous cells, 
deeming them carcinomas (Dimri et al., 2005).  Almost all breast cancers also develop as 
carcinomas, in the mammary gland, with the initial conversion of a normal human 
mammary epithelial cell (HMEC), which lines the milk-forming ducts of the mammary 
gland, into a cancerous cell (Dimri et al., 2005; Taylor-Papadimitriou et al., 1993).  The 
process of epithelial transformation to malignancy has multiple steps, is governed by a 
multitude of environmental, genetic and dietary factors and will involve a number of 
key mutated genes (Hanahan and Weinberg, 2000).  
 Cells of the mammary gland are usually under tight control, with a finite life span 
which prevents their over-proliferation.  Mammary cell tumorigenesis involves several 
steps that cause the loss of the control of cell senescence leading, essentially, to HMEC 
immortalisation (Dimri et al., 2005).  Initial carcinoma-causing transformations in the 
mammary gland usually occur either in the ducts, specifically in the terminal ductal-
lobular units (TDLUs) or in the lobes, leading to the two histologically distinct subtypes 
of breast cancer; ductal or lobular carcinomas respectively (Bombonati and Sgroi, 2011).    
 The more common of the two histological subtypes, ductal carcinoma, is 
described to progress through several stages of epithelial transformation from normal 
through to flat epithelia, followed by atypical ductal hyperplasia and continuing through 
to ductal carcinoma in situ (DCIS) resulting in the most common form of breast cancer, 
invasive ductal carcinoma (IDC) (Bombonati and Sgroi, 2011).  Essentially, epithelia 
situated on the basement membrane of a mammary gland start to proliferate 
abnormally, due, for example, to a mutation in a tumour suppressor gene such as p53.  
The resulting carcinoma may be altered due to additional epigenetic or genetic changes 
which deem it a carcinoma in situ, i.e. one that is still present on the basement 
membrane (Lopez-Garcia et al., 2010).  The development of slower-growing mammary 
lobular carcinomas is a similar multi-step process of transformation from normal lobular 
epithelium, to transformed atypical hyperplasia which leads to lobular carcinoma in situ, 
the precursor of invasive lobular carcinoma (Bombonati and Sgroi, 2011; Simpson et al., 
2003).   
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1.1.4 Metastatic Spread 
 Metastasis is the spread of cancer from one part of the body to another and can 
occur at some point during tumorigenesis of the original tumour.  Metastasis in 
mammary carcinomas occurs as a result of disruption and fragmentation of the 
underlying basement membrane allowing the carcinoma cells to metastasise or migrate 
and become invasive through the acquisition of additional cellular and genetic changes 
(Siegal et al., 1981). The migration of cells from a primary site, i.e. metastasis, is 
proposed to be driven by the process of epithelial-mesenchymal transition (EMT) a 
process involving a cellular phenotypic switch between epithelial and mesenchymal 
morphology via the loss of epithelial cell contact (Thiery, 2003; Moreno-Bueno et al., 
2008).   Interestingly, it is thought that EMT is reversible through the process of 
mesenchymal-epithelial transition (MET) whereby cells regain their contact-dependence 
through the expression of E-cadherin (Liu et al., 2013).  Metastasis, potentially driven by 
EMT, can therefore result in the formation of a secondary tumour site which is said to 
be driven by the process of MET (Thiery, 2002).  EMT will be discussed in further detail 
in Section 1.1.7. 
 
1.1.5 Breast Cancer Heterogeneity 
 In both pathology and molecular profile, human breast cancers tend to be 
hetereogenous.  Cell type diversity between and within breast cancer tumours is a 
relatively novel area of research, facilitated by technological advances, such as whole-
genome sequencing, which allow for a more thorough analysis of tumour properties 
(Burtucci and Birnbaum, 2008).  It appears that, similar to blood cancers, breast cancers 
can initiate in multiple different cell types and that not one sole pathway is responsible 
for tumour progression (Weigelt et al., 2010; Polyak, 2007), as is the case in colon 
cancer, for example (Stingl and Caldas, 2007).   Breast cancers often have a significant 
amount of intra- and inter- tumoral genetic variations which are only now being fully 
explored (Hutchinson, 2010). 
 Breast cancer is often thought to progress in a non-linear manner through the 
clonal expansion of initial transformed cells, via multiple acquisitions of genetic and 
epigenetic alterations, which add to the overall heterogeneity of the resulting tumour 
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or tumours (Polyak, 2008; Almendro and Fuster, 2011).  Additionally, breast cancer 
heterogeneity may be, in part, due to the presence of cancer ‘stem-like’ cells (CSCs)  
(Section 1.1.7) which are thought to be the reason that many tumours relapse after 
treatment and so are an important yet difficult target in research for more efficient 
therapies (Lawson et al., 2009).  CSCs may have a role in heterogeneity primarily due to 
their ability to produce all cell types (Stingl and Caldas, 2007).  Indeed, some evidence 
does exist to support this theory where CSCs isolated from multiple cancer types, 
including breast cancer, have given rise to cancers which are very similar to and contain 
all the different cell types of the original tumour (Pietras, 2011; Al-Hajj et al., 2003).  In 
contrast, non-stem cancer cells generate either no tumours or tumours which lack many 
of the original cancer's features (Al-Hajj and Clarke, 2004; Al-Hajj et al., 2003). 
 
1.1.6 Subtypes of Breast Cancer  
 Given the prevalence, heterogeneity and potential severity of breast cancer, 
accurate methods of classification which assess various aspects of the cancer are vital in 
order to help diagnose and treat the disease, as well as helping to progress scientific 
research.   
 Although several common genetic mutations can indeed be identified in breast 
cancer cases, there are a vast number of other, less common, potential mutations in 
breast cancer giving rise to a large variation in mutational status between individual 
cases.  Awareness of the many subtypes and heterogeneity of this malicious disease is 
vital in order to tailor patient treatment strategies.   
1.1.6.1 Histopathology 
 The traditional method of classification relies on visual assessment of the 
morphology of tumour cells and their orientation or organisation within a tumour.  An 
initial differentiation of the cancer is utilised which defines a cancer as in situ carcinoma 
or invasive carcinoma.  The former subtype can subsequently be classified as ductal or 
lobular, via assessment of cell growth and morphology.  As mentioned in section 
1.3.1.2, DCIS cases are far more common than lobular carcinoma in situ (LCIS).  DCIS is 
sub-classified by the spatial organisation of cells into five architectural subtypes:  
Comedo, Cribiform, Micropapillary, Papillary and Solid (Malhotra et al., 2010).   
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 Modern diagnoses tend not to rely solely on this method due to the potential 
confounding factors including assessor subjectivity, regions of interest or distinct 
morphologies within a tumour in addition to the fact that it does not take into account 
any genetics or molecular markers of the particular case.  As a consequence, oncologists 
and researchers will take into account other features of the cancer to make a final 
diagnosis. 
 
1.1.6.2 Hormone Receptor Status 
 Immunohistochemical markers, primarily assessing the cancers’ hormone 
receptor status, may also be used as diagnostic and prognostic tools in breast cancer 
(Subramaniam and Isaacs, 2005; Walker, 2008).   
 Immunohistochemistry (IHC) has facilitated the assessment of molecular 
markers, specifically, of hormone receptor expression levels.  The cancer cell's 
oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth 
factor receptor (HER2) status further allows the categorisation of breast cancer (Althius 
et al., 2004).  Cells which overexpress a receptor, and so will proliferate when 
stimulated by the specific hormone ligand are described as receptor-‘positive’.  
‘Negative’ expressers do not respond to the specific hormone since they do not exhibit 
the appropriate receptor.  According to this IHC method of characterisation, cells are 
described as ‘ER-positive’, ‘ER-negative’, ‘PR-positive’, ‘PR-negative’, ‘HER2-positive’ or 
‘HER2-negative’.  Additionally, cancers can be negative for all receptors and are thus 
deemed ‘triple-negative breast cancer’ (TNBC).  ER/PR-positive cancers tend to be the 
most common, representing around 60% of all cases (Buzdar, 2009), whereas HER2 and 
TNBC cases are less common and form approximately 20% of cases each (Anders and 
Carey, 2009).  As a general rule, breast cancers which are positive for hormone 
receptors have a better prognosis due to the presence of hormone- or hormone-
receptor targeting agents as first line treatment options.  TNBC is a more difficult target 
for treatment due to the inefficacy of hormone therapies on cells which lack hormone 
receptor expression.    
 Breast cancer cells often have a mixed receptor expression pattern, e.g. ER-
negative, HER2-positive, or may lack expression of all of these receptors as is the case 
TNBC (Cleator et al., 2007).  In addition to individual cells expressing different 
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combinations of receptor, the heterogeneity of breast cancer means that an individual 
patient’s cancer may be made up of a collection of cells which have varied hormone 
expression status between cells, and thus some cells may respond to treatment, whilst 
others remain unaffected.  Although hormone receptor classification does provide a 
great advantage in selecting the first line therapy, it is often not reflective of this 
heterogeneity and thus treatments may not be as effective as expected. 
 
1.1.6.3 Molecular subtypes 
 The molecular subtypes of breast cancer, determined by gene expression 
profiling and microarray analysis which analyse the levels of mRNA expression of 
specific genes, can be defined as: luminal A; luminal B; basal; ErbB2 (HER2) 
overexpressing and normal-like (Sorlie et al., 2001; Brenton et al., 2005), with each 
subtype exhibiting differing risk factors for incidence, treatment responsiveness, disease 
progression and potential to metastasise (Polyak, 2011).  An additional, sixth molecular 
subtype was defined as claudin-low, which has facilitated further differentiation 
between the molecular subtypes (Prat et al., 2010).  This method of classification in 
combination with histological data on morphology has enabled for correlations in 
certain gene subsets to be identified, further aiding with diagnoses and prognoses 
(Stingl and Caldas, 2007; Malhotra et al., 2010). 
 Genetic screening and gene-expression profiling can be utilised in order to 
establish a prognosis (Sotiriou et al., 2006) and aid in the identification of individuals 
who are expected to be at a higher initial risk of developing breast cancer, for example, 
those with a known family history of the disease.  Mutations in the autosomal dominant 
genes BRCA1, BRCA2, phosphatase and tensin homolog (pTEN) and p53 increase the risk 
of developing certain types of breast cancer by 5-10%.  BRCA1 and 2 mutations are the 
leading cause of hereditary breast cancer (Mincey, 2003).  
 It is not feasible, however, to perform microarray analysis as a routine measure 
as the procedures involved are quite costly.  There are such benefits from having such 
in-depth molecular classification, however, that a 50-gene signature, known as PAM50, 
has been determined.  The PAM50 provides a way of way of classifying tumours using 
varied molecular subtypes by utilising quantitative real time PCR (qRT-PCR) and has 
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been demonstrated to greatly enhance the ability to predict risk of relapse (Parker et 
al., 2009). 
 A combination of the different forms of diagnosis and prognosis methods is the 
best approach in order to fully establish the characteristics of the individual case, 
including gaining the best representation of the heterogeneity of the cancer (Kreike et 
al., 2007). 
 
1.1.6.4 Experimental Models of Breast Cancer  
 Immortalised breast cancer cell lines are commonly used as an in vitro model of 
breast cancer which provide, in effect, ‘unlimited’, self-replicating models of breast 
cancer with no terminal differentiation.  The available cell lines, which include both 
animal and human derived cells, quite accurately represent the many different 
molecular subtypes of breast cancer (Neve et al., 2006).  These cell lines are able to 
replicate some of the heterogeneity of breast cancer due to gene expression variations 
that develop in some cells (Neve et al., 2006).  The cell lines used, as they have been 
initially extracted from patients, represent different breast cancer subtypes with varying 
hormone receptor status’, gene expression levels, mutations, cellular compositions and 
many other features which define particular cancers (Kao et al., 2009) and so provide a 
valuable resource for research into potential treatment targets and strategies. 
 
1.1.7 Breast Cancer Stem-like Cells 
 The mammary gland contains a subset of multipotent mammary stem cells 
which initiate the development of the gland at the early stages of embryogenesis and 
maintain it throughout life (Williams and Daniel, 1983; Blanpain et al., 2011).  It has 
been shown that a single mammary epithelial cell is capable of producing an entire 
mammary gland, demonstrating a multipotent phenotype of these cells and elucidating 
their stem cell-like behaviour (Blanpain et al., 2011). Following on from this knowledge, 
the most recent models of cancer initiation and progression revolve around the 'CSC 
hypothesis', which was in fact first proposed around 150 years ago (Wicha et al., 2006), 
with relatively little mention of it for decades until the mid 1990’s.  The hypothesis 
states that cancers originate from progenitor, stem-like cells which have surpassed the 
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normal self-renewal regulation processes.  The resulting tumours, therefore, are said to 
contain a subsection of cells which retain these stem-like properties, including self-
renewal and differentiation (Wicha et al., 2006) and thus contribute to the maintenance 
and spread of disease.  Additionally, it is thought that these tumour-initiating or CSCs 
are slower growing and more resistant to chemotherapy and thus are often a cause of 
disease relapse. 
 The interest in CSCs is growing within cancer research due to the potential for 
these cells to drive tumour metastasis and contribute largely to drug resistance and 
disease relapse.  Although fairly difficult to prove the existence of CSCs in patients 
directly, via use of cell surface proteins, recent studies have been able to provide both 
in vitro and in vivo evidence in support of the idea of CSCs by utilising techniques which 
measure properties such as self-renewal (Al-Hajj and Clarke, 2004; Al-Hajj et al., 2003, 
Pietras, 2011).   
 
1.1.7.1 Epithelial-Mesenchymal Transition 
 The idea of CSCs goes hand in hand with the concept of EMT (mentioned in 
section 1.1.4), which is also thought to play a key role in organism development (Thiery 
et al., 2009).  EMT is a type of cell plasticity which involves the loss of adherens 
junctions between epithelial cells and the gain of properties exhibited by mesenchymal 
cells, including increased motility and altered gene expression (Kalluri and Neilson, 
2003).  Multiple signalling pathways have been identified that are shared between EMT 
or EMT-like processes in normal and tumour development, helping to facilitate an 
understanding of the process and further implicating its role in tumour development 
(Thiery, 2002).   
1.1.7.2 Breast Cancer Stem Cell Plasticity 
 Plasticity, in breast cancer, describes the conversion of non-stem breast cancer 
cells to breast CSCs and is thought to occur via the processes of EMT and MET 
(Thompson and Haviv, 2011; Liu et al., 2013) (Section 1.1.7.1).  The roles of EMT and 
MET in embryogenesis, wound healing and tumorigenesis in particular give evidence for 
their likely roles in plasticity (Drasin et al., 2011; Luo et al., 2015).  Plasticity may occur 
within a population of tumour cells that facilitates their adaptation when certain 
conditions, for example when undergoing therapy, drive their need to change in order 
Chapter 1: General Introduction 
 
 O A Hayward   13 
 
to survive.  Essentially, only in a situation where a certain stem-like trait should newly 
arise in a subset of cells which did not previously have this trait could plasticity be 
declared as having truly occurred.  A study such as this has been performed in human 
mammary epithelial cells, whereby plasticity was demonstrated to be occurring in both 
untransformed and cancerous cell subsets (Chaffer et al., 2011). 
1.1.7.3 Experimental Models of Breast Cancer Stem Cells 
 Cell lines have been used as a tool for studying cancer stem cells in vitro for 
many years, due to the observations that, like primary tissue, they contain a small 
population of cells with stem cell-like properties, as evaluated using stem-cell like 
markers and further evidenced with in vivo tumour initiation experiments.  Although 
not as representative as primary tissue or in vivo studies, it is often beneficial to utilise 
cell lines for studying CSCs, in particular, for relatively high-throughput drug screening 
studies due to their availability, ease of handling and relatively low cost.  Utilising cell 
lines to study cancer stem cells in vitro will reduce the requirement on in vivo 
experiments for studying a very interesting and important aspect of cancer, with 
particular emphasis on the potential for studying CSC targeted therapeutics.  The 
primary disadvantage of using cell lines in vitro in general, and for studying CSCs, is the 
loss of the inter-relationships between cells and between cells, the heterogeneity of a 
tumour, and the existence of a tumour microenvironment that would exist in vivo 
(Holliday and Speirs, 2011).  Ideally, cell lines would be utilised to perform initial screens 
to evaluate drug effects on CSCs, which would be followed up with work on primary 
cells and tumour initiation in vivo, when a potential drug candidate or candidates have 
been identified. 
The in vivo mouse xenograft tumour initiation assay is considered the ‘gold 
standard’ experimental model of CSCs.  Essentially, human cancer cells are serial 
transplanted at different doses into immunocompromised mice and assessed at several 
time points for tumour formation.  Once formed, cells from the tumour are extracted 
and grafted into a second animal to evaluate their self-renewal ability (Han et al., 2013).   
Although possibly the closest representation to a human tissue in situ, these studies are 
often difficult to reproduce, require specific strains of mouse and sites of implantation 
and therefore are often not the most cost effective and accurate way to evaluate 
therapeutic strategies for targeting CSCs. 
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 Some key in vitro models which aim to isolate breast CSCs do also exist, 
however, and although many were initially developed using primary tissue, they have 
been also shown effective at isolating CSCs when utilising immortalised breast cancer 
cell lines as a basis (Iglesias et al., 2013).  These in vitro models require much less time 
and resources than animal models and facilitate a more high-throughput screening 
process for compound testing.  Ideally, in order to draw complete conclusions on cell-
stemness, in vitro assays would ideally need to be backed-up by an in vivo experiment.    
The optimal in vitro assay would provide quantitative, specific data and be able to 
measure low frequency stem cells, whilst also being relatively high-throughput.   
 Perhaps the most well-known and utilised in vitro model is the tumoursphere 
assay, developed by Dontu et al. (Dontu et al., 2003).  This protocol was developed by 
making appropriate modifications to the neurosphere assay which was designed and 
developed by Reynolds and Weiss to culture cells that exhibit stem cell properties from 
the adult brain (Reynolds and Weiss, 1992).  The tumoursphere assay involves the 
formation of non-adherent 'tumourspheres' which are enriched in cells which exhibit 
the functional characteristics of stem cells, specifically, their ability to survive in 
suspension culture compared to non-stem cells. When established cell lines are plated 
in single cell suspension in non-adherent conditions, achieved using reduced-serum 
media and low-attachment cell culture plates, the non-stem cells will die and only the 
breast cancer ‘stem cells’ will remain due to their anoikis resistance.  After 
approximately 7 days, the breast CSCs will have formed clusters of cells which are 
termed ‘tumourspheres’ (Dontu et al., 2003).  Tumourspheres, which contain both stem 
and non-stem cells, are counted to obtain a quantity of tumoursphere forming units and 
then broken-up to be re-processed in the same was as initially in order to assay the self-
renewal ability of the population, another key property of CSCs (Figure 1.2).   
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Figure 1.2:  Steps involved in the tumoursphere forming assay.   
1) Adherent breast cancer cells are plated in non-adherent conditions, using a specific media 
and cell culture plate.  2) Non-stem cells will be unable to survive, leaving only the breast cancer 
stem cells to survive. 3) After approximately 7 days, the breast cancer stem cells will have 
formed clusters of cells, termed 'tumourspheres' which are counted under light microscope. 4) 
Tumourspheres contain a mixture of stem- and non-stem cells which are broken up and 
repassaged to assay for self-renewal. 
 
 An additional assay for progenitor-like, rather than specifically cancer stem-like 
cells is the colony forming assay, also known as the clonogenic or CFU assay.  The assay 
is often interpreted as a clonal and proliferation assay (Zhang and Waxman, 2010).  The 
CFU assay been routinely used to evaluate cell reproductive death after radiation, but 
has more recently been use to test cytotoxic agents.  Some studies suggest that single 
cells, obtained by plating at low densities, which are capable of forming colonies of over 
32 cells are representative of stem cells.  The colonies that form in this assay are 
deemed 'holoclones' and are thought to represent stem cells due to the expression of 
certain survival and self-renewal genes (Barrandon and Green, 1987), including p63 
(Pellegrini et al., 2001) and BMI-1 (Claudinot et al., 2005).  Essentially, cells are plated in 
adherent conditions at a very low density in order to monitor their ability to exhibit 
these properties under different assay conditions, for example in the presence or 
absence of a drug, or different treatment regime.   
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 Label-retention assays are also often utilised to measure cancer stem-like cells in 
vitro, although the process does not facilitate high-throughput testing, of, for example, 
therapeutic agents (Clarke et al., 2006). 
  
 
1.1.8 Breast Cancer Treatment 
 Breast cancer screening consists of a combination of patient history, clinical 
examination, mammography results and ultrasound assessment (Howard and Bland, 
2012).  Once diagnosed, treatment for breast cancer, like any cancer type, depends 
primarily on the stage and grade of the case.  A review of the molecular, histological and 
clinical features (Section 1.1.6) of the cancer will be performed in order to select the 
most suitable treatment strategy (Malhotra et al., 2010).   
 For a long time, the primary and almost exclusive treatment method for breast 
cancer involved the use of cytotoxic chemotherapeutics but developments in research 
have enabled a more targeted approach often using multiple treatment options (Tinoco 
et al., 2013).  In general, treatment will begin using a combination of surgery, to remove 
the cancerous mass, with radiotherapy to treat the surrounding tissue and prevent 
recurrence, although individual cases may require a different initial treatment strategy.  
Treatment tailoring will be most important at this stage whereby hormone or chemo- 
therapy will usually follow surgery in order to attempt to further reduce the cancer 
whilst also aiming to help prevent relapse (Section 1.1.8.2) (Tinoco et al., 2013).   
 Ultimately, all cancer treatment aims to reduce or eliminate cancerous cells, 
either via physical removal or through the induction of cell death, thus preventing their 
growth and metastasis.  The target of the treatment will vary between cancer cases: 
from targeting the physical mass to specifically hitting particular gene targets. 
 
1.1.8.1 Treatment Targets in Breast Cancer  
 Many targets exist in breast cancer; from hormones and their receptors, to 
oncogenes and specific proteins in signalling pathways.  Hormone receptor positive 
tumours, which make up around 60% of all cases (Clarke et al., 1984), will generally be 
treated using endocrine therapy, i.e. hormone targeting agents.  TNBC cancers or cases 
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where a tumour has become resistant to endocrine therapy will be primarily targeted 
using radiotherapy and cytotoxic chemotherapy.   
 ER-positive cancers are the earliest example of a successful targeted therapy in 
breast cancer, through targeting expression of the ER itself (Jordan and Murphy, 1990).   
Tamoxifen, for example, is a non-steroidal ER blocker, which acts via binding to and 
inducing conformational changes in the ER-receptor (McDonnell and Wardell, 2010).  
More recently, however, aromitase inhibitors, which reduce levels of the hormone 
oestrogen are becoming more widely prescribed for ER positive cancers (Fabian, 2007).  
The HER2 receptor has also proved a viable target for drug development, with the 
production of the HER2-targeting agent trastuzumab (brand name Herceptin), a 
monoclonal antibody which binds to and blocks a portion of HER2.  Although these 
drugs are highly specific to their hormonal targets, they are still commonly used in 
combination with chemotherapeutic agents in order to produce the greatest anti-cancer 
effects and attempt to overcome the resistance that can occur due to upregulation of 
different signalling pathways (Schlotter et al., 2008; Leary et al., 2007) (Section 1.1.8.2).   
 Chemotherapeutics generally target highly proliferating cells, often impairing 
such processes as mitosis (Table 1.1).  Chemotherapeutic agents such as Paclitaxel and 
Cisplatin are highly cytotoxic drugs which are associated with multiple side effects from 
relatively mild, yet unpleasant effects of nausea and vomiting, to more substantial 
issues including neuropathy, thrombosis and myalgia (Partridge et al., 2001).  These 
drugs are effective at killing some cancer cells, but their non-specific cytotoxicity means 
these side effects are common and thus research is more focused into generating or 
improving compounds in order to exhibit more specificity and selectivity for cancer cells 
(Chari, 2008).   
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Table 1.1: Summary of Chemotherapeutic Drugs 
(Hassan et al., 2010; Cardoso et al.., 2014; Senkus et al., 2013) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Type Mechanism Cancer Targets Examples 
Alkylating agents Direct DNA damage 
– prevent cell 
reproduction 
Leukaemia, 
lymphoma, 
Hodgkin disease, 
multiple 
myeloma, 
sarcoma, lung, 
breast, ovary 
Cyclophosphamide 
Antimetabolites Interfere with DNA 
and RNA production 
Leukaemia, 
breast, ovary, 
intestinal 
5-fluorouracil, 
gemcitabine, 
methotrexate 
Anti-tumour 
antibiotics e.g. 
Anthracyclines 
Interfere with 
enzymes involved in 
DNA replication 
Breast, leukaemia, 
lymphoma, 
bladder, Hodgkin 
disease, lung 
cancer 
Doxorubicin, 
Epirubicin 
Topoisomerase 
inhibitors 
Interfere with 
topoisomerase 
enzymes involved in 
DNA separation in S-
phase of cell cycle 
Leukaemias, lung, 
ovarian, 
gastrointestinal 
Topo I inhibitors: 
Topotecan, 
Irinotecan 
Topo II inhibitors: 
Etoposide 
Mitotic Inhibitors Stop mitosis in M 
phase of cell cycle 
and can prevent 
enzymes producing 
proteins needed for 
cell reproduction 
Breast, lung, 
myeloma, 
lymphoma, 
leukaemia 
Taxanes: Paclitaxel & 
docetaxel Vincristine 
Platinum Agents Inhibition of DNA, 
RNA and protein 
synthesis 
Ovarian, lung, 
breast (TNBC). 
Cisplatin, carboplatin 
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 Some agents which are thought to target CSCs have been evaluated, although 
many failed at early stages of research, some showing serious side effects which may be 
due to harming normal stem cells required for normal cell regenerative processes (Hu 
and Fu, 2012).  Some agents have, however, made it on to the market.  Vismodegib, for 
example, a hedgehog-signalling inhibitor has been approved for use in basal cell 
carcinoma.  The specificity for Vismodegib, however, in targeting the stem cell 
population has not been clearly established; therefore it is not necessarily a true CSC-
targeting agent (Sandhiya et al., 2013).  Tarextumab is a monoclonal antibody, targeting 
Notch pathway proteins.  Results from a safety study using a combination of 
Tarextumab and conventional pancreatic cancer drugs were overall very positive, with 
83% of 29 patients' pancreatic tumours stabilising or shrinking over 8 weeks to one 
year.  This drug is now in phase II trials for pancreatic and lung cancer (Yen et al., 2015).  
Verastem is a company set up by Dr Max Wicha which exists to screen already licensed 
drugs for the ability to block focal adhesion kinase, an enzyme highly implicated in 
cancer progression and metastases due to its ability to aid cell adhesion and cancer 
stem cell survival.  The first FAK inhibitor candidate did not show promising results in 
clinical trials, however, another agent, Reparixin, which was initially developed to target 
transplant rejection, appeared to eliminate cancer cells through blocking a receptor 
involved in their growth.  Reparixin demonstrated early promise in a safety study on 
triple-negative breast cancer, and is now in a phase II trial of breast cancer (Kaiser, 
2015). 
1.1.8.2 Combination Therapies in Breast Cancer 
 The idea of using several different chemotherapeutics in combination as a 
treatment regime in cancer was first proposed in 1970s (Bonadonna et al., 1976).  
Combination therapies have been increasingly common in the treatment of breast 
cancer, especially in advanced, metastatic stages of the disease (Carrick et al., 2009; 
Overmoyer, 2003).  Several commonly used chemotherapeutic combinations include 
‘FEC’ – 5-Flurouracil (5-FU), Epirubicin and Cyclophosphamide (Zamagini et al., 1991), 
‘AC’ – Doxorubicin (brand name Adriamycin) and Cyclophosphamide (Fisher et al., 
1990), and ‘CMF’ – Cyclophosphamide, Methotrexate and 5-FU (Bonadonna et al., 
1976).   The drugs used in these combination therapies have varied mechanisms of 
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action thus allowing them to target different pathways and features of cancerous cells.  
These wide acting therapies are compiled in order to help facilitate an increased chance 
of successful treatment, i.e., long-term disease-survival (Buzdar et al., 1982) and 
attempt to overcome issues of resistance and relapse.   
 Combination therapies can also include the co-treatment of a patient using 
chemotherapy and hormonal therapies, as mentioned in section 1.1.8.2, surgery and 
radiotherapy.  Drugs with different mechanisms of action may be utilised as adjuvant 
therapies after the initial treatment has begun, or occasionally as neoadjuvant therapy, 
before the primary treatment has begun (Mauri et al., 2004).  Ultimately, this will lead 
to a combination therapy treatment course with drugs administered at different stages, 
the schedule of administration being particularly important since the effects of these 
drugs are often schedule-dependent (Fujimoto-Ouchi et al., 2001).    
1.1.8.3 Treatment Challenges in Breast Cancer 
 Despite some treatments being successful in breast cancer, resistance and 
relapse are a common occurrence.  Both resistance and relapse can be explained by the 
presence of CSCs (Section 1.1.7) which exhibit promoting properties of self-renewal; 
apoptosis resistance; independent growth abilities; and metastatic potential, thus 
allowing cancers to survive treatments and reseed at different locations.  CSCs share 
many properties of normal stem cells, i.e., they exhibit properties which facilitate a long 
lifespan such as: relative quiescence; resistance to drugs and toxins (due to the 
expression of ATP-binding cassette (ABC) transporters); ability to repair DNA damage; 
apoptosis resistance (Dean et al., 2005).  CSCs are therefore generally resistant to 
cancer drugs, in addition to radiotherapy, surviving even after a rigorous treatment 
regime which may successfully eliminate the bulk cells.  CSCs therefore provide an 
important yet challenging target in the search for more efficient therapies which 
prevent the successful seeding of new tumours and slow the growth of already 
developed ones by removing their self-renewal potential (Figure 1.3) (Lawson et al., 
2009).   
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Figure 1.3: Cancer Stem Cell Targetted Therapies aim to Significantly Reduce the Risk 
of Relapse 
A) Most current treatments are able to successfully eliminate a large proportion of the bulk 
tumour cells, although do not act on the CSC population.  B) CSC targetted treatments, in 
combination with conventional bulk targetting agents, aim to elimminate the CSC population, 
thus signifcantly reducing the risk of relapse (Adapted from Verastem, Accessed 2015). 
 
 Heterogeneity (Section 1.1.5) is a major consideration for cancer therapeutics, 
and although combination therapies provide some means to target multiple cell types 
within a tumour, heterogeneity still remains a challenge as cancers mutate and change 
throughout the course of disease and often become more difficult to define and 
therefore treat, as is the case in TNBC (Hutchinson, 2010).   
 An additional challenge is the fact that most anti-cancer agents or regimes do 
not target only the cancer cell population, thus, the therapeutic efficacy of these 
treatments is limited by their additional toxicity to ‘normal’ healthy cells and so the 
patient is left weak and immunocompromised, often experiencing highly unpleasant 
side effects (Chari, 2008).   
A 
 
    
 
 
 
 
 
 
B 
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 These challenges mean that treatment and research into treatment is evolving 
to become more target based in order to achieve a higher specificity and a lower 
general toxicity of the therapeutics and ultimately provide new and refined treatment 
strategies (Binkley et al., 2012).  Additional treatment strategies in cancer include 
agents which aim to target one of the hallmarks of cancer, apoptosis evasion, by 
inducing apoptosis in cancer cells, allowing for a more cancer-cell targeted effect 
(Discussed in Section 1.2.2). 
 
1.2 Apoptosis 
1.2.1 Introduction 
 Apoptosis, or programmed cell death (PCD) is a crucial process for the 
maintenance of tissue homeostasis and therefore of normal organism development 
(Shirley and Micheau, 2010).  The process is characterised by a series of precisely 
regulated mechanisms observed in mammalian cells during the genetically defined cell 
suicide.  Apoptosis initiation may occur due to an immune reaction, response to disease 
(Norbury and Hickson, 2001), cellular aging, or by chemical agents, hormones and drugs 
(Elmore, 2007).  Broadly, apoptosis is divided into the intrinsic, i.e. dependent on 
intracellular signals and mitochondria-mediated, and the extrinsic pathway, which 
requires the binding of death ligands to death receptors (DRs) present on the surface of 
cells. 
 The intrinsic pathway, sometimes known as the mitochondrial pathway, involves 
non-receptor mediated signals.  A key feature of the intrinsic pathway, sometimes 
referred to as the p53-mitochondrial pathway, involves mitochondrial membrane 
permeabilization.  This permeabilization is performed in a controlled manner, regulated 
by proteins of the Bcl-2 family, mitochondrial lipids, metabolic proteins and other key 
permeability regulating proteins.  The result is the release of pro-apoptotic proteins into 
the cell cytosol, which then mediate caspases further down in the pathway to further 
activate PCD and induce other cell death processes such as nuclear DNA fragmentation 
(Green and Kroemer, 2004). 
 The extrinsic pathway is initiated through ligand binding to DRs which are 
members of the tumour necrosis factor (TNF) superfamily.  These TNF superfamily DRs 
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all contain a cytoplasmic death domain (DD) of around 80 amino acids in length 
(Ashkenazi and Dixit, 1998).  When an appropriate death ligand, such as TNF-related 
apoptosis inducing ligand (TRAIL) (Section 1.2.2) binds, which is usually a trimeric 
structure; an adaptor protein will be recruited on the cytoplasmic portion of the 
receptor.  The initial adaptor protein contains a DD which is able to bind with the DD 
present on the receptor and thus functions to convey the initial ligand binding signal 
further along to the intracellular components of the pathway.  Apoptosis is then 
mediated by a series of procaspases which are cleaved to become the activated 
caspases (Ashkenazi and Dixit, 1998; Elmore, 2007).  
 Disturbances in the regulation of apoptosis can promote cancer initiation due to 
prolonging the life of cells beyond their normal lifespan.  Consequently, it follows that 
apoptosis is often reduced in cancer cells, which is likely controlled by anti-apoptotic 
proteins taking precedence over apoptosis-inducing proteins (Section 1.2.2.6 and 1.3) 
(Schlotter et al., 2008; Wong, 2011). 
 In the case of the mammary gland, microarray profiling has been performed on 
the mouse mammary gland during several key processes: pregnancy; lactation; and 
involution.  Post-lactation, during the remodelling process of involution, a number of 
changes involving high levels of PCD occur in the mammary gland.  The previously 
important cells required during lactation undergo apoptosis controlled by multiple 
apoptosis-related proteins, which were identified by the screen as multiple members of 
the TNF-α superfamily.  TRAIL, amongst other TNF ligands, was detected as a possible 
apoptosis-inducing ligand in the mammary gland (Clarkson et al., 2004). 
 
1.2.2 TRAIL Induced Apoptosis  
 TRAIL is an endogenous death ligand and a member of the TNF superfamily. The 
20 kDa protein is primarily expressed on immune cells due to its significant roles in both 
T-cell homeostasis and natural killer (NK) or T-cell killing of both virally and 
oncogenically transformed cells (Wang and El-Deiry, 2003). 
 TRAIL is a type II transmembrane protein, containing an extracellular domain 
which is cleaved to form the biologically active soluble form of TRAIL.  The protein was 
initially identified based on a high sequence homology with CD95 ligand (28% 
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homologous) and TNFα (23% homologous).  The fact that TRAIL has a cleavable 
extracellular carboxy portion, which forms the active soluble form, however, makes it 
unique from CD95L and TNF-α (Mariani and Krammer, 1998).   
 TRAIL has two transmembrane surface receptors: DR4 and DR5 which are 
capable of inducing apoptosis.  The two remaining TRAIL receptors are the decoy 
receptors (DcR), DcR1 or DcR2 (Pan et al., 1997), which lack the functional DD and thus 
do not facilitate apoptosis due to the lack of signal transduction after TRAIL binding 
(Ashkenazi, 2002).   A fifth TRAIL receptor does exist, osteoprotegerin (OPG) which is a 
secreted TNF family member that acts to inhibit osteoclastogenesis (Emery et al., 1998). 
 The two active TRAIL receptors, DR4 and DR5, consist of an extracellular 
cysteine-rich domain (CRD) and an intracellular DD.  Homotrimerisation of TRAIL leads 
to conformational changes in the receptors, including their oligomerisation which 
enables the receptors DD to recruit and bind, via a DD:DD interaction, to intracellular 
Fas-associated death domain (FADD).  FADD, in its role as an adaptor protein, then 
recruits and interacts, via the DED domains, with the zymogen caspases, procaspase-8 
or -10, forming the death inducing signalling complex (DISC) and leading to the initiation 
of the caspase cascade (Ashkenazi and Dixit, 1998; Medema et al., 1997).  Cleavage of 
procaspase-8/-10 to their active caspase subunits, p18 in the case of caspase-8, 
facilitates the subsequent activation of ‘executioner’ caspases, primarily involving 
caspase-3, ultimately leading to apoptosis (Figure 1.4).   
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Figure 1.4: Simplified Schematic of TRAIL induced extrinsic apoptosis 
TRAIL binds to its surface receptors DR4 or DR5, that trimerise and recruit the adaptor protein 
FADD via DD interactions.  FADD in turn recruits procaspase-8 which is cleaved to the active 
caspase-8 form which then leads to apoptosis through cleavage of downstream caspases or 
through the intrinsic pathway of apoptosis, via Bid cleavage. 
 
 The active caspase-8 is also able to induce the protein ‘Bcl2 homology domain 3 
interacting domain’ (BID) which in turn initiates activation of the intrinsic, mitochondrial 
pathway of apoptosis.  Bid cleavage to truncated Bid induces activation of Bax and Bak 
which translocate and form pores in the mitochondrial membrane, facilitating the 
release of cytyochrome C.  An interaction between apoptotic protease factor-1 (Apaf-1) 
with caspase-9 can then occur, thus completing the formation of the apoptosome 
complex and in turn, activating caspase-9.  Caspase-9 leads to further activation of 
effector caspases and enhances the signal induced via the extrinsic pathway (Chen et 
al., 2000; Ashkenazi and Dixit, 1998).   
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1.2.2.1 Alternative roles of TRAIL 
 Conversely to its role in both the extrinsic and intrinsic forms of apoptosis, TRAIL 
is able to activate several pathways involved in cell survival, including the NF-κB, MAPK 
and JNK pathways, depending on the components that make up the DISC complex 
(Johnstone et al., 2008).  Although not fully established, it is thought that some of the 
key proteins involved in the alternative functions of TRAIL are FADD, TNFR type 1-
associated DD (TRADD), procaspase-8/-10, replication protein A-interacting protein 
(RIP), c-FLIP and inhibitor of apoptosis proteins 1 and 2 (IAP1/2) (Johnstone et al., 2008).  
DISC composition, therefore, can regulate TRAIL-susceptibility.  
1.2.2.2 Regulation of TRAIL Signalling 
 The multistep pathway of TRAIL induced apoptosis has many potential areas, 
from receptor level to intracellular signalling components, which may be altered in 
order to regulate responses to TRAIL.  In particular, expression of the death receptors 
can impact cell sensitivity or resistance to TRAIL.  Lack of surface expression of DR4 or 
DR5, which has been observed in neuroblastoma tumour cells, for example, is 
correlated with reduced TRAIL sensitivity (Yang et al., 2003). However, DR4 or DR5 
expression levels have not been found to impact on breast cancer cell TRAIL sensitivity 
(Rahman et al, 2009; Zhang and Zhang, 2008).  Localisation of DRs in lipid rafts, due to 
palmitoylation controlled by O-glycosylation enzymes can alter TRAIL sensitivity. This 
occurs in DR4 only, impacting on the ability of the receptor to form trimers in lipid rafts 
when TRAIL is unbound (Wagner et al., 2007; Rossin et al., 2009).  Internalisation of DRs 
can occur by endocytosis, with the absence of DR4 conferring TRAIL resistance in 
leukaemia cancer cells (Cheng et al., 2006).  Of particular interest is that endocytosis of 
both TRAIL receptors can impact on breast cancer cell sensitivity to TRAIL (Zhang and 
Zhang, 2008) 
 Expression of the decoy receptors, DcR1 or DcR2, which compete with DR4 and 
DR5 for binding with TRAIL and do not induce apoptosis due to lack of a DD have been 
shown to induce TRAIL resistance when overexpressed (Rahman et al., 2009).  
Expression of the decoy receptors, however, in breast cancer cell lines (or indeed in 
other tumours) is not clearly associated with TRAIL resistance, despite appearing to 
contribute, at least in part, to the TRAIL resistance in normal cells (Rahman et al., 2009; 
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Le Blanc and Ashkenazi, 2003).  Binding of TRAIL to the fifth TRAIL receptor, OPG, does 
not lead to apoptosis induction due to the fact that OPG is secreted, and, thus the 
response upon TRAIL-binding is similar to that observed with the DcRs.  The TRAIL-
inhibiting effect of OPG has been observed in Jurkat cells, using overpexpression of OPG 
to prevent TRAIL-induced apoptosis (Emery et al., 1998).  Contradictory information 
surrounds OPG, however, since, although expression levels have been correlated with 
poor prostate cancer prognosis (Brown et al., 2001), it has also been demonstrated to 
reduce bone metastases in a model of breast cancer (Morony et al., 2001).  
 Mutation, rather than overall expression levels, of the TRAIL receptors, however, 
may have at least a partial role in TRAIL sensitivity.  In a study of 57 clinical breast 
cancer samples, three samples were found to have mutations in the DD of DR4, and 
four in the DD of DR5 which impinged their ability to induce apoptosis.  These mutations 
were only observed in the metastatic set of 34 samples, whereas no mutations were 
observed in the 23 non-metastasised samples (Shin et al., 2001). 
 As mentioned in Section 1.2.2, the additional roles of TRAIL, i.e. its ability to 
induce cell survival rather than apoptosis, depending upon the DISC components, is an 
area in which resistance mechanisms can be explored.  The regulation of procaspase-8/-
10 activation can be controlled by several anti-apoptotic proteins, such as Bcl-2 and, in 
particular, cellular FLICE-Like Inhibitory Protein (c-FLIP), which acts via directly 
preventing the ability of FADD to recruit procaspase-8/-10 (Scaffidi et al., 1999; Safa, 
2012). We and others have demonstrated that c-FLIP contributes to TRAIL resistance in 
breast cancer and that targeted inhibition of c-FLIP by siRNA is able to partially sensitise 
adherent breast cancer cells to TRAIL whilst also eliminating the breast CSC population 
(Piggott et al., 2011). c-FLIP and its role in TRAIL resistance will be discussed in Section 
1.3.   
 The Myc oncogenic pathway can enhance TRAIL sensitivity by transcriptional 
repression of c-FLIP (Ricci et al., 2004).  Furthermore, Myc has been shown to increase 
DR5 expression and thus, caspase-8 activation (Wang et al., 2004).  Myc hac been 
demonstrated to regulate TRAIL-dependent transcription of several genes, including NF-
κB and cellular inhibitor of apoptosis protein 2 (CIAP2), which impact on TRAIL 
sensitivity (Ricci et al., 2007). 
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1.2.2.3 TRAIL and Untransformed Cells 
 The ability of untransformed cells to resist TRAIL, whilst apoptosis is induced in 
cancer cells, is one of the major factors that makes TRAIL such a desirable cancer 
therapy (Ashkenazi et al., 1999; Walczak et al., 1999; Gura, 1997).  Although the exact 
mechanism of this TRAIL resistance has not been fully elucidated, evidence for many 
potential mechanisms does exist.  It is thought that TRAIL resistance in normal cells is 
partly controlled by an elevated expression of the decoy receptors (Zhang et al., 2000; 
LeBlanc and Ashkenazi, 2003; Daniels et al., 2005).  Several normal adult tissues have 
been shown to express one or more decoy TRAIL receptors which may be contributing 
to the resistance to TRAIL induced apoptosis (Sheridan et al., 1997).  In addition, studies 
have shown that normal stem cells are resistant to TRAIL induced apoptosis (Szegezdi et 
al., 2009; Kim et al., 2000).   
 Additionally, the anti-apoptotic proteins XIAP, Bcl-2 and c-FLIP are thought to 
contribute in part to the lack of TRAIL sensitivity in non-transformed cells.  However, it 
is likely that a combination of these proteins is required in order to elicit TRAIL 
resistance in non-transformed cells, rather than just one required in cancerous cells 
(van Dijk et al., 2013). 
 Being a naturally secreted ligand, it is unsurprising that TRAIL is well tolerated by 
animals, including mice, monkeys and chimpanzees (Rahman et al, 2009).   Thus, there 
is clearly much evidence to demonstrate the cancer specific properties of TRAIL and 
provide reason for its use as a therapeutic in the clinical setting. Furthermore, the initial 
in vitro observations of TRAIL-resistance in normal cells has been confirmed in phase I 
trials using TRAIL which showed no systemic toxicity, even when administered at high 
doses (Section 1.2.2.5) (van Dijk et al., 2013).   
 
1.2.2.4 TRAIL as a Therapeutic Agent in Cancer  
 Many anti-cancer agents function via a non-specific cytotoxicity, by targeting 
processes such as DNA replication, which, although often altered in cancer cells, are 
also key functions in non-cancerous cells thus leading to the side effects that are 
associated with many chemotherapeutics.  An ability to cause cancer cells to undergo 
apoptosis (PCD), either by methods of direct activation of apoptotic pathways, or re-
sensitisation to previously redundant pathways, is a desirable property of a cancer 
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therapeutic since it targets one of the key hallmarks of cancer: apoptosis evasion 
(Hanahan and Weinberg, 2000) and leaves the untransformed cells unharmed.  Many in 
vitro studies have demonstrated that TRAIL is indeed able to preferentially induce 
apoptosis in a wide range of human tumour cells, whilst sparing the non-transformed 
cells (Ashkenazi et al., 1999; Gura, 1997; Takeda et al., 2001; Kim et al., 2000; Wiezorek 
et al., 2010). 
 In addition to the direct ability of TRAIL to induce apoptosis in cancer cells when 
administered in recombinant form, there is much interest in the antitumour effects of 
endogenous TRAIL.  Secreted mainly by cells involved in immune regulation, including 
NK cells, T cells, monocytes and neutrophils, TRAIL has been shown to have a role in the 
natural immune defence system by virtue of its specific toxicity to transformed cells 
(Takeda et al., 2001).  TRAIL was first observed to have a role as a tumour suppressor in 
2001, in an in vivo study which demonstrated NK cell-mediated cytotoxicity on tumour 
xenografts to be at least in part dependant on TRAIL expression from mouse NK cells in 
the liver.  The study was able to demonstrate, using a neutralizing monoclonal antibody 
against TRAIL, a significant increase in liver metastases of several TRAIL sensitive tumour 
cell lines (Takeda et al., 2001).  Similarly, an in vivo study in 2005, using mice which are 
deficient in TRAIL, demonstrated an increase in spontaneous lymphoid tumour 
formation compared with those with normal levels of TRAIL (Zerafa et al., 2005).   
 There is clearly much evidence to support the potential of TRAIL as an anti-
cancer therapy, and, as such, several TRAIL receptor agonists have entered clinical trials. 
 
1.2.2.5 TRAIL in Cancer Clinical Trials 
 There are currently two categories of TRAIL receptor agonists being tested 
clinically: recombinant forms of TRAIL and agonistic antibodies specific for DR4 or DR5.  
Early stage clinical trials have demonstrated TRAIL-pathway agonists to be safe and well 
tolerated, and to show some anticancer activity with partial or complete responses in 
both non-small-cell lung cancer and non-Hodgkin's lymphoma patients when treated 
with Dulanermin, a recombinant form of TRAIL, in combination with other anti-cancer 
agents (Soria et al., 2010; Belada et al., 2010).  Several TRAIL receptor agonistic 
antibodies have demonstrated anticancer activity in combination with chemotherapy in 
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multiple cancer types, although the effects were modest and non-significant (Lempke et 
al., 2014).  
 Recombinant TRAIL was first tested in phase I clinical trials in two prevalent 
cancers; lung cancer and lymphoma to establish overall safety and tolerability, and was 
shown to be well-tolerated at serum levels above the therapeutic concentrations used 
in preclinical studies, demonstrating no overall toxicity (Herbst et al., 2010).  In addition, 
several monoclonal antibodies against DR4 and DR5 have also been well tolerated 
(Stuckey and Shah, 2013).  One such monoclonal antibody, mapatumumab, which acts 
on DR4, entered Phase II testing for non-Hodgkin lymphoma and generated a promising 
response in around a third of the trial patients, with one showing a complete recovery 
(Younes et al., 2010).  
 Most recently, Tigatuzumab, an agonistic anti-DR5 antibody has been tested, in 
combination with Paclitaxel, in a clinical trial of patients with triple-negative breast 
cancer (Forero-Torres et al., 2015). Tigatuzumab functions to trigger apoptosis in DR5 
expressing human tumour cells and has demonstrated in vitro and in vivo activity when 
tested on basal-like breast cancer cells, when administered in combination with 
chemotherapeutic agents.  Although the responses were relatively modest, the 
Tigatuzumab-Paclitaxel combination prolonged progression free survival in several 
patients, thus supporting further studies and trials into anti-DR5 agents as a means of 
activating the TRAIL pathway in cancer.  Indeed, this trial was performed in triple-
negative breast cancer, which has been demonstrated in vitro to be TRAIL sensitive 
(Rahman et al., 2009) including in studies performed both in vitro and in vivo using anti-
DR5 antibodies. 
 There are some clinical trials, however, which have been less successful for 
TRAIL, primarily when tested as a combination therapy with chemotherapeutic agents, 
despite in vitro studies showing promise for such regimes (Lempke et al., 2014; Shrader 
et al., 2007).  Although further demonstrating a high systemic tolerance to TRAIL, 
minimal anticancer activity has been observed in many studies (Lemke et al., 2014) 
(Table 1.3).   Therefore, there are needs to improve the clinical performance of TRIAL, 
and identify those patient subsets which will benefit from TRAIL treatment.  
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Table 1.2: Clinical Trials for rhTRAIL.   
All clinical trials presented here demonstrated safety for the drug tested. 
Phase Agent Cancer Combination n Efficacy Ref 
I 
 
 
rhTRAIL 
Advanced 
cancers 
- 71 
2 patients with 
metastatic 
chondrosarcoma had 
partial responses. 33 
patients had stable 
disease for longer than 
6 months.  
Herbst 2010 
IA 
 
rhTRAIL 
Advanced 
Cancer and 
Lymphoma 
- 39 None reported Ling 2006 
IA rhTRAIL CRC, sarcoma, 
NSCLC  
- 31 
1 partial response,  
5 stable disease 
Pan 2007 
I 
rhTRAIL 
Colorectal 
+ Chemotherapy 
+ Bevacizumab 
23 13 partial responses 
Wainberg 
2013 
I 
rhTRAIL 
Colorectal 27 6 partial responses 
Kasubhai 
2012 
I rhTRAIL Lung 24 
1 complete response, 
 13 partial responses 
Soria 2010 
II rhTRAIL Lung 213 No responses Soria 2011 
I 
 
rhTRAIL 
Colorectal 
+ Chemotherapy 
+ Cetuximab 
30 
Evidence of activity - 
ongoing 
Yee 2009 
I rhTRAIL Lymphoma 
+ Rituximab 
7 
2 complete responses, 
 1 partial response 
Yee 2007 
II rhTRAIL Lymphoma 48 No responses Belada 2010 
Ib/II 
Monoclonal 
Ab 
Non-Hodgkin’s 
Lymphoma 
- 40 
3 patients with 
follicular lymphoma 
responded: 2 complete, 
1 partial 
Younes 2010 
II 
Monoclonal 
Ab 
TNBC + Chemotherapy 64 
3 complete remissions, 
8 partial, 11 stable 
Forero-
Torres 2015 
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1.2.2.6 TRAIL Resistance in Cancer 
 One of the most prevalent issues with any anti-cancer agent is the issue of 
resistance.  Cells often adapt and change in order to overcome treatment by certain 
drugs; however, resistance to TRAIL appears to be a more cell-type specific 
phenomenon (Rahman et al., 2009).  Studies have shown that approximately 60% of 
tumour cell lines are TRAIL resistant, which significantly limits the clinical potential of 
TRAIL as a monotherapy (van Dijk et al., 2013).  It is possible that TRAIL-resistance can 
be overcome if used in combination with other clinical agents.  An understanding of 
TRAIL-resistance and regulation mechanisms is therefore vital in order to attempt to 
establish a viable treatment regime (Section 1.2.2.2). 
 The efficacy of TRAIL as a therapeutic in breast cancer is severely hampered by 
the existence of several subtypes of the disease, which make up a large proportion of 
breast cancer cases, that are resistant to TRAIL (Rahman et al., 2009).  Several in vitro 
studies of TRAIL mediated apoptosis in breast cancer cell lines showed that whilst the 
triple-negative MDA-MB-231 cell line sensitive to TRAIL mediated apoptosis, a large 
proportion of cell lines were highly TRAIL resistant (Ashkenazi et al., 1999).  Further 
studies have shown that TRAIL sensitivity of breast cancer cells can be categorised by 
the disease subtype, with triple-negative breast cancers of a mesenchymal phenotype 
demonstrating the greatest sensitivity to TRAIL.  In contrast, the more prevalent ER-
positive cancers, of a more luminal phenotype, were highly TRAIL resistant, more so 
than the HER2 lines which had a modest response to TRAIL (Rahman et al., 2009). 
 Resistance in these cancers involves several previously mentioned pathways of 
TRAIL regulation (Section 1.2.2.2).  Dysfunctions in the death receptors DR4 and DR5, 
the adaptor protein FADD, or the initial caspase caspase-8, due to mutations, can lead 
to TRAIL resistance in cancer (Zhang and Fang, 2005).  Primarily, however, anti-
apoptotic proteins such as c-FLIP are thought to be the key drivers of TRAIL-resistance in 
cancers (Section 1.3) (van Dijk et al., 2013; Safa and Pollok, 2011). 
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1.2.2.7 TRAIL Sensitisation Agents 
 The majority of current therapeutic strategies in cancer aim to overcome two of 
the key hallmarks of cancer: excessive proliferation and apoptosis resistance (Hanahan 
and Weinberg, 2011).  Therapeutics which slow or prevent cancer cell proliferation are 
likely to achieve a stable disease state, through limiting the growth of tumour cells, 
whereas therapeutics which are able to induce apoptosis may have the potential to 
eliminate cancer cells, thus potentially forging a route to cure (Lemke et al., 2014).  The 
observation that the endogenous death ligand TRAIL can preferentially target cancer 
cells through the cancer-cell specific induction of apoptosis (Ashkenazi et al., 1999; 
Walczak et al., 1999) makes it a highly desirable anti-cancer therapy.   Indeed, there are 
now a multitude of in vitro studies which provide evidence of this cancer cell-specific 
effect (Section 1.2.2).  Although initial in vitro studies demonstrated great promise for 
TRAIL as a cancer-cell specific therapy, these clinical trials, at phases I, II and III, 
performed in multiple cancer types have demonstrated positive, although much less 
significant results for TRAIL as a potential therapeutic.  In addition, many in vitro studies 
have confirmed the existence of multiple TRAIL-resistant cell lines in both breast and 
other cancer types (Rahman et al., 2009), which may partially explain the reason for the 
modest in vivo effects.  These observations have evidentially decreased the initially 
apparently broad therapeutic range of TRAIL as a monotherapy.  Ways of overcoming 
TRAIL resistance and increasing the therapeutic efficacy of TRAIL are becoming an 
important research target.    
 Agents which enhance TRAIL-mediated apoptosis do exist, acting in a variety of 
different in vitro cancer cell lines and via several mechanisms of action.  Mechanisms of 
these agents include increasing expression of TRAIL receptors, particularly DR5, 
increasing expression or activation of caspases, including caspase-8, and 
downregulating c-FLIP (Section 1.3.6) amongst several other mechanisms (Trivedi and 
Mishra, 2015).   
 GGTI-298, for example, is a geranylgeranyltransferase I (GGTase I) small 
molecule inhibitor which was shown to augment TRAIL-induced apoptosis in a panel of 
lung cancer cell lines.  Reduced c-FLIP levels were also observed, which may have been 
due to the inhibition of Akt phosphorylation, although the primary mechanism of action 
was suggested to be via induction of DR4 and DR5 expression (Chen et al., 2010).  The 
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actions and effects of GGTI-298 are similar to that of farnesyltransferase (FTase) 
inhibitors, that is, reducing Akt phosphorylation in some cell lines and enhancing the 
apoptosis-inducing ability of TRAIL (Qiu et al., 2007). 
 In the last year, a novel caspase-8 selective small molecule has been developed 
using in silico modelling which potentiates TRAIL-induced death in prostate cancer cells 
by directly binding to and promoting caspase-8 activation (Bucur et al., 2015). 
 There are many additional TRAIL sensitising agents that exist, although the 
majority act via a relatively non-specific targeting of several involved proteins.  Agents 
which regulate c-FLIP, and thus, TRAIL sensitivity are further explored in Section 1.3.6. 
 
1.2.3 DED Containing Proteins  
 Many of the key proteins involved in the extrinsic pathway of apoptosis, 
introduced in Section 1.2, are death effector domain (DED) containing proteins.  The key 
proteins involved include FADD, procaspase-8/-10 and c-FLIP.  The reason that the TRAIL 
pathway can have such opposing effects of inducing apoptosis or cell survival is based 
on which DED-containing proteins make up the DISC complex Section 1.2.2.1 (Johnstone 
et al., 2008). 
 The DED domain is a site of protein interaction which, as the name suggests, is 
mostly associated with the induction or processing of apoptosis, although the domain 
itself has no enzymatic activity.  DED domains facilitate predominantly hydrophobic 
interactions (Eberstadt et al., 1998) between TNF receptor (TNFR) family members 
followed by recruitment of the DED containing linker protein, FADD, and the induction 
of a caspase cascade usually involving procaspase-8/-10 (Valmiki and Ramos, 2009).  
 In addition to the key TRAIL signalling proteins, additional DED containing 
proteins include: death effector domain containing DNA binding (DEDD), DEDD2 and 
phosphoprotein enriched in astrocytes 15-KDa (PEA-15), which are more commonly 
involved in TNF-α receptor family processes (Figure 1.3).  These additional proteins 
demonstrate further that not only are DED proteins required for apoptosis induction, as 
is the case with procaspase-8/-10 but, conversely, they also have roles in processes such 
as transcription, migration and proliferation (Valmiki and Ramos, 2009). 
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Figure 1.5: The family of some of the key DED domain containing proteins 
Summary of the key DED (shown in red) containing proteins. Displayed sizes are relative 
to protein base pair length (Adapted from Valmiki and Ramos, 2009). 
 
1.2.3.1 DED Domain Structure  
 The structure of the DED domain is generally very highly conserved between 
proteins and was first defined in 1995, in a transient transfection assay using FADD 
(Chinnaiyan et al., 1995).  Basic computer modelling was used to predict the folding of 
the DED initially, before full NMR characterisation was performed in 1996, enabling the 
elucidation of  the structure of FADDs DED (Eberstadt et al. 1998).  FADD is a member of 
the death domain (DD) superfamily and thus has the features of an amphipathic, 
antiparallel bundle of six α-helices (Figure 1.6), shared between members of the DD 
superfamily, despite the family having an overall low sequence homology (Weber and 
Vincenz, 2001).  
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Figure 1.6: NMR structure of DED domain from FADD.   
Protein chains are coloured from N- to C-terminal using a rainbow spectral colour gradient 
(Image from PDB-1A1W). 
 
 
 Many DED proteins have an ‘FL motif’ which, in tandem DED proteins, will be 
present on DED1 and thus occupy a pocket in the surface of DED2 (Dickens et al., 2012).  
FADD, containing one DED only, has an FL motif at F25/L26 which is not buried within 
another domain and is therefore available to form interactions with other DED proteins, 
including procaspase-8/-10 or c-FLIP (Eberstadt et al., 1998).  Further detail into DED 
structure and interactions is provided in Section 1.3.7. 
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1.3 Cellular FLICE-like Inhibitory Protein (c-FLIP)   
1.3.1 Introduction 
 c-FLIP, otherwise known as Casper, FLAME-1, iFLICE, CASJ, CLARP, CFLAR or MRIT 
(Schuchmann et al., 2006; Safa and Pollok, 2011), has been demonstrated to be a key 
regulator of apoptosis.  The identification of c-FLIP, as a cell expressed homolog of viral 
FLIPs (v-FLIPs), in 1997, sparked an interest in research to divulge the function of this 
novel cellular expressed protein (Irmler et al., 1997).  Although 13 splice variants of c-
FLIP have been identified, only 3 isoforms appear to be expressed as proteins: 55 kDa c-
FLIP long (L), 26 kDa c-FLIP short (S) and 24 kDa c-FLIP Raji (R) (Figure 1.7).  The two 
shorter forms of c-FLIP, c-FLIP S and R still contain two functional DED domains but lack 
the caspase-like domain.  All three forms of c-FLIP have been demonstrated to have a 
role in the regulation of signalling pathways including both survival and apoptosis, 
although the least is known about the role of c-FLIP R (Safa et al., 2008; Safa, 2012).   
 
 
Figure 1.7: Basic structures of the 3 c-FLIP splice variants which are expressed as 
proteins and the 2 cleaved products.   
c-FLIP-L, the longest form of c-FLIP is made up of two DEDs; DED1 and DED2.  The carboxyl tail is 
made up of two subunits, p20 and p12 which are not present on c-FLIP-S or –R.  Upon 
homodimerisation or heterodimerisation with procaspase-8 (or-10), c-FLIP may be cleaved to 
one or both of the cleaved products shown. Sizes are relative to protein length (Adapted from 
Safa, 2012). 
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 In addition to the cellular forms of c-FLIP, v-FLIPs also exist, initially identified in 
molluscum contagiosum virus (MCV) and in forms of γ-herpesviruses with one of the 
most studied v-FLIPs being the MCV, MC159 (Garvey et al., 2002)   These FLIP variants 
have been demonstrated to block the activation of DRs at the point of DISC assembly in 
the same manner as c-FLIP (Thome and Tschopp, 2001) and are thought to have evolved 
to inhibit apoptosis of infected host cells in MCV (Garvey et al, 2002).  Like c-FLIPs, v-
FLIPs also contain 2 tandem DED domains which have been demonstrated to be able to 
interact with the DED domains of both FADD and procaspase-8 (Yang et al., 2005; Li et 
al., 2006).  
 
1.3.2 c-FLIP Structure  
 c-FLIP L is 55 kDa protein, highly homologous to procaspase-8 (Scaffidi et al., 
1999; Naito et al., 2004), containing two N terminal DEDs, DED1 and DED2, which, like 
procaspase-8, allow binding to the DED of FADD when in complex with TRAIL receptors 
DR4 or DR5.  Unlike procaspase-8, c-FLIP does not have an active caspase domain, due 
the substitution of tyrosine for a conserved cysteine residue in its C-terminal caspase-
like domain, and is therefore caspase-inactive (Irmler et al., 1997; Peter, 2004).  The 
DED domains, DED1 and DED2 of c-FLIP and procaspase-8 are able to interact with the 
one DED present on FADD, when in complex with the membrane bound death receptors 
DR4, DR5, DcR1 or DcR1.  The complex of these proteins results in the formation of a 
DISC.  Since c-FLIP is catalytically inactive, binding to FADD competitively inhibits the 
induction of apoptosis by procaspase-8/10 (Grunert et al., 2012; Safa and Pollok, 2011).  
Furthermore, in addition to preventing apoptosis competing with procaspase-8 for 
FADD binding, c-FLIP is also able to bind to procaspase-8 itself, thus preventing the 
formation of a complete DISC, which has recently been proposed to consist of 'chains' of 
processed caspase-8 homodimers, bound initially to FADD via a DED:DED interaction 
(Dickens et al., 2012). 
 The caspase-like C-terminal domain of c-FLIP has been resolved by 
crystallography, however, the full protein, including its DED domains has not been yet 
been resolved.  The crystal structure of v-FLIP, MC159’s DED domains have, however, 
been resolved, which is useful for aiding in silico studies of c-FLIP (Dickens et al., 2012) 
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(Chapter 3) and indeed other DED domain containing proteins (Li et al., 2006).  c-FLIP S, 
in particular, is similar in structure to the v-FLIPs; the main difference being the 
presence of 20 additional amino acids on c-FLIP S which are important for its 
ubiquitination and proteosomal degradation.  c-FLIP R, similarly to v-FLIPs, contains the 
two DED domains but lacks the additional C-terminal amino acids.  c-FLIP L has a much 
extended C terminus to c-FLIP S and R which is similar to the C-terminals of procaspase-
8/10, although the substitution of a cysteine residue in this domain deems c-FLIP 
catalytically inactive and thus does not act as a caspase (Safa et al., 2008). 
 
1.3.3 Functions of c-FLIP   
 Many roles for c-FLIP in cellular processes have been elucidated since its 
discovery, with regulation of apoptosis being the primary of its functions.  At a cellular 
level, it has been shown to have a dual-role in both cell death, i.e. apoptosis and 
necroptosis, and cell survival processes.  On a larger scale, in vivo studies have shown c-
FLIP to have an important role in T-cell proliferation (Zhang et al., 2008) and the 
development of heart tissue in early embryonic development (Yeh et al., 2000).   
1.3.3.1 c-FLIP prevents Apoptosis 
 Exploring the reasons for TRAIL resistance indicates that c-FLIP expression plays 
a key role in this mechanism, and indeed with the mechanism of resistance to Fas-L and 
TNF-ɑ induced apoptosis (Section 1.2.2.6) (Safa and Pollok, 2011).  Indeed, c-FLIP (both 
long and short) expression levels have been correlated with TRAIL-responsiveness, with 
elevated expression of c-FLIP shown to correlate with resistance to both TRAIL and 
chemotherapy-induced apoptosis (Safa and Pollok, 2011; Safa, 2013).  
 c-FLIP is described as a regulator of death-receptor induced apoptosis, and 
amongst its other functions, a key focus of research is on its ability to compete with 
procaspase-8 (or procaspase-10) at the DISC and thus inhibit TRAIL induced apoptosis 
(Section 1.2.2.6) (Griffith et al., 1998; Safa et al., 2008; Cheung et al., 2009; Grunert et 
al., 2012).  In addition to causing TRAIL resistance, c-FLIP has been shown to have anti-
apoptotic roles in Fas and TNF-α-mediated signalling and has been demonstrated to 
induce chemotherapeutic drug resistance in several diseases (Safa et al., 2008; 
Micheau, 2003). 
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 Both c-FLIP L and S have been shown to have anti- and pro- apoptotic roles in 
additional signalling pathways, including an ability to activate or upregulate pro-survival 
signalling proteins such as Akt, ERK and NF-κB (Safa, 2012).  c-FLIP expression is 
demonstrated to enhance tumorgenicity and result in a poor clinical outcome for many 
cancer types due to its effects on enhancing resistance to chemotherapeutics and TRAIL 
(Day and Safa, 2009).  Akt, serine-threonine kinase involved in cell survival regulation, is 
a key protein with which c-FLIP interacts.  This interaction enhances the anti-apoptotic 
functions of Akt through modulation of Gsk3β and is mediated by regulation of p27 and 
caspase-3 expression as assessed by Yeast-2-hybrid in several cancer cell lines 
(Quintaville et al., 2010).  An increased response to TRAIL has been observed when the 
Akt pathway is downregulated, for example, by suppressing DNA-protein kinase (DNA-
PK) in the human chronic myelogenous leukemia cell line, K562 (Kim et al., 2009).  The 
anti-apoptotic role of c-FLIP has also been demonstrated in primary pancreatic tumour 
cells (Haag et al., 2011), in primary T-cells (Lens et al., 2002) in addition to other primary 
cells.  
 Not only has c-FLIP been demonstrated to compete with procaspase-8/-10 for 
binding with FADD, it has also been shown to interact directly with DR5, FADD and 
caspase-8 in order to form an apoptotic inhibitory complex (AIC) in the MCF-7 breast 
cancer cell line (Day et al., 2008).  The anti-apoptotic interactions of c-FLIP will be 
explored further in Section 1.3.7. 
1.3.3.2 c-FLIP Activates Cell Survival Pathways  
 c-FLIP is able to directly activate cytoprotective pathways which involve cell 
survival, proliferation and carcinogenesis (Safa, 2012).  In fact, even its interaction with 
procaspase-8 can be pro-apoptotic as opposed to anti-, in that in certain conditions it 
can actually directly activate caspase-8 (Micheau et al. 2002; Dohrman et al, 2005).  c-
FLIP overexpression is able to activate NF-κB and ERK pathways through binding to 
proteins involved in these pathways (Safa, 2012; Ueffing et al., 2008).  The key proteins 
with which c-FLIP binds in these pathways are TRAF2 and RIP1, although more efficient 
binding and robust activation is achieved with the processed p43 N-terminal fragment 
of c-FLIP L (Dohrman, et al., 2005; Safa, 2012).   
 c-FLIP L appears to have a role in the modulation of Wnt signalling through 
the inhibition of β-catenin ubiquitylation (Naito et al., 2004).  The nuclear 
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translocation of c-FLIP and promotion of β-catenin-mediated gene transcription is 
able to enhance Wnt signalling.  This nuclear localisation, controlled though the 
functional bipartite nuclear localization signal (NLS) present at the C-terminus, could 
allow c-FLIP to accumulate and thus allow cells to re-acquire stem cell properties via 
Wnt-mediated transcription (Katayama et al., 2010).   
1.3.4 Transcriptional and Post-Translational Regulation of c-FLIP 
 c-FLIP is the target of many different transcription factors, which can induce or 
suppress its expression.  These factors are generally involved in survival and apoptosis 
signalling pathways and are activated by a multitude of cytokines, growth factors and 
ligands involved in DR signalling.  c-FLIP levels are primarily regulated by ubiquitin or 
proteosomal directed degradation (Safa et al., 2008) although other methods of can 
regulation control c-FLIP. 
 The protein, Akt is thought to positively regulate the expression of c-FLIP since 
suppression or activation of Akt was shown to decrease or increase c-FLIP levels 
respectively (Panka et al., 2001).  The two proteins are able to interact, within the C-
terminus of c-FLIP, via Akt's binding to and phosphorylation at S273, resulting in the 
subsequent stabilisation of c-FLIP L (Shi et al., 2009).  Conversely to Akt, JNK activation, 
induced by the E3 ubiquitin ligase, Itch causes the polyubiquitination of c-FLIP and thus 
targets it for degradation at the proteosome (Chang et al., 2006).   
1.3.5 c-FLIP in Cancer 
 Abnormal expression levels of c-FLIP have been observed in a range of disease 
states including multiple sclerosis, Alzheimer’s disease, diabetes mellitus, rheumatoid 
arthritis and cancer (Micheau, 2003).  Elevated levels of c-FLIP have been demonstrated 
in multiple cancer cell lines in vitro, and are generally associated with resistance to 
apoptosis induced by death ligands such as TRAIL.  Increased c-FLIP expression has been 
observed in prostate (Gao et al., 2005), colorectal (Ryu et al., 2001), gastric (Nam et al., 
2003), pancreatic (Elnemr et al., 2001), ovarian (Xiao et al., 2003) and breast (Wang et 
al., 2005) cancers, and also in melanoma (Griffith et al., 1998).  Additionally, analysis of 
primary tissues and cells has shown increased c-FLIP in B-cell chronic lymphocytic 
leukaemia (Olsson et al., 2001), gallbladder (Zong et al., 2009), non-small cell lung and 
in several other cancer types (Shirley and Micheau, 2010).  These observations are 
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primarily on c-FLIP L, although upregulation of c-FLIP S has been observed in some 
gastric and pancreatic cancer cell lines, and in lung adenocarcinoma primary samples 
(Shirley and Micheau, 2010). 
 Several groups have demonstrated that suppression of c-FLIP sensitises 
cancer cells to TRAIL killing (Cheung et al., 2009; Li et al., 2012; Murtaza et al., 2009; 
Geserick et al., 2008).  In addition, our lab have demonstrated that suppression of c-
FLIP using siRNA, in combination with TRAIL treatment, can selectively eliminate 
cancer stem cell activity in all breast cancer cell lines tested, in the in vitro model of 
cancer stem cells (Section 1.1.7.3) (Piggott et al., 2011).    
 Despite expression levels of c-FLIP appearing to correlate with TRAIL 
sensitivity, we have recently published data demonstrating that localisation of c-FLIP 
may be more of an important determinant in TRAIL-sensitivity of several breast 
cancer cell lines.  TRAIL-sensitivity appeared to be associated with breast cancer cells 
which expressed c-FLIP in the nucleus, whereas cells which expressed the protein in 
the cytoplasm were TRAIL-resistant (French et al., 2015 in press).  Inhibition of c-FLIP, 
whether sensitivity is controlled by localisation or expression levels, however, is 
clearly a potential method for TRAIL sensitization.   
 
1.3.6 c-FLIP Targeting Agents  
 We have previously demonstrated that a combination of c-FLIP elimination, by 
siRNA, and TRAIL causes a significant reduction in viability of the bulk population of 
several usually resistant breast cancer cell lines (Piggott et al., 2011).  More 
interestingly, perhaps, is the fact c-FLIP siRNA combined with TRAIL is able to entirely 
eliminate the tumoursphere forming cells present in several TRAIL-resistant, and one 
TRAIL-sensitive, breast cancer cell line in vitro (Piggott et al., 2011).  Cancer stem cells 
are a very important target for new therapies (Section 1.1.7), and, thus, this observation 
in particular highlights the potential impact of a c-FLIP inhibitor in combination with 
TRAIL.  Furthermore, the demonstrated correlation between c-FLIP overexpression and 
resistance to death ligand, i.e. FasL or TRAIL induced apoptosis, further highlights that c-
FLIP may be a suitable target for cancer therapy (Safa and Pollok, 2011; Safa, 2012).   
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 Many approaches to enhancing the degradation or inhibiting c-FLIP in vitro have 
been studied, including the use of transcriptional regulators, si/shRNA and degradation 
or ubiquitination inducing agents.  Although targeted suppression of c-FLIP using such 
methods as si/shRNA do sensitise cancer cells to TRAIL in vitro, this cannot currently be 
translated to a clinically viable therapy, thus, the use of pharmacological inhibitors of c-
FLIP is being considered. However, the development of such inhibitors is made complex 
by the homology between the DEDs of c-FLIP and procaspase-8 (Goltsev et al.¸ 1997; 
Safa, 2012), i.e. inhibiting the DED of c-FLIP would potentially also inhibit procaspase-8.  
Currently, agents which result in inhibition or degradation of c-FLIP are non-specific. 
 Histone Deacetylase Inhibitors (HDACi), which are able to significantly 
downregulate c-FLIP expression have been proposed to be inhibitors of c-FLIP, although 
their action is relatively non-specific (Safa et al., 2008).  These inhibitors, alone, have 
been demonstrated to induce re-differentiation in tumour cells and thus re-establish 
sensitivity toward apoptosis-inducing agents.  Vorinostat (suberoylanilide hydroxamic 
acid (SAHA), for example, has been shown to down-regulate levels of c-FLIP in various in 
vitro cell models of cancer, thus increasing their sensitivity to apoptosis, particularly 
that induced by TRAIL.  Pre-treatment of breast tumour cells with SAHA has been 
demonstrated to cause increased sensitivity to TRAIL (Yerbes and Lopez-Rivas, 2012).    
 A novel small molecule HDAC inhibitor, 4-(4-choloro-2-methylphenoxy)-N-
hydroxybutamamide (CMH) or Droxinostat has been identified through use of a high-
throughput chemical library screen in which downregulated c-FLIP mRNA expression 
was identified (Schimmer et al., 2006; Mawji, et al., 2007).  Although able to partially 
sensitise MCF-7 cells to TRAIL, this molecule was significantly toxic to cells alone, which 
is not a desirable property of a c-FLIP inhibitor.  In addition, CMH-induced additional off-
target effects of degradation of poly(ADP-ribose) polymerase (PARP) thus 
demonstrating its lack of specificity (Bijangi-Vishehsaraei et al., 2010).  
 Several Akt inhibitors have been analysed as inhibitors to c-FLIP and therefore 
TRAIL-sensitising agents, due to the known ability of the two proteins to interact.  API-1, 
for example, is a small molecule Akt inhibitor, which binds to, and blocks the membrane 
translocation of Akt (Kim et al., 2010).  Synergy was demonstrated in non-small cell lung 
cancer (NSCLC) cell lines, using the combination of API-1 and TRAIL, although the precise 
mechanism was not elucidated.  Additionally, a cell line tested which was described to 
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be 'relatively resistant' to TRAIL and showed high levels of c-FLIP expression, was not 
sensitised to TRAIL by API-1.  Furthermore, the overexpression of c-FLIP L or S did not 
fully abrogate the ability of API-1 to sensitise to TRAIL, thus suggesting the effects not to 
be primarily c-FLIP-mediated (Li et al., 2012). 
 Another agent which acts to inhibit Akt, Celecoxib, has been explored in models 
of colon cancer, for an ability to reduce c-FLIP levels (Chen et al., 2011).  This agent is a 
marketed COX-2 inhibitor which is used as an anti-inflammatory and analgesic drug; 
however, it has also been demonstrated to exhibit chemopreventive effects and is 
known to reduce the risk of colon cancer, although little is known about the mechanism 
behind this.  In general, the antitumor effects of celecoxib are considered to be linked 
with its ability to induce apoptosis (Thun et al., 2002) via inactivation of PDK1/Akt, 
upregulation of CHOP/GADD153 and calcium ion increase in several cancer cell types 
(Schonthal, 2006).  Apoptosis induced by celecoxib is able to downregulate c-FLIP via a 
proteasome mediated pathway, through the inhibition of GSK3.  The study thus 
assessed the effects of a GSK3 inhibitor on TRAIL induced apoptosis, which was indeed 
enhanced (Chen et al., 2011).  Celecoxib, and subsequently GSK3 inhibitors have 
therefore been shown to enhance the effects of TRAIL, with an ability to downregulate 
c-FLIP, however, like API-1, these effects are relatively non-specific. 
 There are several other Akt inhibitors, such as Perifosine, which have been 
demonstrated to have similar effects to API-1 and Celecoxib, i.e. they can enhance TRAIL 
which appears to be mediated through the downregulation of several proteins involved 
in DR signalling, including c-FLIP (Tazzari et al., 2008).   
 As with all cancer therapies, the ideal candidate is one that is highly specific and 
targeted to the desired protein.  Although many non-specific c-FLIP inhibitors or down 
regulators are available, at the time of this study, no specific ways of targeting c-FLIP 
clinically, or c-FLIP specific agents and small molecule inhibitors existed of which were 
aware. 
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1.3.7 Interactions of c-FLIP in TRAIL Resistance 
 In depth knowledge of the anti-apoptotic interactions that c-FLIP is involved in is 
imperative in order to be able to attempt to alter or prevent these, as a c-FLIP specific 
therapeutic strategy.  No mutational studies had been performed on the DEDs of c-FLIP 
L at the time of this study, however, which would elucidate any information about the 
importance of either DED or specific residues within the DED.   
Many studies have shown that the DEDs of c-FLIP, and of procaspase-8/-10 and 
not the caspase-like domain are important for the interaction with FADD (Irmler et al., 
1997).  Furthermore, studies have demonstrated that the DEDs of procaspase-8/-10 can 
interact with FADD and with each other to form intracellular filaments or fibers known 
as death effector filaments (DEFs) (Dickens et al., 2012; Ueffing et al., 2008).  The 
formation of complete DEFs can be blocked by v-FLIP proteins (Siegel et al., 1998).    
One study on a form of c-FLIP, murine c-FLIP R did look into several DED 
mutations and the impact of these on interactions with FADD.  Mutations were only 
performed on the FL motif present on DED2 at F119G/L120G which did demonstrate an 
increase in sensitivity to CD95-mediated apoptosis, with increased caspase-8 
processing.  Results suggested that only one DED domain of murine c-FLIP R was 
required for its anti-apoptotic role.  In addition, in contrast to c-FLIP L, murine c-FLIP R, 
did not prevent FADD self-association, and thus is not directly comparable (Ueffing et 
al., 2008). 
There are several mutational studies which have been performed on the single 
DED domain containing protein, FADD, which have various effects on the proteins 
functions and interactions.  Additionally, unlike c-FLIP or procaspases-8, the NMR 
structure of the DED of FADD has been resolved, which has helped to provide insight on 
DED proteins.  Furthermore, some groups have looked into the importance of residues 
present on procaspase-8 and v-FLIP with regards to the important TRAIL mediated 
interactions.  A review of the literature surrounding the importance of these DED 
mutations is required in order to attempt to comprehend the anti-apoptotic 
interactions of c-FLIP and therefore to target it therapeutically in order to sensitise to 
TRAIL.   
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 There are other protein interactions which c-FLIP is involved in (mentioned in 
Section 1.3.3.1), however, in this study we focus on the DED interactions of c-FLIP, 
although future work could involve targeting other domains on the protein. 
 
1.3.7.1 FADD DED Mutational Studies 
 The NMR structure of FADD revealed the existence of two hydrophobic patches 
(Eberstadt et al., 1998) and enabled a more specific selection of residues which have 
been analysed in several mutagenesis studies.   
 Mutation of residues F25 (part of the FL motif) and K33-R38, present in alpha 
helix 3 of the DED of FADD are able to alter DED interactions between FADD and c-FLIP 
as demonstrated by co-immunoprecipitation, in addition to  interactions between FADD 
and procaspase-8 (Kaufmann et al., 2002).  Interestingly, the F25Y FADD mutant was 
shown to bind procaspase-8 as well as wild-type FADD (Eberstadt et al., 1998), although 
the interaction with c-FLIP was significantly reduced, which suggests the two proteins 
have slightly different binding affinities to FADD and thus show some promise for the 
development of inhibitors (Kaufmann et al., 2002).   
 It is known that FADD, like c-FLIP and procaspase-8, can self-associate, although 
it is unlikely that this self-association occurs in the same way as between FADD and 
different proteins.  Muppidi et al., used CFP and YFP FRET constructs to demonstrate 
the existence of FADD:FADD interactions in living cells.  When the DED was removed 
from one or both of these constructs, no FRET was observed, thus suggesting the DED of 
FADD is also required not only for interaction with other proteins, but for its own self-
association also.  This study used the NMR structures from the previous work by 
Eberstadt et al. to further understand FADD self-association.  The first hydrophobic 
patch, mentioned by Eberstadt et al., contains residues F25, L26 (making up the FL 
motif), L28, L66 and L70 and is important for the interaction between FADD and 
procaspase-8.  The slightly less conserved second hydrophobic patch contains residues 
M1, P3, L5, V6, L43, L50, P57 and F82.  Mutations of the residues in this second patch 
did not disrupt the self-association of FADD or Fas signalling, suggesting that the first 
hydrophobic patch is key to its interactions with the DISC proteins (Muipiddi et al., 
2006).      
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 In addition to the FL motif, the RXDLL motif is conserved between many DED 
containing proteins, and indeed, the DED of FADD contains the sequence 'RHDLL' 
between amino acids 72 and 76.  Studies performed on v-FLIP demonstrated that 
specific point mutations within this domain were important for its antiapoptotic activity 
(Garvey et al.,2002) thus, Muippidi et al., performed mutagenesis on the RXDLL motif of 
FADD.  Several point mutations were introduced and a combination of co-
immunoprecipitation and FRET showed these residues do have a key role in FADD self-
association but that they were not important for its interaction with procaspase-8.  The 
study did demonstrate, however, that the mutant forms of FADD were unable to initiate 
TRAIL-induced apoptosis, despite retaining their ability to bind procaspase-8 and thus 
conclude that FADD self-association is required for induction of apoptosis but not for 
proper folding of the FADD DED (Muipiddi et al., 2006).   
 Carrington et al., however, have shown slightly different work to Muipiddi et al., 
regarding the site of FADD self-association.  This study suggested that the site of self-
association is around F25 of the FL motif in FADDs DED domain but agrees that FADD 
self-association is at a site distinct to that of procaspase-8 binding.  They suggest that 
FADD interacts with only one of the DED domains of procaspase-8, and that the 
residues S12, R38, D44 and E51 were potentially involved in the interaction with 
procaspase-8.  Additionally, two residues F25 and K33, previously mentioned for their 
ability to bind procaspase-8 (Eberstadt et al., 1998) or c-FLIP (Kaufmann et al., 2002) 
were also analysed.  A mutation at F25 of the FL motif was indeed shown to disrupt the 
ability of FADD to induce apoptosis in addition to being required for FADD self-
association (Carrington et al., 2006) 
 
1.3.7.2 Procaspase-8 Mutational Studies 
 In addition to the studies performed on the DED of FADD, several groups have 
looked specifically at mutations on the DEDs of procaspase-8 for their impact on 
interactions with FADD in the DISC.  Information elucidated about procaspase-8 
interactions could provide vital information surrounding the interactions of c-FLIP since 
c-FLIP and procaspase-8 bind to FADD in the same manner, and thus areas of 
importance on the structure of procaspase-8 may also feature on c-FLIP.  
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 A naturally occurring caspase-8 mutant with a deletion of leucine 62, located in 
DED1 of procaspase-8 was identified in human vulvar squamous carcinoma cells, which 
are a TRAIL resistant cell line.  This procaspase-8 mutant was shown to have no 
apoptotic activity when overexpressed in several cell lines, suggesting the presence of 
leucine 62 is vital for caspase-8 to induce apoptosis.   Analysis into the interactions of 
this procaspase-8 mutant showed that it was unable to interact with FADD, unlike 
overexpressed wildtype- procaspase-8 in addition to being unable to oligomerise with 
itself, or wildtype- procaspase-8.  In addition, it was shown that this mutant retained its 
enzymatic activity, governed by the N-terminus of the protein, thus, the lack of 
apoptosis was not due to a mutation in the caspase-domain of the protein (Liu et al., 
2002). 
 Another study has identified a short form of procaspase-8 which encodes DED1 
and only a small section of DED2 and has shown it to be present in multiple cell lines, 
using RT-PCR.  This short form of caspase-8 was demonstrated, by co-
immunoprecipitation, to still bind to FADD.  However, the procaspase-8-mutant was 
unable to induce apoptosis and therefore this suggests that DED1 alone of caspase-8 is 
sufficient to induce apoptosis (Xu et al., 2009). 
  A recent paper by Dickens et al. provides further insight into the structure of the 
DISC, with particular reference to the interactions between FADD and procaspase-8.  
This study observed FADD to be substoichiometric relative to TRAIL-Rs or DED-only 
proteins, conversely to the previously accepted triplet expression.  Approximately nine 
times more procaspase-8 than FADD was observed to be present at the DISC, upon 
stimulation with TRAIL.  A model was proposed which suggests that procaspase-8 
molecules interact sequentially via their DED domains to form a caspase-activating 
chain, which fits in with previously observed DISC ‘filaments’, and that both DED 
domains of procaspase-8 are required for this for full induction of apoptosis.  Mutating 
key interacting residues in procaspase-8 DED2 was shown to abrogate chain formation 
and disrupt, but not fully prevent, DISC mediated procaspase-8 activation and thus 
apoptosis induction which suggests that DED1 may be the important domain for initial 
FADD binding (Dickens et al., 2012).   
 In silico modelling was used to study the interactions involved in the Dickens 
caspase-8 chain model.  Caspase-8 DED1/2 were modelled by constructing a homology 
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model using the crystal structure of v-FLIP MC159 (Carrington et al., 2006; Li et al., 
2006; Yang et al., 2005).  DED interactions between different procaspase-8 proteins 
were modelled based on the interaction interface that exists between DED1 and DED2 
(FL motif of DED1) in the tandem DEDs of caspase-8 (Dickens et al., 2012).  Mutation of 
F122G/L123G of procaspase-8 DED2 was able to disrupt death effector filament 
formation, reduced procaspase-8 recruitment to the DISC and prevented procaspase-8 
activation.  Procaspase-8 recruitment, however, was not totally prevented, thus, they 
propose that it is unlikely that procaspase-8 is recruited to FADD only by interaction 
with DED2.  The group suggested that it is more likely that either procaspase-8 is 
recruited to FADD by DED1 or by DED1 and DED2 simultaneously, rather than by DED2 
alone (Dickens et al., 2012).  
 The findings of Dickens et al. do not fully agree with research by Yang et al., who 
suggested that procaspase-8 DED2 does indeed mediates recruitment to FADD.  Yang et 
al. proposed this due to the fact that their mutant of F122 reduced interactions with 
FADD, whilst the double FL mutant, F122G/L123G completely abolished co-IP 
detectable interactions (Yang et al., 2005).     
1.3.7.3 v-FLIP Mutational Studies 
 Although no studies had been performed on c-FLIP at the time of this study, and 
in particular, when constructing our models, there are studies which have looked into 
mutations on the viral form of the protein, v-FLIP, which may elucidate information into 
the residues or domains of importance in c-FLIP. 
 The DED domains of v-FLIP, MC159, exhibit intramolecular interactions: DED1 
interacts with DED2 via an 'FL' hydrophobic motif conserved in nearly all DEDs, which 
was used by the previously mentioned study performed by Dickens et al. to assist in the 
construction of a procaspase-8 homology and interaction model.  In tandem DED 
proteins (including c-FLIP and procaspase-8), the FL motif present on DED1 appears to 
occupy a pocket in the surface of DED2.  FADD only has 1 DED and so its own FL motif, 
F25/L26, is not buried at an intramolecular interface and thus is free to be able to 
recruit procaspase-8, or c-FLIP.  Mutation of this FL motif in FADD has been shown to 
prevent caspase-8 binding (Eberstadt et al., 1998).   
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 The highly DED-conserved RXDLL motif is present in v-FLIP.  In v-FLIP studies 
performed by Garvey et al., double mutants of the RHDLL to AHALL or RHDAA, but not 
point mutations, were sufficient to reduce anti-apoptotic activity.  12 mutants of v-FLIP 
were produced in this study, seven of which had mutations within DED1 and protected 
against Fas-mediated apoptosis in HeLa cells.  Two of the mutants, with residues altered 
within DED1 showed a loss of protection from Fas- and TRAIL-mediated apoptosis in 
Jurkat cells.  In comparison, two mutants which had mutations in DED2 retained TRAIL-
resistance. Garvey and team also explored mutations of the RXDL motif of both DED1 
and 2, which demonstrated the motifs in both domains to have a role in death effector 
filament formation and the anti-apoptotic role of v-FLIP, but not in binding to 
procaspase-8 or FADD.  Furthermore, they showed that two mutations which led to a 
loss of caspase-8 binding were present within DED1.  Mutations performed on the FL-
motif present on DED1, F30A, resulted in a reduced binding to caspase-8 and altered 
the ability of v-FLIP to prevent apoptosis.  This group suggest, therefore, that DED1 is 
required for the anti-apoptotic role of v-FLIP in TRAIL-mediated apoptosis (Garvey et al., 
2002).   
 Summarising the relevant mutational studies demonstrates some key residues 
involved in the DED interactions (required for Chapter 3) (Table 1.2). 
 
Table 1.3: Summary of Key Mutational Studies performed on FADD, v-FLIP and Procaspase-8 
at the time of Modelling Study (2012/2013). 
Although at the time of the modelling component of this project (November 2012 - March 
2013), no mutational studies had been performed on the DEDs of c-FLIP, several studies 
involving FADD, v-FLIP or procaspase-8 had been carried out, which provided us with 
information regarding the importance of DEDs and specific residues within them. 
Protein Residues 
Mutated 
Functional Consequence Reference 
FADD F25 K33-R38 (FL 
motif) 
Altered DED interactions with 
c-FLIP 
Kaufmann et al., 
2002 
FADD F25Y (FL motif) Bound with procaspase-8 as 
well as wt FADD 
Eberstadt et al., 
1998 
FADD F25G or F25V (FL 
motif) 
No loss in apoptotic activity 
Weaker binding with c-FLIP 
Eberstadt et al., 
1998 
FADD DED removal No FADD self-association Muppidi et al., 2006 
FADD RXDLL motif Altered FADD self-association Muppidi et al., 2006 
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No impact on procaspase-8 
interaction 
Unable to induce TRAIL 
mediated apoptosis 
FADD F25 (FL motif) Alters self-association Carrington et al., 
2006 
FADD S12, R38, D44, 
E51 
Alter procaspase-8 
interaction 
Carrington et al., 
2006 
FADD F25 Disrupted apoptosis 
induction 
Reduced self-association 
Carrington et al., 
2006 
Procaspase-8 L62 (DED1) Deletion associated with 
TRAIL resistance 
No apoptotic activity 
Unable to interact with FADD 
Unable to self-associate 
Retained enzymatic activity 
Liu et al., 2002 
Procaspase-8 DED2 (protein 
containing DED1 
and short 
section of DED2) 
Retained FADD binding 
Unable to induce apoptosis 
Xu et al., 2009 
Procaspase-8 F122G, L123G 
(FL motif), DED2 
Mutations of residues in 
DED2 abrogated DISC chain 
formation but did not 
completely prevent apoptosis 
MacFarlane et al., 
2012 
Procaspase-8 F122/L123G Abolished detectable 
interactions with FADD 
Yang et al., 2005 
v-FLIP RHDLL (RXDLL 
motif) 
Point mutations altered anti-
apoptotic activity but not 
interaction with FADD or 
caspase-8 
Garvey et al., 2002 
v-FLIP F30 (FL motif), 
DED1 
Mutations in DED1 reduced 
anti-apoptotic abilities and 
binding to caspase-8 
Garvey et al., 2002 
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1.4 Aims of the Study 
 Agonists of the endogenous death ligand TRAIL clearly show promise as 
therapeutics, despite the somewhat mixed responses from early phase clinical trials.  Its 
ability to induce apoptosis preferentially in cancer cells is a highly desirable property 
and one that should be exploited. Although triple-negative forms of breast cancer are 
TRAIL sensitive in vitro, a large subset of breast cancer types are resistant to treatment 
with the death ligand.  Overcoming this resistance is clearly an important objective in 
order to widen the therapeutic potential of TRAIL.  
 Many studies have proven the role of c-FLIP in TRAIL resistance (Safa and Pollok, 
2011; Safa, 2012). While we and others have demonstrated that targeted suppression 
of c-FLIP by si/shRNA sensitise both cancer cells and CSCs to TRAIL (Piggott et al., 2011; 
Safa, 2012; Day et al., 2009), this method of suppression cannot currently be translated 
to a clinically viable therapy.  It is known that the ability of c-FLIP to prevent TRAIL 
induced apoptosis is due to its competition with procaspase-8 at the DISC, however, the 
specific residues which are required for this interaction are not known.  In addition, 
although there are some compounds including histone deacetylase (HDAC), Akt 
inhibitors and the compound CMH, which exhibit non-specific inhibition of c-FLIP and 
therefore show general toxicity (Shanakar et al., 2005; Chen et al., 2011) (Section 1.3.6), 
there are currently no c-FLIP specific inhibitors available.   
 Drug development is constantly changing and adapting to new technologies.  
One of the more recent developments is the ability to design drugs that are specific to 
particular features present on protein surfaces, by using the latest in silico modelling 
technologies.  In addition, in silico protein modelling can help to elucidate information 
about certain amino acid residues which may be vital for certain cellular processes.   
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In this study we set out to use a form of in silico modelling to design novel small-
molecule inhibitors of c-FLIP and then to verify these inhibitors using cell-based in vitro 
assays.  More specifically, our objectives were to: 
 Model the structures of c-FLIP and procaspase-8 DEDs in order to subsequently 
model relevant interactions between c-FLIP, FADD and procaspase-8 
 Use pharmacophore screening to select and develop specific small molecule 
pharmacological inhibitors to c-FLIP 
 Use in vitro assays of cell viability and cancer stem-like cells to test the ability of 
inhibitors to sensitise to TRAIL 
 Validate the mechanism of action of identified inhibitors 
 Identify residues which may be involved in the anti-apoptotic role of c-FLIP and 
could be used to perform mutational studies 
 
 The desired action of a small molecule c-FLIP inhibitor was to sensitise breast 
cancer cells and CSCs to TRAIL induced apoptosis, through interference with the c-
FLIP:FADD interaction (Figure 1.8), whilst having low toxicity on ‘normal’ non-cancerous 
cells.  The development of such inhibitors, however, might be complicated by the 
homology between the DEDs of c-FLIP and procaspase-8 which could lead to off-target 
binding of the compounds to caspase-8.  Thus, the potential inhibitors should be 
analysed for their ability to inhibit c-FLIP whilst allowing procaspase-8 to bind FADD and 
activate apoptosis.  In addition, exploring the potential important residues involved in 
the interaction would provide alternative ways of targeting c-FLIP, should it not be 
possible to generate active inhibitors. 
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Figure 1.8: TRAIL Pathway and Simplified Schematic of c-FLIP Inhibitor 
A) TRAIL induced apoptotic pathway, inhibited by the interaction of c-FLIP with FADD via 
a DED:DED protein domain interaction (highlighted in yellow circle). B) c-FLIP inhibitors 
will be designed to inhibit the c-FLIP FADD DED interaction (yellow circle in A), whilst 
sparing the FADD:Procaspase-8 DED interaction, thus allowing apoptosis to progress.
A 
B 
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Chapter 2: Materials and Methods  
2.1 Cell Culture 
2.1.1 Cell Lines 
 In this study, we utilised multiple established human breast cancer cell lines 
which represent the main receptor-defined subtypes of breast cancer: ER-positive; 
HER2-positive; and TNBC.  The principal breast cancer cell lines used were MCF-7, BT474 
and MDA-MB-231 respectively.  MCF-7 cells are human luminal-like cells derived from a 
patient with metastatic breast cancer in 1970 (Brooks et al., 1973), which are epithelial-
like and represent ER-positive cancer cells.  An additional epithelial-like, ER-positive cell 
line, BT474, was derived from a solid invasive ductal breast carcinoma (Lasfargues et al., 
1978).  The mesenchymal-like MDA-MB-231 cell line, derived from the pleural effusion 
of 51 year old patient with long term metastatic breast cancer, represents TNBC.  SKBR3 
cells were also used, in order to analyse a HER2+ve, ER-ve breast cancer type.  MCF-10A 
cells were used to represent ‘normal’ non-tumorigenic mammary epithelial cells, 
although it was recognised that these cells were both transformed and of ductal origin.  
 Human  breast cancer cell lines MDA-MB-231 and MCF-7 cells were kindly 
supplied by Dr Julia Gee, Cardiff School of Pharmacy,  BT474 and SKBR3 cells were 
purchased from ATCC and MCF-10A cells were obtained from Dr Steven Hiscox, Cardiff 
School of Pharmacy.  HeLa human cervical cancer cells were a gift from Dr Ladislav 
Andera, Institute Molecular Genetics, Prague.  MDA-MB-231, MCF-7, BT474 , SKBR3 and 
HeLa cells were cultured in RPMI-1640 medium (Invitrogen) supplemented with 10% 
foetal bovine serum (FBS), 2 mM L-glutamine (Invitrogen) and 50 units/ml penicillin-
streptomycin. MCF-10A cells were cultured in 1:1 DMEM/F12 (Invitrogen) medium with 
5% horse serum (Sigma), 50 units/ml penicillin-streptomycin, 100 ng/ml cholera toxin 
(Sigma), 20 ng/ml epidermal growth factor (EGF) (Sigma), 0.5 mg/ml hydrocortisone and 
10 µg/ml insulin.   
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2.1.2 Cell Culture Maintenance 
 Cells were kept in a logarithmic growth phase in 25 cm2 cell culture flasks (T25) 
(Nunc, Thermo) at 37°C in a sterile incubator with a humidified atmosphere of 5% CO2 
and 95% air by passaging or refreshing media when required.  Cells were passaged 
when they had reached 80-100% confluency.  Passaging was performed by removing 
culture medium, before adding an appropriate amount of 0.05% Trypsin-EDTA 
(Invitrogen) for the size of the flask.  Cells were incubated in trypsin for around 5 
minutes at 37°C before all cells could be seen to have lifted off the vessel surface and 
rounded up, at which point, a volume at least 10 times that of trypsin of serum 
containing media was added to inactivate the trypsin.  Cells were passaged at 
appropriate ratios for the cell line (Table 2.1) and remaining cells were discarded or 
used as required.  Cell lines were kept to a passage number of around 40, after which, a 
fresh aliquot of low-passage cells would be revived from liquid nitrogen.   
 
Table 2.1: Conditions and maintenance of cell lines used within this study  
(Adapted from Holliday and Speirs, 2011) 
Cell Line Media (before 
supplementation) 
Passage 
Ratio 
Breast Cancer 
Subtype 
Classification 
MCF-7 RPMI 1:8 ER +ve, PR +/-, 
HER2- 
Luminal A 
BT474 RPMI 1:8 ER +ve, PR +/-, 
Her-2 + 
Luminal B 
SKBR3 RPMI 1:8 ER -, PR-, Her-2 + HER2 +ve 
MDA-MB-
231 
RPMI 1:10 TNBC Claudin-low 
MCF10-A DMEM-F12 1:6 Non-tumorigenic NA 
HeLa RPMI 1:10 N/A (Cervical 
Cancer) 
NA 
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2.1.3 Cell Storage 
 Cells were frozen at low passage number and cryo-stored in liquid nitrogen.  To 
prepare cells for storage, cells were trypsinised and pelleted by centrifugation for 5 
minutes at 234 g after which pellets were resuspended in 1 ml complete media with 
10% DMSO (Sigma) in 1.5 ml cryo-tubes (Nunc).  Around 2 x 106 cells were frozen per 
aliquot. Cryo-tubes were left overnight at -80°C in an isopropanol cell freezing container 
after which tubes were transferred to long term storage in liquid nitrogen.  To revive 
cells, tubes were defrosted rapidly in a 37°C waterbath before being spun for 5 minutes 
at 234 g to obtain a cell pellet.  The cell pellet was resuspended in 5 ml of the 
appropriate growth medium and cultured in a T25 flask, or other appropriately size 
vessel, depending on cell pellet size. 
 
2.1.4 Activation and Suppression of Apoptosis 
 Activation of caspase-8 mediated cell death was initiated in cell culture with 
recombinant soluble human TRAIL (super-killer TRAIL, Enzo Life Sciences) at 20 ng/ml 
(unless otherwise stated) for 18 h.  Inhibition of caspase activity was performed with 
Pan-caspase-inhibitor Z-VAD-FMK (R and D Systems), 10 µM (unless otherwise stated).   
 
2.2 In Silico Protein Modelling 
 All molecular modelling was performed on a MacPro dual 2.66 GHz Xeon running 
Ubuntu 9. Crystal structures for FADD and v-FLIP were downloaded from the Protein 
Data Bank (PDB) (www.pdb.org).  
 
2.2.1 c-FLIP and Procaspase-8 Homology Models 
 Crystal structures for the DED domains of c-FLIP and procaspase-8 had not been 
resolved and thus these were constructed based on a homology model.  Amino acid 
sequences for c-FLIP and procaspase-8 were obtained from Genbank. The structures of 
the two DEDs of c-FLIP and procaspase-8 were generated using MOE (Molecular 
Operative Environment, 2010) based on sequence alignment homology models with the 
published 3D structure of MC159 (PDB ID: 2BBR).  MC159 was imported to MOE where 
hydrogen atoms were added to the protein and residue ionisation was set to pH 7.4.  
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The structure was minimised to keep all heavy atoms fixed until the root mean square 
deviation (RMSD) gradient of 0.05 kcal moll-1 Å-1 was obtained.  
 MOE-Search PDB was used to identify a suitable template for performing c-FLIP 
and procaspase-8 model construction.  The sequence of target protein, the 'query' is 
entered and a search is performed of PDB entries in order to find one with a high level 
of homology for constructing the model.  In this case, MC159 was identified as the best 
template for performing our homology models. 
 MOE-Align was the first step in building our homology models, whereby the 
sequence of our target proteins (c-FLIP and procaspase-8) was entered and compared 
with the sequence of our template protein, MC159.  MOE-Align was used to align the 
sequences which appropriately aligned amino acids, entering gaps where required, in 
order to obtain a likely sequence to secondary structure of the template protein order.   
 MOE-Homology was subsequently used to generate a complete, energy-
minimized (i.e. 'relaxed' protein conformation) 3D model of our target proteins, based 
on the template structure MC159.  This application creates a number of potential 
models, constructed using a series of Boltzmann-weighted choices of sidechain 
rotamers and loop conformations using the selection of protein fragment components 
present in the built-in library of crystalised, high-resolution protein structures.  An 
average model of the target proteins were then constructed and a level of energy 
minimization was selected, in this case, AMBER99 (Assisted Model Building with Energy 
Refinement).  AMBER99 essentially simulates energy force fields to minimise excessive 
bond stretching within the protein. 
  
2.2.2 Modelling Intermolecular Interactions 
 The intramolecular interface (a known interaction (Dickens et al., 2012) between 
the FL-motif of DED1 and DED2 of c-FLIP and procaspase-8 was used to model the 
intermolecular interactions between DED2 of procaspase-8 and DED1 of c-FLIP.  This 
interaction was then used to analyse the c-FLIP DED1:FADD and procaspase-8 
DED1:FADD interactions (FADD crystal structure from PDB, ID: 1A1W).  In brief, c-FLIP or 
procaspase-8 DED1 was aligned and superimposed to the DED of FADD in MOE in order 
to simulate the intramolecular interactions that occur within the protein.  FADD was 
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then manually moved into position so that it mimicked this interaction, but on the outer 
surface of DED1 of c-FLIP or procaspase-8. 
 Protein complexes were subjected to in silico minimisation processes to create 
the optimum energy-minimised models. Hydrogen atoms were added to the protein 
and ionization of residues was performed at a pH of 7.4 in MOE.  The system was kept 
minimized by fixing the heavy atoms to obtain an RMSD gradient of 0.05 kcal mol-1 Å-1.   
An average model of the target proteins is then constructed and a level of energy 
minimization was selected, in this case, AMBER99 (Assisted Model Building with Energy 
Refinement).  AMBER99 essentially simulates energy force fields to minimise excessive 
bond stretching within the protein, in this case, we ensured the gradient of 0.05 kcal 
mol-1 Å-1 was maintained.  
 Following this, GROMACS software 4.5 (Hess et al¸ 2008) was used to perform 
molecular dynamics on the protein complexes using Gromos 96 forcefield and NPT 
working environment.  Interaction simulations were performed at 300 K, 1 atmosphere 
and a time step of 0.002 ps.  Next, the whole system was equilibrated for 100 ps after 
which the structure was solvated in a dodecahedron simulation box using spc216 water 
molecules, to generate a minimum of 9 Å water between the protein and the edge of 
the box, thus setting boundary constraints to the system.  Finalised models were 
visualised in VMD (Visual Molecular Dynamics). 
 
2.2.3 Protein Analysis and Pharmacophore Design 
 A pharmacophore query was run on c-FLIP using MOE to identify features on the 
protein surface which could be targeted by small molecule inhibitors to block the 
interaction with the FL motif on FADD.  The FL motif of FADD was used as if it were a 
compound-like ligand to set up the query on the surface of DED1 on c-FLIP.  After user 
defined refinement of these features a library of over 350,000 compounds (Specs 
Database) was virtually screened to identify potential inhibitors to these sites. 14000 
positive hits were docked on our modelled interactive surfaces of c-FLIP and 
procaspase-8 using MAESTRO (Schrodinger) software.  2000 compounds were obtained 
as a result, which were re-docked on the structures of c-FLIP and procaspase-8.  The 
Glide feature was used to ‘score’ these compounds based on their ability to bind the 
proteins.  Several docking steps were utilised to obtain a final, refined, 200 compounds 
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which had high scores for c-FLIP and low scores for procaspase-8.  These were analysed 
visually using MOE, comparing compound binding on the pocket of c-FLIP to the pocket 
on procaspase-8; those which scored highly for c-FLIP binding and low for procaspase-8 
binding, and visually appeared to fit those criteria were selected (19 compounds 
initially) (further detail in Chapter 3). 
 
2.3 Cell Based Assays 
2.3.1 Cell Subculture: Seeding for Assays 
 Culture medium was removed and trypsin added as in Section 2.1.2.  Once 
detached, cells were passaged as required and the remaining cells were moved to a 15 
ml falcon tube (Nunc).  Cells were fully resuspended to ensure a single cell suspension 
before being counted using a Fastread 10-chamber counting grid (Immune Systems).  
 10 µl of cell suspension was added to the counting chamber and cells were 
counted according to manufacturer's instructions in order to calculate the require 
volumes for cell seeding. The average of four counting squares was obtained and 
multiplied by the required factor to obtain the number of cells per millilitre.  The 
appropriate dilution for the assay was made before seeding cells into the assay plate 
required.  Cell numbers and media required for sub-culturing varied between assays and 
plates (Table 2.2). 
 
Table 2.2: Subculture tissue culture plates  
Plate Type (No. of wells) Relative Surface Area Media Required (µl) 
96 0.2 100 
48 0.4 200 
24 1 500 
12 2.5 1000 
6 5 3000 
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2.3.2 Cell Titre Blue Viability Assay 
 Cell Titre Blue (Promega) gives a measure of cell viability using metabolism as a 
marker; it measures the ability of cells to convert resazurin into resorufin, a fluorescent 
product.  Cells which are not viable will not be able to do this and thus will not result in 
a fluorescent signal.   
 Adherent cells were removed from culture plates using 0.05% Trypsin/EDTA and 
were plated in 96 well plates in 100 µl media at a concentration of 100000 cells/ml in 
order to achieve an appropriate confluency for assay the next day.  After 24 h 
incubation, media was refreshed with control or test containing medium and left 
overnight after which CellTiter blue viability assay was performed according to 
manufacturer’s instructions; 20 µl reagent was added to 100 µl media in the 96 wp and 
left for 1-4 h at 37°C at 5% CO2 in the dark.  Fluorescence was measured using 
excitation/emission wavelengths of 560/590 nm using FluoStar Optima plate reader 
(BMG Labtech).   
 
2.3.3 Caspase-8 Activity Assay 
 Caspase-Glo 8 assay (Promega) is an assay that uses luminescence as a measure 
of caspase-8 activity.  Caspase-Glo reagent results in cell lysis followed by caspase 
cleavage of the substrate and a resulting luminescent signal which gives a measure of 
caspase-8 activitiy within the sample.  In brief, adherent cells were plated and treated 
as in Section 2.3.1 using black walled 96 well plates.  After 24 h incubation, caspase-Glo 
8 assay was performed according to manufacturer's instructions.  Luminescence of 
samples and media control was measured using FluoStar Optima plate reader (BMG 
Labtech). 
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2.3.4 Functional Stem-Like and Progenitor Cell Assays 
2.3.4.1 Tumoursphere Assay - Adherent Treatment 
 The tumoursphere assay aims to enrich for cancer stem cells either from cell 
lines or primary cultures by testing their ability to resist anoikis growth conditions and, 
upon passaging, self-renewal.  Adherent cells were plated as described in section 2.3.1 
and treated after 24 h.  After 18 h, cells were trypsinised, disaggregated to achieve 
single cell suspension and transferred to the tumoursphere medium, Mammary 
Epithelial Cell Growth Medium (MEBM) (Lonza) serum-free epithelial growth medium 
supplemented with B27 (Invitrogen), 20 ng/ml EGF (Sigma), 5 mg/ml insulin (sigma), 
0.0008% v/v β-mercaptoethanol (Sigma), and 1 mg/ml hydrocortisone (Sigma).  Cells 
were seeded in 200 µl of supplemented MEBM into ultra-low attachment plates (Costar, 
Corning) at a density of 5000 cells/ml and incubated for 7 days at 37°C and 5% CO2 after 
which, tumourspheres were counted.  After counting, tumourspheres were then 
collected by centrifugation at 278 g and dissociated by trypsinising in 0.05% trypsin, 
0.25% EDTA (Invitrogen) and reprocessed as before, seeding at a density of 5000 
cells/ml and left for a further 7 days to obtain a second passage count. 
 
2.3.4.2 Tumoursphere Assay - Non-adherent Treatment 
 Adherent cells were trypsinised and plated in ultra-low attachment plates in 200 
µl supplemented MEBM (Section 2.3.4.1) at a density of 5000 cells/ml.  Immediately 
after plating into anoikis conditions, appropriate wells were treated with control or test 
compound.  Cells were left for 7 days at 37°C and 5% CO2 after which, tumourspheres 
were counted.  After counting, tumourspheres were then disaggregated and 
reprocessed as described in 2.3.4.1 and left for a further 7 days to obtain a second 
passage count. 
 
2.3.4.3 Colony Forming Assay 
 The clonogenic assay is an in vitro assay which tests one of the functional 
characteristics of stem cells: the ability to propogate colonies from single cells through 
enhanced proliferative potential (Harrison et al., 2010; Locke et al., 2005).  The assay is 
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not as selective for CSCs as the tumoursphere assay since between 10% and 70% of any 
given cell line population can form colonies.  
 Cells were plated in 6 or 12wp in order to obtain 50 cells per cm2 (Harrison et al., 
2010; Locke et al., 2005), and left to attach.  After attachment, media was refreshed 
with appropriate control or test medium.  Colonies were left to form for 10 days.  After 
10 days, colonies were stained by first removing media and washing gently with two 5 
minute washes in 1 X PBS.  Crystal violet in ethanol solution (Sigma) was then added for 
15 minutes to stain the colonies, followed by three 1 x PBS washes for 5 minutes each.  
Colonies were then visualised and photographed under white light.  Colonies of at least 
32 cells in size (i.e. those that had undergone 5 or more cell divisions) were counted 
using GelCount plate reader and computer software (Oxford Optronix) by setting a 
minimum and maximum size threshold for colonies of 100-1000 µm.  
 
2.4 Compound Handling 
 All compounds obtained from SPECS or synthesised at Cardiff School of 
Pharmacy were stored in solid form at 4°C.  Substances were dissolved in an 
appropriate volume of DMSO (based on molecular weight and mass), using 
vortexing/heating as required, to achieve stock solutions of 100 mM (unless otherwise 
stated), and stored in 10 µl aliquots at -20°C. 
2.4.1 Compound Solubility 
 Compounds were prepared in antibiotic free media at concentrations of 10 nM, 
100 nM, 1 µM, 10 µM and 100 µM. In a 96 well plate, 100 µl of each concentration of 
each inhibitor was left in an incubator overnight 37°C and 5% CO2.  Wells were visually 
inspected the following day to observe and record the solubility of each compound in 
media at increasing concentrations. 
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2.5 Co-Immunoprecipitation (Co-IP) and Western Blot Protein 
Analysis 
2.5.1 Solutions Used for Co-IP and Western Blot 
 Solutions were prepared for use at different steps during Co-IP and Western blot 
(Table 2.3). 
 
Table 2.3: Solutions and Reagents required for Protein Analysis Protocols 
Solution Composition 
RIPA Buffer 5 ml 1 M Tris pH 7.4, 10 ml 10% Nonidet-P40 (Roche 17545999), 
0.25 g Sodium Deoxycholate, 3 ml 5 M NaCl, 0.4 ml 0.25 M EGTA, 
up to 100 ml with dH2O, pH to 7.4 
5 X Laemmli Buffer 60 mM Tris-Cl pH 6.8, 2% SDS, 10% glycerol, 5% β-
mercaptoethanol, 0.01% bromophenol blue 
PBST 1 X PBS solution (Fisher): 5 tables in 500 ml dH2O plus 0.5 ml 
Tween (Sigma) 
TBST 1 X TBST solution - dissolve 1 TBST tablet (Merck Millipore) in 500 
ml ddH2O  
Co-IP Resolving Gel 
Buffer 
2.5 ml ddH2O, 3 ml bis-acrylamide (Sigma) 1.88 ml 1.5 M Tris-HCl 
pH 8.8 and 75 µl 10% SDS 
Co-IP Stacking Gel  75 µl APS and 7.5 µl TEMED in 2.5 ml ddH2O, 500 µl bis-
acrylamide, 625 µl 0.5 M Tris HCl pH 6.8 and 37.5 µl SDS 10% 
Western blot 
Resolving Gel Buffer 
1.5 M Tris-HCl, pH 8.8 
Western blot 
Stacking Gel Buffer 
0.5 M Tris-HCl, pH 6.8 
10 X Electrophoresis 
Buffer 
30 g Trizma (Sigma), 144.4 g Glycine (Sigma) pH 6.8, dH2O up to 1 
l 
1 X SDS-PAGE 
Running Buffer 
895 ml dH2O, 100 ml 10X Electrophoresis running buffer, 5 ml SDS 
(Sigma) 
1 X Western 
Transfer Buffer 
700 ml dH2O, 200 ml Methanol, 100 ml 10 X Eletrophoresis 
running buffer 
Blocking Buffer 5 % w/v non-fat milk powder (Marvel): 0.75 g in 15 ml PBST/TBST 
per transfer membrane  
Antibody Dilution 
Buffer 
5 % w/v BSA (Sigma): 0.1 g in 2 ml PBST per antibody 
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 Several antibodies and their respective secondary antibodies were utilised for 
protein detection (Table 2.4). 
 
Table 2.4: Primary Antibodies and Respective Secondaries used for Co-IP and Western Blot 
Antibody Species Dilution Source Target Size 
c-FLIP 5D8 
(mAb) 
Mouse 1:750 Santa Cruz 
Biotech 
55 kDa 
GAPDH Mouse 1:1000 Santa Cruz 
Biotech 
35 kDa 
FADD (IP) Mouse 1:1000 BD 610400 25 kDa 
FADD (IB) Rabbit 1:500 Santa Cruz 
Biotech sc5559 
25 kDa 
Caspase-8 Mouse 1:1000 Cell Signalling 
4927 
55 kDa 
 
2.5.2 Sample Extraction and Preparation for Co-Immunoprecipitation 
 Following experimental treatment, MDA-MB-231 and MCF-7 cells were washed 
twice with cold PBS and harvested using 700 µl lysis buffer (20 mM Tris HCl pH 7.5, 150 
mM NaCl, 10% fresh glycerol, 1% Triton X-100, 2 mM EDTA with protease and 
phosphatase inhibitors) left on a rocker at 4˚C for 20 minutes.  Cells were scraped and 
collected followed by centrifugation at 13793 g for 15 minutes at 4˚C. Supernatant was 
collected and an extra 30 µl was set aside for quantification. 20 µl Protein A beads were 
added to 5 µl sample and left on spinner at 4°C for 45 minutes.  Samples were spun at 
735 g for 1 minute and quantified using BCA protein assay kit (Pierce) and following 
manufacturer's instructions (Section 2.5.4).  After this, an equal amount of FADD 
antibody (BD, 610400) 1:1000 was added to each tube.  Samples were left spinning at 
4°C overnight. 
2.5.3 Sample Preparation for Western Blot 
 Cells from culture plates were trypsinised and centrifuged for 5 minutes at 234 
g.  Cell pellets were washed with 1 X PBS, twice, to remove remaining serum containing 
media.  Cell pellets were resuspended in 100 µl RIPA buffer with complete protease 
inhibitors (25 X solution, Roche), 200 nM NaVO3, 1 M NaF and 100 nM Na4P2O7.  23-
gauge needles on 1 ml syringes were used to break the samples up by passing them 
through 8-10 times.  Samples were transferred to 1.5 ml microcentrifuge tubes and left 
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on ice for 30 minutes.  Tubes were then centrifuged at 13793 g for 15 minutes at 4°C, 
after which, the supernatant was collected in 100 µl aliquots and stored at -20°C. 
2.5.4 Protein Quantification 
 The BCA assay was used to quantify levels of protein prepared for Co-IP or 
Western blot. In brief, 5 µl of sample or BSA standard was mixed with 25 µl BCA reagent 
and left at 37°C for 30 minutes, before being put on ice.  A standard curve for 
determining protein concentration was produced using a Nanodrop with standards of 
2.5, 5 and 10 mg BSA per ml protein buffer.   
2.5.5 Western Blotting 
 Protein samples were prepared at equal concentrations in Laemmli buffer after 
protein extraction in appropriate lysis buffer (Section 2.5.2 for co-IP extraction).  
Samples were heated to 95°C for 2 minutes and used immediately after or stored at -
20°C. 
2.5.6 SDS-PAGE  
2.5.6.1 SDS-PAGE: Co-Immunoprecipitation 
 12% resolving gel was prepared using 50 µl APS (Sigma) plus 10 µl TEMED 
(Sigma) added to resolving gel buffer (Table 2.3), mixed and immediately poured. dH2O 
was quickly pipetted over the top of the gel to ensure the gel remained level. Once set, 
dH2O was poured off and stacking gel was mixed and immediately poured, after which, 
combs were inserted and the gel allowed to set.  Gels were placed into the gel running 
tank (BioRad), in an electrophoresis gasket, and the central gasket was filled with 
running buffer.  Samples were loaded at equal quantities, of 20-30 µl in addition to a 
molecular weight marker (Pageruler Plus, Fermentas, Fisher).  Gels were run at 125 V 
for approximately 1.5 hours. 
 
 
2.5.6.2 SDS-PAGE: Western Blot 
 10% resolving gel was prepared using 100 µl APS (Sigma) with 15 µl TEMED 
(Sigma), added to the resolving gel buffer before immediately mixing and pouring.  
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dH2O was quickly pippetted over the top of the gel to ensure the gel remained level.  
After 15 minutes, dH2O was poured off before addition of the stacking gel, prepared by 
the addition of 100 µl APS to 4% stacking gel buffer.  After pouring stacking gel, a comb 
was immediately inserted into the gel and left to set for approximately 15 minutes.  
Once set, gels were inserted into the electrophoresis gasket and placed in a gel running 
tank (BioRad).  Running buffer was used to fill the centre of the gasket, ensuring the 
buffer overflowed so that a depth of around 3 cm was achieved. 20-30 µl of prepared 
protein samples were loaded, alongside a molecular weight marker (Pageruler, 
Fermentas, Fisher).  Gels were run at 180 V for approximately 1 hour. 
2.5.7 Protein Transfer to PVDF Membrane 
 Western transfer sandwich was prepared by layering sponge, 2x filter paper, 
protein gel, Polyvinylidene Fluoride (PVDF) membrane, 2x filter paper and sponge onto 
the transfer cassette.  Each layer was soaked in transfer buffer beforehand.  PVDF 
membrane was activated in methanol prior to soaking in transfer buffer for 5 minutes.  
A stripette was rolled over each layer to ensure no air bubbles were present. The 
cassette was shut and entered into the transfer tank, along with an ice block.  Transfer 
buffer was added to fill the tank and the transfer was run in the cold room, at 4°C.   
Transfer was run at 80 V for 45 minutes. 
 
2.5.8 Membrane Probing 
 After transfer, membranes were washed 3 times in PBST/TBST (1 x 15 min, 2 x 5 
min) before immersion in blocking buffer (5% w/v non-fat milk in PBST/TBST) with 
rocking for 1 h.  Membranes were transferred to tubes containing 4 ml of appropriate 
primary antibody made up in 5% BSA and left rotating overnight at 4°C.  Following this, 
membranes were washed 3 times in PBST/TBST as before and transferred to a tube 
containing 4 ml of appropriate secondary antibody (Table 2.4) and left to rotate at room 
temperature for 1 h.  Membranes were washed 3 times in PBST/TBST, as before, before 
protein detection and film development using ECL prime (Amersham) (Section 2.5.7). 
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2.5.9 Protein Visualisation 
 Immobilised proteins were detected using ECL or ECL Prime according to 
manufacturer’s instructions.  Solutions of ECL were mixed well and left to activate for 1 
minute, before adding directly to the membrane. Approximately 1 ml was added to 
each membrane, depending on its size.  X-Ray film (Amersham) was used to detect 
proteins, using an automatic X-Ray film processor (Xograph). 
 
2.6 Expression of Recombinant Proteins 
2.6.1 Expression Constructs 
 The eCFP-CI and eYFP-C1 vector plasmids were kindly provided by Dr David 
Stanek, Institute of Molecular Genetics, Prague. Full-length c-FLIP, FADD and 
procaspase-8 were kindly provided by Dr Ladislav Andera, Institute of Molecular 
Genetics, Prague.  CFP-YFP fusion protein was obtained from Liusheng He and 
Jehonathan Pinthus (Addgene plasmid # 24520). 
 
Table 2.5: Constructs Used within this Study 
Construct Expression System Antibiotic 
Selection 1 
Antibiotic 
Selection 2 
Reference 
eCFP-C1 Fluorescent plasmid Kanamycin Neomycin Clontech 
eYFP-C1 Fluorescent plasmid Kanamycin Neomycin Clontech 
CFP:YFP Fluorescent plasmid Kanamycin - He  et al., 
2003 
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2.6.2 Plasmid Propagation 
 
2.6.2.1 Transformation into E.coli 
 E.coli OneShotStbl3 cells (Invitrogen), for FRET constructs, or E.coli  XL-blue cells 
(Stratagene), for SDM were stored at -80°C were thawed on ice in 50 µl aliquots.  1 µl of 
DNA to be transformed was added to one 50 µl bacterial cell aliquot and incubated on 
ice for 30 minutes.  Heat-shock was then performed for 45 seconds at 42°C followed by 
a 2 minute incubation to allow the bacterial cells to recover. 250 µl pre-warmed (to 
37°C) SOCS media (Invitrogen) was added to the transformations and left for shaking at 
225 rpm for 1 hour at 37°C.  The culture was then spread on an agar plate made up with 
the appropriate antibiotic, and left to incubate overnight (for approximately 12 hours) 
at 37°C. 
 Colonies were selected by inoculation of a pipette tip, which was placed into 2 
ml (for mini-culture) of LB broth containing the appropriate antibiotic, and incubated 
with shaking at 225 rpm for approximately 16 h at 37°C before DNA extraction. 
 When preparing DNA from maxi- culture, the pipette tip was placed into 80 ml of 
LB broth, unless a starter culture was required, in which case this initial 2 ml culture was 
added to 80 ml LB-broth with appropriate antibiotic and left at 37°C for 16 hours, with 
shaking at 225 rpm before DNA extraction. 
 
2.6.2.2 DNA Extraction 
 DNA extraction from culture was performed using a mini- or maxi- endotoxin-
free DNA extraction kit (Qiagen) according to the manufacturer’s instructions.  In brief, 
cultures were pelleted after the 16 h incubation, by centrifugation at 8161.4 g for 3 
minutes, for a mini-prep or 1741 g for 15 minutes for a 50 ml preparation.  Re-
suspension of the cell pellet was performed in buffer P1, after which, buffers P2 and N3 
were added in order to lyse the cells for extraction.  Centrifugation was performed at 
13793 g for 10 minutes, before the supernatant was transferred to a DNA-binding 
column.  An additional centrifugation at 13793 g was performed for 1 minute, with all 
subsequent centrifugations being performed in these conditions.  Washing of the DNA-
binding column with buffers PB and PE was performed, before a final centrifugation to 
remove any remaining ethanol before eluting the DNA.  30 µl (or 1 ml in the case of a 
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maxi-prep) of buffer TE was added to the column and incubated for at least 1 minute at 
room temperature before centrifugation of the column was performed to collect DNA in 
a fresh endotoxin-free micro-centrifuge tube.  DNA concentration was measured using a 
Nanodrop (GE healthcare, UK). 
 
2.6.2.3 Sequencing Plasmids 
 DNA extracted from colonies was diluted to between 50 and 100 ng/µl in 15 µl 
and primers were diluted to 2 pM.  Sequencing was carried out by BIOSI sequencing 
core, Cardiff University. 
 
2.6.3 Site Directed Mutagenesis 
 Site directed mutagenesis was performed on the pcDNA3.1c-FLIP construct, 
using the QuickChange Kit (Stratagene) according to manufacturer’s instructions.  
Plasmids were custom-designed in order to target specific residues on c-FLIP (I6G, H7A, 
R38A and D42A).   
2.6.3.1 Primer Design 
 Primers were designed by following the Stratagene guidelines.  Essentially, 
primers were designed in order to achieve the desired mutation within the middle of 
the primer sequence, including up to 15 bases of correct sequence flanking it. The 
specific conditions to adhere to were as follows: 
 Primers to be between 25-45 bp 
 Melting temperature of ≥78°C  
 GC content of ≥40% 
 Primer to end with one or more G or C bases 
 The primers were designed to mutate regions of interest within DED1 of c-FLIP.  
All primers were purchased from Sigma (Table 2.6). 
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Table 2.6: Mutagenic primers 
Target 
Mutation 
Primer 
H7A 3’-CAGACGACTTCAGTAGCGAGTCCAACTTCTTCGTG- 5’ 
5’-GTCTGCTGAAGTCATCGCTCAGGTTGAAGAAGCAC- 3’ 
R38A 3’ –CACCAAGGTGGATTACAGCGCCTGGAAGACCTATAAAATG- 5’ 
5’ –GTGGTTCCACCTAATGTCGCGGACCTTCTGGATATTTTAC- 3’ 
D42A 3’ –TTACAGTCCCTGGAAGACCGATAAAATGCCCTTTCTCCATTC- 5’ 
5’ –AATGTCAGGGACCTTCTGGCTATTTTACGGGAAAGAGGTAAG- 3’ 
I6G 3’ –CAGACGACTTCAGCCGGTAGTCCAACTTCTTCG- 5’ 
5’ –GTCTGCTGAAGTCGGCCATCAGGTTGAAGAAGCA- 3’ 
 
2.6.3.2 PCR Amplification 
 Each mutagenesis used 50 ng of double-stranded DNA template (pcDNA3.1c-
FLIPL) made up in 5 µl reaction buffer.  125 ng of each mutagenic (forward and reverse) 
primer was added, in addition to 1 µl of 10 mM dNTP mix and 1 µl of Pfu DNA 
polymerase (NEB).  dH2O was added to 50 µl before running the PCR on a Biorad T100 
Thermal Cycler machine using the manufacturers guidelines (Table 2.7) 
 
Table 2.7: PCR conditions for mutagenesis 
Cycle Temperature Time Step 
1 95°C 30 s Denaturation 
12 95°C 30 s Denaturation 
 55°C 1 min Annealing 
 68°C 6.5 min (2 min/kb 
of plasmid) 
Extension 
1 68°C 10 min Final Extension 
- 4°C - Incubation 
 
2.6.3.3 Digestion of Template DNA Strand 
 After completing the PCR cycle, 1 µl of Dpn1 restriction enzyme was added to 
the 50 µl reactions and incubated at 37°C for 1 h.  Following this, E.coli XL1-blue cells 
(Stratagene) were transformed (using the protocol defined in Section 2.6.2.1) with 
prepared DNA, with the remainder being stored at -20°C.  DNA was extracted as per 
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Section 2.5.2.2 and sequencing was carried out at BIOSI sequencing core, Cardiff 
University performed using primer T4 to check for successful mutations. 
 
2.6.4 FRET Construct DNA Preparation 
 Plasmids were designed in order to facilitate the cloning of either FADD, c-FLIP 
or procaspase-8 into the FRET plasmids e-CFP-C1 or e-YFP-C1.  A positive control 
plasmid of CFP fused to YFP was also purchased (He et al., 2003) (Table 2.5). 
2.6.4.1 Primer Design 
 FRET constructs were designed via use of EditSeq and DNAStar software in order 
to facilitate the cloning of FADD, c-FLIP or procaspase-8 into either e-CFP-C1 or e-YFP-C1 
FRET plasmids. FADD tagged to CFP, c-FLIP(L) tagged to YFP and caspase-8 tagged to 
CFP.  Oligonucleotides were custom-designed and purchased from Sigma. 
 
Table 2.8: Primers used for FRET 
Primer Name Primer Sequence 
c-FLIP_BglII_fwd GTACTGGAAGATCTaggatgtctgctgaagtcat 
c-FLIP_BglII_rev GTACTGGAAGATCTtgtgtaggagaggataagtt 
Casp8_HindIII_fwd GTACTGGAAAGCTTgggagatggacttcagcagaaa 
Casp8_BamHI_rev GTTCAGCAGGATCCatcagaagggaagacaagtt 
FADD_HindIII_fwd GTACTGCAAAGCTTgggccatggacccgttcctggt 
FADD_BamHI_rev GTTCAGCAGGATCCggacgcttcggaggtagatg 
 
2.6.4.2 Cloning of FRET Constructs 
 c-FLIP and FADD were subcloned into the vectors eCFP-C1 and eYFP-C1.  
PCR for the oligos was performed using Phusion High-Fidelity DNA Polymerase (M0530 
NEB) and was used to amplify inserts (DNA ratios used according to manufacturer's 
instructions) (Table 2.9).   
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Table 2.9: PCR conditions for FRET Constructs 
Cycle Temperature Time Step 
1 98°C 30 s Denaturation 
12 98°C 10 s Denaturation 
 56°C 1 min Annealing 
 72°C 1.5 min (30 sec/kb 
of plasmid) 
Extension 
1 72°C 10 min Final Extension 
- 4°C - Incubation 
 
 
 A Qiagen PCR purification kit was used to purify the insert DNA.  Restriction 
digestion of purified vector and insert was performed using restriction enzymes BamHI 
(NEB) and HindIII (NEB) for FADD (and caspase-8), BglII (NEB) was used for c-FLIP using 
optimised digestion times: overnight for vectors and 1h for inserts (Table 2.9).   
 Antarctic phosphatase (NEB) was used to dephosphorylate the vectors post 
digestion, according to manufacturer’s instructions.  Digested insert and vector were 
run on a 1% agarose electrophoresis gel (Section 2.5.3) to check successful digestion 
before purification of vector and insert was performed using Qiagen gel purification kit. 
 
2.6.5 Agarose Gel Electrophoresis and DNA Extraction 
 Agarose gel electrophoresis was utilised to analyse DNA digests. 5 µl of Nucleic 
Acid Stain (Safe View, NBS Biologicals, Cambridgeshire) was added to 50 ml of prepared 
1% w/v agarose gel and immediately poured into a gel cast, with a comb inserted.  Gels 
were allowed to set for around 20 minutes.  8 µl of DNA for analysis was mixed with 2 µl 
of loading dye (GelPilot DNA Loading Dye, 5X, Qiagen) and this 10 µl was loaded on the 
gel, along with 5-10µl of DNA molecular weight marker (Easy Ladder I, Bioline, London).  
Gels were run at 80 V for around 1 hour.  UV light was used to identify DNA bands for 
extraction and purification using the Qiagen gel purification kit, following 
manufacturer’s instructions.  DNA concentrations were measured using a Nanodrop. 
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2.6.6 DNA Ligation 
 After DNA extraction and purification, vector (e-CFP-C1, e-YFP, C1) and insert (c-
FLIP, FADD and procaspase-8) DNA was ligated. Protocol optimisation was required in 
order to obtain successfully cloned plasmids.  The optimum ratio of vector to insert in 
the ligation reaction for all sets of cloning was 1:3 vector:insert. Cloning was optimised 
for use with T4 DNA Ligase (NEB) and transformation in Stbl3 E. coli cells (Section 
2.6.2.1) according to manufacturer's instructions.  Colonies were selected and grown 
overnight in kanamycin LB media.  The following day, Qiagen mini prep kit was used to 
purify plasmids and DNA concentration was read on a nanodrop.  DNA was then sent for 
sequencing (Section 2.6.2.3), or run on a gel, to observe ligation success. 
2.6.7 Transient Transfection 
 The TRAIL resistant MCF-7 or HeLa cells were transiently transfected with 
constructs using the transfection reagent Lipofectamine 3000 (Life Technologies).  
Transfection conditions were optimised in order to obtain viable, successfully 
transfected cells (Table 2.10).  We observed a significant amount of cell death upon 
transfection with our c-FLIP and FADD FRET constructs which was rescued by pre-
treatment with a pan-caspase inhibitor, Z-VAD-FMK (R and D Systems) for 1 h before 
transfection, thus, this pre-treatment was used for all FRET transfection experiments. 
 
Table 2.10: Optimised DNA ratios for FRET Plasmid Transfection 
Amounts are for transfection of 3 wells of a 96 well plate, in 100 µl media. 
Transfection Condition  (with Z-
VAD-FMK pretreatment) 
DNA 
(µl) 
OptiMEM 
(µl) 
P3000 
(µl) 
Lipofectamine 
3000 (µl) 
Control 0 24 1 1.2 
CFP alone (FADD) (433.5 ng/µl) 0.5 23.5 1 1.2 
YFP alone (c-FLIP) (130.5 ng/µl) 1 23 1 1.2 
CFP:YFP +ve control (608 ng/µl) 0.5 23.5 1 1.2 
CFP + YFP Control 0.5 + 1 22.5 1 1.2 
CFP + YFP TRAIL 0.5 + 1 22.5 1 1.2 
CFP + YFP OH14 0.5 + 1 22.5 1 1.2 
CFP + YFP OH14 + TRAIL 0.5 + 1 22.5 1 1.2 
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2.7 FRET Analysis 
 In our experiments, eCFP and eYFP served as the donor-acceptor pair for AP-
FRET.  If donor (eCFP) and acceptor (eYFP) FRET constructs are within < 10 nm of each 
other and in the correct orientation to each other, upon donor excitation, energy 
transfer to the acceptor will occur.  A subsequent slight decrease in donor emission will 
occur, in parallel to an increase in acceptor emission.  When the acceptor is bleached, 
by using the YFP appropriate laser at high power, energy transfer will not occur, and 
thus an increase in donor emission will be observed.   
2.7.1 Confocal Microscopy 
 Measurements were performed on a Zeiss LSM 710 confocal microscope (Zeiss, 
Germany).  For intensity measurements, a HXP120V 150W metal halide mercury lamp 
(Zeiss, Germany) was used, the output intensity of which could be controlled remotely. 
The lamp was turned on at least 30 minutes before starting experiments so as to avoid 
artefacts due to warming up of the lamp.  Images were recorded on the Zeiss LSM 710 
capture camera and LASOS Argon Laser with 458/488/514 nm band excitation filters 
was used for CFP imaging and YFP imaging and photobleaching. All FRET measurements 
were performed at 37°C and 5% CO2. 
 
2.7.2 FRET Cell Stimulation 
 A viable cell with similar intensity CFP and YFP expression, standardised by first 
analysing CFP:YFP fusion protein transfected cells, was selected for analysis, keeping 
laser exposure times to a minimum. At least 10 cells were recorded per experimental 
condition. Typically, exposure times were kept between 100-500 ms when locating cells 
with an appropriate expression of CFP and YFP for evaluation of FRET.  20X 
magnification was selected for imaging.  Multi-track line imaging was selected (for 
sequential imaging of the CFP and YFP channels).  Spectra were recorded using a 
458/514 nm double dichroic excitation to facilitate excitation of CFP with the 458 nm 
laser and YFP with the 514 laser line. 
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 For experiments, a pinhole of 1 Airy disk unit in the CFP channel was selected, 
with the YFP channel Airy unit selected to ensure the optical section thickness was the 
same as CFP.  Laser power of the CFP laser was set to 9%, and 4% for YFP.  Digital gain 
did not exceed 750.  Bleaching with the 514 nm laser line was set to 100%.  A region of 
interest (ROI) was defined on the cell of interest, large enough to enable intensity 
measurements containing at least 900 pixels, in order to minimise image data noise.  10 
bleaches, with 1 second between each was chosen to ensure sufficient YFP bleaching 
occurred.  Image acquisition was set to obtain 5 intensity recordings prebleach and 60 
seconds postbleach (approximately 40 recordings).  
 LSM 710 software measured average intensity in the ROI which was plotted on a 
curve for each time point. 
 
2.8 TALEN  
 TALENs contain a FokI nuclease domain at their carboxyl termini, similar to zinc 
finger nucleases (ZFNs), which allows them to create the targeted DNA double-strand 
breaks required by such genome modification techniques.  TALEN DNA-binding domains 
utilise TALEs - naturally occurring proteins derived from Xanthomonas spp. plant 
pathogenic bacterium.  These DNA-binding domains are made up of a tandem array of 
33-35 amino acid repeats, which are both able to recognise a single-base pair present 
within the major targeted groove.  Specificity and thus, the ability to design TALEN pairs, 
is achieved by the two amino acids present at positions 12 and 13, the hypervariable 
‘repeat variable diresidues’ (RVDs) (Kim and Kim, 2014).  Two TALEN proteins are 
required to make a functional genome-editing endonuclease, allowing for the 
recognition of 34 bases, and, with the incorporation of a FokI DNA-cleaving domain, 
modifications can take place.  When designing TALEN pairs, a target downstream of the 
translation start codon is chosen for the creation of double-strand breaks, which will be 
repaired by the process of nonhomologous end joining, thus creating out of frame 
deletions or insertions into the genetic code (Cermak et al., 2011; Christian et al., 2010).   
The process of clonal selection involved with TALEN, and indeed other genetic 
modifying processes such as with the use of zinc finger nucleases, results in a 1.6 - 34% 
fraction of successfully modified cells (Ding et al., 2013). 
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 TALEN binding pairs were constructed targeting exon 4 of c-FLIP(L) (Figure 2.2) 
and purchased from the TALEN Library Resource (Seoul National University).   
 
 
 
 
Figure 2.1: Location of c-FLIP TALEN Pairs. 
A) Genomic loci and TALEN positions for c-FLIP left (upstream) and right (downstream) TALEN 
constructs.  B) TALEN mRNA constructs for c-FLIP. 
 
 The sequences for our c-FLIP TALEN construct primers (Table 2.11) target a site 
29.18% into the coding DNA sequence of c-FLIP: 
Table 2.11: TALEN primer sequence 
Name Target Primer 
TALEN-c-FLIP-L Left target sequence TAAATCTGGTTGCCCCAGAT 
Spacer Spacer CAACTGGATTTA 
TALEN-c-FLIP-R Right target sequence TTAGAAAAATGCCTAAGAA 
 
A 
B 
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2.8.1 TALEN Transfection  
 Transfection efficiency was optimised by testing 3 different transfection 
reagents:  Lipofectamine2000, jetPEI or GeneCellen on MCF-7 cells with GFP or m-RFP 
co-transfected to observe cells effectively transfected and to allow for cell sorting.  
Lipofectamine2000 and mRFP were chosen as the optimum transfection conditions, as 
assessed by fluorescence microscopy, and the optimum cell confluence at transfection 
of 60% was used. After optimisation, MCF-7 cells were transfected, using 
Lipofectamine2000, with equal amounts (2 µg) of TALEN-L and -R constructs (Table 2.1) 
as well as mRFP (donated by Dr David Stanek, Institute of Molecular Genetics, Prague).  
 
2.8.2 FACS Sorting and Clone Culture Conditions 
 Transfected MCF-7 cells were sorted using FACS, selecting around 80% mRFP 
expressing cells (not 100%) and subcloned into 96 well plates, plated to achieve one cell 
per well.  Cells were plated in MCF-7 conditioned medium in order to obtain optimal cell 
growth and media was changed after 5 days.   
 Wells were checked for the presence of single colonies.  After around 2 weeks, 
80 single colonies were observed and allowed to grow until a relatively high confluence 
was achieved, after which they were split and re-plated into two replicates, one for 
further propagation, the second for gDNA isolation, which was used to confirm the 
knock-down (Section 2.8.3.1).  
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2.8.3 TALEN Transfection Analysis 
 Several reagents were utilised in order to extract, isolate genomic DNA from 
MCF-7 TALEN transfected cells, before analysis could be performed (Table 2.12).  
 
Table 2.12:  Reagents required for genomic DNA isolation. 
Reagent Composition 
Lysis Buffer 10 mM Tris pH 7.5, 10 mM NaCl, 10 mM 
EDTA pH 8.0. 0.5% sarcosyl + proteinase K 
added just before cell lysis, 10 mg/ml was 
diluted 1:100 
NaCL:Ethanol 150 μl of 5 M NaCl was mixed with 10 ml 
of 96% ethanol 
Phusion Reaction Mixture 4 μl buffer, 0.4 μl of 10 mM dNTPs, 2 μl of 
primer mix (5 + 5 μM), 1 μl of template, 
0.2 μl of Phusion, 12.4 μl of H2O 
DreamTaq Reaction Mixture 2 μl of primer mix (5 + 5 μM), 1 μl of 
template, 10 μl of 2x master mix, 7 μl of 
H2O 
 
2.8.3.1 gDNA Isolation 
 Isolation of genomic DNA was performed in order to PCR-analyse the first round 
of TALEN transfected MCF-7 cells.  TALEN transfected MCF-7 TALEN clones in 96 well 
plates, were washed 2 times with PBS and lysed in 50 μl of lysis buffer. The plates were 
incubated overnight in 55°C to degrade all contaminating proteins, then 100 μl of 
NaCl:ethanol was added and the plate was incubated for 1 hour. Precipitated DNA was 
washed by very careful removal of the supernatant and two additions of 150 μl of 70% 
ethanol. DNA was dried at 55°C and finally diluted in 50 μl of Tris/EDTA, with 
resuspension to ensure full DNA dilution. 
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2.8.3.2 Confirmation of Expression 
 Folowing gDNA extraction of TALEN clones, Phusion and DreamTaq DNA-
polymerases were used according to the manufacturer’s protocol (Thermo Scientific) 
(Table 2.6.3) and compared, using normal MCF-7 genomic DNA extract, in order to 
decide which would be best for analysis of all clones.  In addition, multiple primer pairs 
were designed and tested in various combinations in order to achieve the most clear 
result for amplifying c-FLIP and checking the transfection of TALEN constructs (Table 
2.13).   
 
Table 2.13: Forward and Reverse Primers for Testing the Efficiency of c-FLIP TALEN Clones 
Oligos for c-FLIPL TALEN Primer Sequence 
c-FLIP_TALEN200_fwd AGCTCTATTGACATTTGTTT 
c-FLIP_TALEN200_rev CCACTGAGAGGCCAAAATTC 
c-FLIP_TALEN300_fwd CTGCCTCAGCCTCCCAAAGTGCTGGGATTA 
c-FLIP_TALEN300_rev ATTTATCAGTCATGATGCCC 
c-FLIP_TALEN400_fwd GCTCAGGCTGGTCTCAAACT 
c-FLIP_TALEN400_rev GAGGCTTTGGTCATCCAGGT 
c-FLIP_TALEN100_fwd CTTGGACCTTGTGGTTGAGT 
c-FLIP_TALEN100_rev TTGTCTTCAGGTCTATTCTG 
 
 
 The program for PCR was as follows: initial denaturation (98°C 1 min), 40 cycles 
(98°C 30 s, 56°C 30 s, 72°C 30 s), final extension (72°C 10 min). The PCR program for 
DreamTaq was as follows: initial denaturation (95°C 1 min), 40 cycles (95°C 30 s, 56°C 30 
s, 68°C 1 min), final extension (68°C 10 min). DreamTaq master-mix provided the best 
result and was subesequently used for the MCF-7 clones analysis together with 200F + 
400R combination of primers (Figure 2.2A and B). Restriction digestion with EcoRI 
enzyme was used to check whether the plasmids contain the correct TALEN.  The 
expected size of the bands was 4260 bp and 2500 bp.  
 The restriction enzyme used to cleave the DNA was BsrI, an enzyme present 
around 50% into the sequence of c-FLIP (Figure 2.1), and, thus, one which would be 
expected to generate products around 200 bp in size.  Reaction mixture containing 2 μl 
of PCR mixture, 1.5 μl of B-buffer, 0.2 μl of BsrI (BseNI by Thermo Scientific), 11.3 μl 
dH2O was incubated for 3 hours in 65°C. For the subsequent gel electrophoresis in 2% 
Chapter 2: Materials & Methods 
 
 O A Hayward   82 
 
agarose gel diluted in TAE buffer and ethidium bromide the whole digestion mixture or 
2 μl of PCR mixture were used (Figure 2.2C). 
 
Figure 2.2: Optimizing of PCR conditions and test of BsrI cleavage.  
a) Two polymerases, Phusion and DreamTaq were tested using our different primer 
pairs.  The best result was obtained using DreamTaq as it provided the cleanest bands. 
b) Different primer pairs were tested, with the combination of 200F:300R and 
200F:400R providing the best combinations. c) When cleaving the primer pairs using 
BsrI, the combination of 200F:400R was the optimal combination. 
 
2.8.4 Second Transfection 
 Second transfection was performed in the same way as Section 2.8.1, and FACS 
sorting was performed as in Section 2.8.2. RNA was extracted as in Section 2.9.1 and 
potential clones were analysed using qPCR (Section 2.9.3).   
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2.9 RNA Analysis 
 Before extracting and handling RNA, all surfaces and pipettes were cleaned 
thoroughly with RNAse Zap (Ambion). 
2.9.1 RNA Extraction 
 Cultured cells were pelleted by centrifugation at 234 g and subsequently 
resuspended in 1 ml PBS to wash off media.  After re-pelleting, PBS was removed and 
replaced with 350 µl Buffer RLT (Qiagen).  RNA was extracted using the Qiagen RNEasy 
kit following the manufacturer’s instructions.  Following this, RNA was incubated with 
DNase (Amplicon) for 15 minutes before inactivation in the appropriate inactivation 
solution.  Concentration was measured using a Nanodrop.  
 
2.9.2 cDNA Synthesis 
 cDNA was synthesised from RNA using M-MLV reverse transcriptase (Promega), 
following the manufacturer's instructions.  Essentially, 50 ng of RNA was mixed with 1 µl 
of 500 µg/ml random of primers, diluted up to 15 µl with dH2O and heated to 70°C for 5 
minutes, before rapid cooling on ice, to melt secondary structure and prevent it from 
reforming.  Tubes were spun to collect solution at the bottom, after which, 1 µl of 10 
mM dNTPs (Promega), 5 µl M-MLV 5X Reaction Buffer, 200 units (1 µl) M-MLV RT, 1 
unit/µl (0.6 µl) RNasin (Promega) and dH2O to 25 µl was added to the original 15 µl 
solution.  Samples were incubated at 37°C for 1 h.  The resulting DNA was stored at -
20°C.  
 
2.9.3 q-RT-PCR Analysis 
 All qPCR experiments were designed to include primers to target c-FLIP in 
addition to beta-actin, as the internal control gene.  Primers for q-PCR were custom 
designed using Primer3 web-based program (primer3.ut.ee) (Table 2.14). 
 
 
 
 
Chapter 2: Materials & Methods 
 
 O A Hayward   84 
 
Table 2.14: qPCR Primers 
Target Forward Primer Sequence Reverse Primer Sequence 
Beta Actin CCCAGCACAATGAAGAtCAA CAGGTGGAAGGTCGTCTACA 
c-FLIP TGATGGCAGAGATTGGTGAG GATTTAGACCAACGGGGTCT 
 
 Levels of beta-actin should be consistent through all cells and thus reflective of 
the total amount of cDNA present in each sample.  A control of no template was also 
included, with the replacement of cDNA with dH2O so as to control for the presence of 
contaminating DNA. 
 A qPCR reaction mix was prepared to include (per reaction): 0.2 µl Sybrgreen 
(Invitrogen), 13.7 µl dH2O (Sigma), 0.1 µl Taq polymerase (GoTaq, Promega), 5 µl GoTaq 
buffer (Promega), 2.5 µl MgCl2 (Promega), 0.5 µl 10mM dNTPs (Promega) and 0.25 µl of 
each 10 mM forward and reverse primers.  22.5 µl of the master-mix was added to 2.5 
µl cDNA in a 96-well plate (Applied Biosystems).  Wells were mixed by careful pipetting.  
The plate was sealed and the experiment run on a RealTime PCR machine running 
StepOne software (Applied Biosystems) using the following protocol:  Initial 
denaturation - 95°C 10 minutes, Denaturation - 45 cycles at 95°C for 15 s and Annealing 
- 60°C for 1 minute.  The software generated a melt curve which was analysed to 
confirm single peaks - indicating single product, and no peak, in empty controls, to 
confirm the lack of contamination. 
 
2.9.3.1 qPCR Data Analysis 
 Data generated by qPCR was analysed by relative quantitation, i.e. target gene 
expression is compared with internal control gene expression in order to normalise for 
input and efficiency variations, and a reference sample.  Expression levels of target 
gene, c-FLIP, were normalised to the endogenous control in order to obtain data 
displaying the change in expression.  Expression change was expressed relative to 1, 
thus, a value above 1 indicated an increase in expression, 0 indicated no change and 
below 1 showed a decrease in expression. 
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2.10 Data Analysis 
 Graphs are displayed with error bars (where applicable) representing standard 
error of the mean values Statistical significance was determined using the Student’s t-
test.  Box plots were constructed in Graph Pad Prism 6. T-tests were performed 
between samples and were performed on sample sizes of n ≥ 3. Statistically significant 
differences were set at p-value <0.05.  The tests were performed using Excel 2010 
software. 
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Chapter 3: Modelling of c-FLIP and Associated Proteins 
 
3.1 Introduction  
 c-FLIP plays a key role in the resistance of several breast cancer cell lines to 
TRAIL induced apoptosis due to its homology, and therefore competition with, 
procaspase-8 for binding to FADD via its DED.  Many studies exist which evidence the 
contribution of c-FLIP to TRAIL resistance in both breast and other cancer types (Section 
1.2.2.6 and 1.3.3.1).  We have previously demonstrated an ability to sensitise resistant 
breast cancer cell lines to TRAIL using siRNA to knock-out c-FLIP, as well as 
demonstrating the elimination of tumourspheres in the same conditions (Piggott et al., 
2011).  To our knowledge, however, there are no reported direct inhibitors of c-FLIP, 
therefore, in this chapter we aimed to design small molecule inhibitors to c-FLIP in order 
to prevent its anti-apoptotic function by using in silico protein modelling and screening. 
 
3.1.1 Molecular Modelling 
 In silico modelling has become more common for understanding protein:protein 
interactions and is increasingly utilised in chemical research to study compounds and 
their potential interactions with proteins.  The ability to visualise protein interactions in 
3D, in simulated conditions of a cell or solute is an extremely useful tool for drug design.  
In particular, the use of protein:ligand docking has greatly enhanced and increased the 
efficiency of the process of target identification and lead optimisation, allowing 
researchers to virtually screen vast databases of compounds in a cost-efficient and high-
throughput manner.   
 With increasing computer processing power available even to non-specialists, 
medicinal chemists are able to design and screen potential drug candidates with 
increasing confidence and accuracy in silico, even taking into account protein-ligand 
dynamic simulations.  The growth in structure-based drug design is also greatly aided by 
the vast array of protein structures available through the Protein Data Bank (PDB). The 
PDB, a database of protein structures resolved by X-ray crystallography and nuclear 
magnetic resonance (NMR), has enabled a vast number of proteins to be studied in such 
a way, even if their own structure has not yet been resolved, by using homology 
modelling (Waszkowycz et al., 2011). 
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3.1.1.1 Homology Modelling  
 Homology modelling provides a vital tool for analysing proteins in silico when 
the X-ray or NMR structure has not yet been resolved (Nayeem et al., 2006).  The 
process of homology modelling relies on the fact that 3D, structural conformations of 
proteins are more highly conserved than basic amino acid sequence, and that 
alterations in this sequence usually result in relatively small alterations to the 3D 
structure (Lesk and Chothia, 1986).  A comparison, therefore, between the sequence of 
a resolved protein and an unresolved protein, provided they are at least 30% 
homologous can allow a model of the unresolved protein to be developed (Xiang, 2006).  
Essentially, a model is developed using several steps:  identification of a template 3D 
protein structure; alignment of this resolved protein with the unresolved target protein; 
model development of the target based on the 3D template and sequence alignment; 
and validation or refining of the model until a final model is constructed (Cavasotto and 
Phatak, 2009).  This process is used widely in protein modelling, since initial discussions 
for the use of structural biology in drug discovery began over 35 years ago, and is now 
fully recognised and used as a drug development system (Congreve et al., 2005).  Many 
successful small molecules have been selected as a result of homology modelling, as 
with the case of serine and cysteine protease inhibitors used as anti-parasitic agents, in 
addition to many other successful examples (Ring et al., 1993).  
 This study utilises the homology modelling algorithm in the drug discovery 
software Molecular Operating Environment (MOE) (Chemcorp) which involves several 
key steps:  the copying of any coordinates where residue identity between the two 
sequences is conserved; Boltzmann-weighted randomized sampling whereby the 
system runs different sections of the protein backbone with alternative side-chains; 
finally, model construction involves the creation of several independent models which 
are scored using a contact energy function.  The finalised model is usually the best 
intermediate model and is subjected to molecular dynamics to further optimise the 
system (Nayeem et al., 2006). 
 
3.1.1.2 Molecular Dynamics  
 Molecular dynamics usually follows molecular modelling and involves the 
computerised simulation of molecular interactions under set parameters following the 
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basic laws of physics.  The purpose of molecular dynamics is to simulate the movement 
of atoms over time and study the forces acting on these atoms in different conditions.  
A trajectory for the motion of each atom is calculated in addition to the overall force 
acting on each atom, as measured by a change in potential energy between two 
positions in order to best predict their behaviour in a solvent (Kitchen et al., 2004). 
 In this study we have used GROMACS (GROningen Machine for Chemical 
Simulations) software which is commonly used to perform molecular dynamics 
simulations using the concept of periodic boundary conditions.  It performs molecular 
dynamics essentially by putting atoms in virtual boxes, surrounded by solvents such as 
water, to solvate the protein in the model.  Energy minimisation and molecular 
dynamics are used to attempt to prevent or eliminate any clashes or breaks in hydrogen 
bonds.  Analysis is run alongside in order to monitor energy of the system and calculate 
the root mean square deviation (RMSD), i.e. the average distance between the atoms 
making up the backbone of the protein. These processes require a high level of 
computer processing power, i.e. a computer which is equipped with multiple central 
processing units (CPU) or graphics processing units (GPU) and can take several days to 
run to completion even in the most advanced systems. 
 
3.1.1.3 Virtual Screening: Structure Based Design 
 Virtual screening is a computational approach utilised to find chemical structures 
which exhibit certain properties, relevant to the specific system, i.e. in a drug discovery 
process, this entails searching a large database of chemical structures in order to detect 
compounds which would be suitable for binding to the target.   
 Two key approaches to virtual screening may be applied:  ligand-based and 
structure based.  Ligand-based screening is utilised when the target 3D structure is 
unknown and thus compounds are selected based on their similarity to the known 
ligand or compound which is known to bind the target.  Conversely, structure-based 
design requires the 3D structure of the target and involves screening and scoring, or 
ranking, multiple compounds for their ability to fit to a specific binding pocket on the 
target.  The ‘scores’ are calculated based on specific algorithms which take into account 
forces acting on the compound and the target, essentially predicting the affinity of the 
compound to the target (Hoelder et al., 2012).   
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 In this study we have used the docking function in MOE to perform virtual 
screening, which uses the 'London dG' scoring function to estimate binding affinity by 
estimating the free energy of binding of a ligand in a certain pose (Dal Ben et al., 2013). 
 As opposed to using multiple docking programmes to screen compounds, we 
screened compounds based on the 3D structures of both c-FLIP and procaspase-8.  
Essentially, compounds were selected which bound with best affinity, i.e. highest 
docking score in MOE on c-FLIP and, in parallel, had a relatively low score for binding to 
procaspase-8.  Visual evaluation and comparison of these compounds on the DED1 
pockets of c-FLIP and procaspase-8 was also performed in order to select which bound 
with best affinity to c-FLIP but were less able to bind to procaspase-8. 
3.1.1.4 Docking Software 
 In silico docking of small molecules to specific protein sites was established over 
30 years ago and has become a vital feature of computerised drug screening (Kitchen et 
al., 2004).  The process allows a prediction of the ligand conformation and orientation 
within the binding site of the target molecule by running algorithms which test multiple 
different ‘poses’ of the ligand within the site.  
 In this chapter we have successfully utilised in silico protein modelling and 
pharmacophore design to model the previously unmodelled structure of the DEDs of c-
FLIP, and the recently modelled DEDs of procaspase-8.  By constructing models of 
interaction with FADD, and pharmacophore design and virtual screening of a library of 
350,000 compounds, we have been able to identify 19 small molecules which are 
potential inhibitors to the c-FLIP DED1:FADD DED interaction. 
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3.2 Results 
3.2.1 Constructing Models of c-FLIP Structure and Interactions   
 In order to fully comprehend and model the interaction between c-FLIP and 
FADD, we performed a comprehensive review of literature on studies into relevant 
mutations available at the time (Section 1.3.7).  There is much contradicting information 
as to which DED on c-FLIP, DED1 or DED2, is most important for binding to FADD and 
thus inhibiting procaspase-8 binding and apoptosis induction.  At the time of this study, 
no mutational studies on the DED domain of mammalian c-FLIP long (or short) were 
available, thus a full review of procaspase-8 and FADD mutational studies was required 
in order to set up in silico interaction models.  In addition, once basic c-FLIP and 
procaspase-8 in silico models were constructed, analysis of the known intramolecular 
interactions that exist between DED1 and DED2 of c-FLIP and also of procaspase-8 was 
used in order to attempt to identify the important residues involved in the interactive 
surface between c-FLIP:FADD and procaspase-8:FADD. 
 Overall, the key FADD mutational studies suggested residues F25, K33, R34 and 
K35 of the FADD-DED are important for apoptosis induction and highlight the relevance 
of electrostatic forces in DED interactions.  It was with a full analysis of all of these 
studies that we chose to model our proteins based on the intramolecular interaction 
between DED1 and DED2 and, following this, between FADDs FL motif and the DED1 of 
c-FLIP or caspase-8, even though other potential sites of interaction are still feasible, 
and indeed, there may be multiple sites of interaction. 
  
3.2.1.1 In Silico Homology Models of c-FLIP and Procaspase-8 Death Effector Domains 
 At the time of this project, the crystal structures for the DEDs of c-FLIP and 
procaspase-8 had not been resolved and were therefore constructed based a 
comparative homology model in MOE. We wished to model both c-FLIP and procaspase-
8 in order to compare the structures of the two proteins, so that compounds could be 
selected based on their ability to bind preferentially to c-FLIP. 
 The protein MC159 (PDB ID: 2BBR), which has previously been analysed for 
modelling DED interactions (Carrington et al., 2006; Yang et al., 2005; Dickens et al., 
2012) was identified as the best protein for basing the construction of c-FLIP and 
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procaspases-8 homology models on, via running a sequence comparison search on MOE 
(Figure 3.1 A summarises the sequence comparison), and was thus used to build the 
DED structures of c-FLIP (Figure 1.2A) and caspase-8 (Figure 3.1B).    
 Our homology models demonstrated that the DEDs of highly homologous 
procaspase-8, which shares 71% sequence homology with c-FLIP (Goltsev et al., 1997), 
did indeed have a very similar 3D structure to c-FLIP, with approximately 22% structural 
homology.  The DEDs of c-FLIP and procaspase-8 both consist of 6 α helices and 5 anti-
parallel β-sheets, although some variations could be identified in the order of residues 
and orientations of the alpha-helices and beta-sheets which can be more clearly 
observed when later assessing the interaction models (Section 3.2.2).  According to our 
models, there was approximately 10% and 12% structural homology between DED1 and 
DED2 of c-FLIP and procaspase-8, respectively as per our model. 
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Figure 3.1: Construction of c-FLIP and procaspase-8 homology models 
A) DED Amino acid sequence comparison with FADD, procaspase-8, c-FLIP and MC159. 
Sequences have been aligned based on DEDs. Shared ‘FL’ sequence highlighed in yellow.  
Amino-acid sequences were obtained from Eberstadt, et al., 1998. Table adapted from 
Eberstadt et al., 1998. B-C) DED structures of B) c-FLIP and c) procaspase-8.  3D structures of the 
two DEDs (DED1 and DED2 from left to right) of A) c-FLIP and B) procaspase-8 modelled in silico 
using a sequence homology model with MC159. 
B                                                                                                                    
A 
C                                                                                                                   
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3.2.2 Generation of c-FLIP:FADD and Procaspase-8:FADD Complexes 
 The known strong, hydrophobic, intramolecular interactions between the 
internal 'FL motif' on DED1 and a pocket on the internal surface of DED2 of c-
FLIP/procaspase-8 (Dickens et al., 2012) were used to model the intermolecular 
interactions between these proteins, with the FL motif of DED2 binding to pocket on 
DED1.  This intermolecular interaction between procaspase-8 and c-FLIP (Figure 3.2A) 
was then used to analyse the c-FLIP:FADD and procaspase-8:FADD interactions.   
 Although there are many potential conformations of interaction, the FL 
(F25/L26) motif of FADD has been previously demonstrated to be important for 
procaspase-8 binding (Eberstadt et al., 1998; Kaufmann et al., 2002) and the recent 
model of DISC formation, which provides evidence that strongly suggests that the DISC 
consists of a 'chain' of procaspase-8 molecules binding each other via their DED1 pocket 
and exposed DED2 FL motif (F122/L123) (Dickens et al., 2012), amongst other FADD 
mutation studies mentioned in Section 1.3.7 meant the first important interaction we 
chose to model was that of c-FLIP/procaspase-8 DED1 with FADD, which involved the 
binding of FADDs external FL motif to a pocket on the surface of DED1 on c-FLIP (Figure 
3.2B) or procaspase-8 (Figure 3.2C).  All constructed models were fully energy 
minimised after molecular dynamics, as assessed using the RMSD energy plots in MOE. 
 Comparison of these surface models and of the ribbon models of c-FLIP and 
procaspase-8 interacting with FADD (Figure 3.2 D and E respectively) demonstrated the 
pocket on DED1 of c-FLIP to appear to form a more tightly fitting interaction with the FL-
motif of FADD than the pocket of DED1 present on the surface of procaspase-8. 
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Figure 3.2: Modelling c-FLIP key protein:protein interactions. 
Models were constructed based on the chain DISC model (Dickens et al.¸2012). A) Interaction 
between FL motif on procaspase-8 DED2 (orange) and c-FLIP DED1 pocket. B) Interaction 
between c-FLIP DED1 pocket and FL motif on DED of FADD (blue).  C) Interaction between 
procaspase-8 DED1 pocket and FL motif on DED of FADD (blue).  Surfaces shown represent 
electrostatic surface charge, negative in green, positive in pink.  D) Ribbon model of c-FLIP 
(orange) DED1:FADD (blue) interaction.  E) Ribbon model of procaspase-8 (red) DED:FADD (blue) 
interaction. 
 
 
 
 
 
 
 
 
 
 
 
 
D      E     
Chapter 3: Modelling c-FLIP & Associated Proteins 
 
 O A Hayward   97 
 
3.2.3 Generation of a Pharmacophore Model: Structure-Based Virtual 
Screening 
 The interactive surface and apparent pocket on c-FLIP when interacting with 
FADD was our target for inhibitors when setting up a pharmacophore model in MOE.  
We utilised a structure-based approach to perform virtual screening on the surface of c-
FLIP and by generating a pharmacophore model, the screening of compounds was made 
specific, as, only those which fit the pharmacophore model would gain high binding 
affinity scores, and therefore be identified as hits.  We set up the pharmacophore query 
using a collection of three-dimensional chemical features to represent the ligand's, i.e. 
the FL motif of FADD, interacting residues and set volume restrictions to limit the 
surface area of the compound binding site.  Compounds were then selected based on 
their ability to interact with c-FLIP in a similar manner to the FL-motif in the areas 
represented by these features, and therefore to compete with the FADD ligand for 
interaction with the residues in and around the designated area on the surface of c-FLIP 
DED1 (Figure 3.3A and B).  Four features were identified, and, of particular interest, 
residues around the ‘pocket’ on c-FLIP were identified to be important for the binding of 
FADD via the FL-motif (Figure 3.3C).   
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Figure 3.3: Characterisation of the DED1 c-FLIP:FADD binding pocket and 
Pharmacophore Model on Binding Surface. 
A) Pocket on surface of c-FLIP DED1 with residues displayed which were key in the FADD 
interaction.  B)  Zoomed view of c-FLIP:FADD interaction showing residues of importance on c-
FLIP DED1 (yellow) (FADD shown in red). C) Pharmacophore model used to filter the database of 
over 350000 small molecules for the virtual screening studies on the interactive surface of c-FLIP 
(red ribbon).  The model consists of 'features' (4 coloured spheres), i.e. areas of interaction of 
the FL-motif of FADD with c-FLIP DED1 which could be targeted by inhibitors.  Features are 
coloured based on their hydrogen acceptor/donor status (blue = aromatic acceptor, green = 
acceptor, purple = donor). Grey spheres represent carbon atoms on surface of c-FLIP. 
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3.2.4 Virtual selection of inhibitors to c-FLIP:FADD interaction 
 Our finalised pharmacophore model was used to screen a library of over 350,000 
commercially available compounds (Specs Database, Delft) in order to identify potential 
inhibitors to these sites.  Approximately 14000 ‘hits’ were identified which were able to 
satisfy the pharmacophore query by their ability to bind to at least 3 out of 4 of the 
features, which were then virtually ‘docked’ on c-FLIP.  Compounds were scored based 
on their ability to bind to the specific features on c-FLIP and after a further two docking 
refinement steps, we selected 2000 compounds with the highest score, i.e. ability to 
bind to the selected features, to analyse and re-run against caspase-8.  The compounds 
which had the lowest score for caspase-8 were of interest, since they would not bind to 
this protein with such affinity (Figure 3.4A).   
 We visually inspected the ‘top’ 100 scored compounds from c-FLIP and ‘bottom’ 
100 from caspase-8 for their ability to bind to the protein and thus to block the 
interaction with FADD (Figure 3.4 B and C).  For a compound to be selected, they 
needed to adhere to the criteria we had put in place: 
1. Compound must fill the pocket on c-FLIP 
2. Compound must not lie outside of the pocket on c-FLIP 
3. Compound must not clash within the protein structure 
4. Compound should not fill pocket on procaspase-8 
5. Compounds selected should be relatively varied in structure 
 Using these criteria, we selected a final 19 compounds using the combination of 
MOE docking scores and visual inspection of the compounds within pockets of c-FLIP 
and procaspase-8.  These compounds were chosen to include a range of chemical 
structures, with varying molecular weights and chemical properties, which were then 
purchased from Specs database (Table 3.1).  All compounds selected adhered to the 
Lipinski rule of 5 (Molecular weight <500, LogP <5 (lipophilicity), H donors <5, H 
acceptors<10 (Leeson, 2012).   
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Figure 3.4: Visual inspection of one of the 19 compounds within the pocket on c-FLIP 
DED1 
A) Summary of in silico user defined compound selection steps. B) Visual evaluation of around 
200 compounds on the FADD-interactive pocket on both c-FLIP and procaspase-8 was 
performed to select inhibitors which would be specific for the c-FLIP pocket.  Compound 
displayed is OH14. 
B 
A 
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Table 3.1 Structure of 19 Compounds Selected from In Silico Screening 
19 Selected compounds all adhered to the Lipinski rules and thus were all valid drug candidates. 
MW = molecular weight to 1 d.p. 
Cpd MW Formula Displayed 
OH1 269.3 C16H15NO3 
 
OH2 286.7 C16H11ClO3 
 
OH3 321.2 C16H10Cl2O3 
 
OH4 397.5 C19H25NO5S 
 
OH5 297.3 C17H15NO4 
 
OH6 342.4 C18H18N2O5 
 
OH7 299.3 C17H17NO4 
 
OH8 455.3 C16H10INO3S2 
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OH9 347.37 C21H17NO4 
 
OH10 278.31 C17H14N2O2 
 
OH11 354.38 C20H19FN2O3 
 
OH12 350.42 C21H22N2O3 
 
OH13 360.2 C18H11Cl2NO3 
 
OH14 360.22 C14H11Cl2NO4S 
 
OH15 382.43 C22H23FN2O3 
 
 Structure unavailable 
OH16 358.4 C17H18N4O3S 
 
OH17 416.3 C19H14BrNO3S 
 
OH18 317.4 
 
C17H19NO3S Structure unavailable 
OH19 309.3 C18H15NO4 Structure unavailable 
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3.4 Discussion 
 Previously we have demonstrated that genetic knock-out of c-FLIP using siRNA is 
an effective way to partially sensitise previously resistant bulk breast cancer cells to 
TRAIL and significantly enhance the sensitivity of breast CSCs, represented by 
tumourspheres (Piggott et al., 2011).  TRAIL itself is a highly cancer cell specific drug, as 
it is able to induce apoptosis in cancer cells whilst sparing the untransformed cells 
(Section 1.2.2.3), however, the fact that many breast cancer cell lines are resistant to 
TRAIL limits its potential as a therapeutic.  Our discovery that c-FLIP suppression is able 
to sensitise to TRAIL suggested that the combination of a small molecule c-FLIP 
inhibitor, in combination with TRAIL, could be a potentially very beneficial therapeutic.  
Currently there are no c-FLIP specific inhibitors available (Section 1.3.6), and, at the time 
of the project, no c-FLIP mutational studies published were able to elucidate any key 
residues which could be targeted by small inhibitors, thus, the aim of this project, and 
particularly of this chapter, was to identify potential small molecule inhibitors that are 
specific to c-FLIP, by the use of in silico protein modelling techniques.  The main 
potential hurdle in selecting a c-FLIP specific inhibitor is the reason it is a potent 
inhibitor of TRAIL induced apoptosis: its homology to procaspase-8, thus, modelling and 
inhibitor screening was performed on procaspase-8 in parallel with c-FLIP to try to avoid 
the unwanted and opposite effect of procaspase-8 inhibition. 
 At the time of this study, the crystal structure of c-FLIP or procaspase-8 had not 
been resolved.  In addition, no in silico models of the DED domains of c-FLIP had been 
generated, thus, this chapter aimed to generate, initially, an in silico model of the 
structure of the DED domains of c-FLIP.  Here, we first constructed these models in MOE 
based on a homology model using v-FLIP, MC159 as the template.  In addition, we 
constructed a model of the DEDs of procaspase-8, again based on a homology model 
using MC159 as the template.  Our models revealed that c-FLIP and procaspase-8 are 
indeed highly homologous proteins in both structure and sequence, showing 71% 
sequence homology in their DEDs, which is in accordance with an initial report also 
demonstrating 71% homology between the DEDs of c-FLIP and procaspase-8 (Goltsev et 
al., 1997). 
 Subsequently, the c-FLIP:FADD interaction, which had not yet been modelled, 
and procaspase-8:FADD interaction, which had recently been studied in silico (Dickens 
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et al., 2012), were modelled.  We constructed our initial model based around the 
intramolecular interactions that exist between DED1 and DED2 on both c-FLIP and 
procaspase-8 (Dickens et al., 2012).  Both models were constructed in MOE, with 
molecular dynamics being performed in order to further optimise the complex and 
validate the stability of the interaction models.  More recently, Majkut and team have 
used in silico modelling to analyse the c-FLIP:FADD DED interaction, also using MC159 to 
construct a homology model.  Their modelling looked at two potential orientations of 
the c-FLIP:FADD interaction  (Majkut et al, 2014).  Although we did recognise that there 
may be other potential conformations of the interaction, due to time constraints and 
the fact we were attempting to identify an inhibitor, we were only able to model and 
screen one interaction.  One of the models generated by Majkut et al., was, however, 
very similar to our model, with c-FLIP DED1 interacting with the FL-motif of FADD 
(Majkut et al., 2014).  Another recent study, by Hwang and colleagues has also modelled 
the c-FLIP:FADD interaction, although they based their model on DED2 of c-FLIP 
interacting with FADD and did not explore the DED1 interaction (Hwang et al., 2014). 
 We decided to target the interactive surface on DED1 of c-FLIP or procaspase-8 
for the generation of our pharmacophore model and structure based virtual screening, 
based on a thorough analysis of previous studies (Section 1.3.7).  Although both DED1 
and DED2 do appear to have an ability to interact with FADD, time constraints of the 
project restricted our focus to only one of the potential interactive conformations.  Our 
interaction model between c-FLIP and FADD was the basis of our virtual inhibitor 
screens, whereby we used the FL motif on the DED of FADD to generate a 
pharmacophore model and identify a panel of potential small molecule inhibitors 
against this interaction.  The models we constructed here revealed that there are some 
structural differences in the interactive surfaces on DED1 of c-FLIP and procapase-8.  
The 'pocket' present on c-FLIP appeared smaller, thus giving rise to a closer interaction 
with FADD, when compared with procaspase-8.  This suggested that an inhibitor 
targeted to this pocket would likely be specific for c-FLIP, due to its size and shape, thus 
sparing procaspase-8, allowing it to bind with FADD and induce apoptosis.  
 We then performed virtual compound screening on this model, using a library of 
over 350,000 commercially available compounds (Specs database, Delft, The 
Netherlands).  Only compounds that satisfied the pharmacophore query were then 
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docked on the surface of c-FLIP and scored based on their ability to bind to at least 3 
identified 'features', i.e. charged residue pockets, on the FADD interactive surface on 
DED1 of c-FLIP.  After several score-refining and compound-eliminating docking screens 
in MOE, 200 inhibitors were visually assessed for their ability to bind c-FLIP specifically.  
We hypothesised that, since c-FLIP and procaspase-8 are similar in structure, screening 
the same library of compounds on the procaspase-8, and then visually analysing those 
which did not score well for procaspase-8 would enable us to select more c-FLIP specific 
inhibitors.  Indeed, several compounds which gained high MOE docking scores, 
appeared to fit well into the pocket on procaspase-8 and so were eliminated as 
potential compounds.  Of the 200 compounds visually screened on both proteins, 19 
structurally diverse small molecule compounds were selected from the initial virtual 
library of over 350,000 compounds for their ability to bind to c-FLIP, preferentially over 
procaspase-8.   
 Using pharmacophore generation and virtual compound screening, a classical in 
silico pharmacological approach, here we have successfully identified a panel of 19 
potential commercially small molecule inhibitors which aim to target specific residues 
on DED1 of c-FLIP protein.  These inhibitors were tested in in vitro assays on breast 
cancer cells for their ability to sensitise previously resistant cells to TRAIL induced 
apoptosis (Chapter 4) and thus to block the c-FLIP:FADD interaction, whilst sparing the 
procaspase-8:FADD interaction (evaluated in Chapter 5).  
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Chapter 4: Evaluation of c-FLIP Small Molecule 
Inhibitors 
 
4.1 Introduction 
 Tumour heterogeneity, drug resistance and the existance of cancer stem cells 
each present distinct challenges to successful treatment of breast cancer and other 
types of cancer.  Indeed, cancer stem cells, themselves, are resistant to many types of 
cancer therapy, including chemo- and radiotherapy.  Agonists of the TRAIL receptor 
pathway have demonstrated an ability to induce apoptosis in cancerous cells, whilst 
sparing untransformed cells, making them highly desirable as cancer therapeutics (Gura, 
1997; Ashkenazi et al., 1999; Lemke et al., 2014).  We and others have previously 
demonstrated an ability to sensitise previously TRAIL-resistant breast cancer cells to 
TRAIL induced apoptosis via c-FLIP knockdown using siRNA (Piggott et al., 2011).   
 Our previous data, in addition to multiple other studies regarding the anti-
apoptotic role of c-FLIP, clearly highlight that a c-FLIP inhibitor could be an effective 
TRAIL sensitising agent and thus a viable combination therapy with TRAIL for treating 
TRAIL-resistant cancers, in particular, breast cancer, particularly due to the ability to 
target cancer stem-like cells (Lempke et al., 2014; Safa and Pollok., 2011; Piggott et al., 
2011).  Currently, however, although agents do exist which alter expression of c-FLIP 
these do not specifically target the protein, and, as such have off-target effects affecting 
other important pathways (Section 1.3.6), there are no c-FLIP specific inhibitors 
available.  The aim of this project, and in particular this chapter, was to evaluate the 
panel of small molecule inhibitors selected in Chapter 3, using a variety of relevant 
assays, for their ability to block c-FLIP and therefore sensitise to TRAIL.  The high degree 
of homology between procaspase-8 and c-FLIP is likely to be one of the key reasons a c-
FLIP small-molecule inhibitor has not yet been developed (Goltsev et al.¸1997; Safa and 
Pollok, 2011).  In chapter 3 we selected several potential inhibitors using in silico protein 
modelling and compound screening, including the issue of cross-reactivity in the 
experimental design. 
 Previous use of siRNA results in a 20% decrease in overall cell viability and a 
100% decrease in tumoursphere formation potential following TRAIL treatment (Piggott 
et al., 2011).  These cell viability data would be adopted as a benchmark for the efficacy 
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of the putative pharmacological c-FLIP inhibitors identified in Chapter 3.  Furthermore, 
the ideal inhibitor, when tested in vitro would be: effective in many cell lines; specific; 
non-toxic to untransformed cells; active at low concentrations; exert metabolic stability; 
and be soluble in multiple solvents.   
 Here we compare the relative ability of the 19 selected compounds identified 
from the in silico screen to sensitize breast cancer cells, and breast cancer stem cells, to 
TRAIL.  These experiments lead to the identification of a single lead compound, OH14, 
which exhibited the best efficacy while also satisfactorily fulfilling the additional 
parameters described above. 
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4.2 Results 
 
4.2.1 Solubility of the compounds in cell culture media 
 Solubility is one of the most important parameters involved in achieving the 
desired concentration of drug in systemic circulation when in a clinical setting.  It 
therefore follows that initial drug evaluation must pay attention to the ability of the 
compounds to dissolve in solutions, as this may otherwise be a barrier to treatment 
further along the timeline of drug development.  In fact, over 40% of new chemical 
entities developed in the pharmaceutical industry are almost completely insoluble in 
water (Savjani et al., 2012). 
 The solubility of the compounds was determined in the culture media used in 
the cell viability assays.  Dimethyl sulphoxide (DMSO) was selected as the solvent to 
prepare our stock solutions due to the fact that it is a commonly utilised agent, which is 
able to dissolve both polar and nonpolar compounds, whilst remaining miscible in 
organic solvents, such as water.  Whilst many of the compounds were soluble in DMSO 
at 100 mM stock solution and remained in solution when further diluted in cell culture 
media, some were only soluble when made up to 50 mM, and others were seen to 
come out of solution once diluted in aqueous soluation after overnight incubation in cell 
assay conditions (Figure 4.1 and Table 4.1).  
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Figure 4.1: Compound Visual Solubility Assessment. 
Representative images of compounds which did not remain in solution in media after overnight 
solubility assessment. A) 0.1% DMSO (highest concentration) alone.  B) Compound OH12 in 
media at 100 µM C) Compound OH15 in media at 100 µM D) Compound OH15 in media at 10 
µM. Scale bar = 100 µm. 
 
 
Table 4.1: Solubility of Initial 19 Compounds in Media.  
Visual assessment of compound solubility in DMSO (initial stock made at 100 mM) or after 
overnight incubation in media at a range of concentrations (100 µM, 10 µM, 1 µM, 0.1 µM, 0.01 
µM). Concentration at which compound was observed to be soluble is shown. 
Compound Stock: DMSO (mM) Working: Aqueous Media (µM) 
OH1 50 0.1
OH2 100 1 
OH3 50 0.1 
OH4 50  10 
OH5 100  100  
OH6 100  100  
OH7 100  10 
OH8 100  100 
OH9 100  100  
OH10 50  100  
OH11 50  1 
OH12 100  1 
OH13 100  100 
OH14 100  100  
OH15 100  1 
OH16 50  100 
OH17 100  100 
OH18 100  1 
OH19 100  100 
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4.2.2 Inhibitors of c-FLIP demonstrate an ability to sensitise to TRAIL in Breast 
Cancer cell lines 
 Initially, compounds were tested on their ability to sensitise the bulk population 
of the cell lines MCF-7 and BT474 to TRAIL using the Cell Titre Blue viability assay.  These 
cell lines were chosen due to their TRAIL-resistance, previously confirmed sensitivity to 
c-FLIP siRNA and TRAIL in multiple assays (Piggott et al., 2011), and for the equal 
expression of c-FLIP between these cell lines (French et al., 2015 in press). The Cell Titre 
Blue assay was chosen since it had been previously successful in demonstrating the 
ability of c-FLIP siRNA to sensitise to TRAIL (Piggott et al., 2011), in combination with the 
fact that it is a high-throughput assay which is beneficial for testing multiple compounds 
at a range of concentrations. 
 
4.2.2.1 c-FLIP Inhibitors Sensitise TRAIL-resistant MCF-7 Bulk Cells to TRAIL  
 The adherent bulk population of MCF-7 cells are TRAIL-resistant (Rahman et al., 
2009; Piggott et al., 2011).  Knocking-down c-FLIP with siRNA in these cells caused 10% 
reduction in viability and, when treated with TRAIL, this increased to 30% (Piggott et al., 
2011).  We hypothesised that similar relative levels of cell death would be obtained with 
an efficient c-FLIP specific small molecule inhibitor.  Compounds which demonstrated 
this synergistic effect with TRAIL, at several concentrations, with no solubility issues 
were of most interest for further investigation. 
 For viability evaluation, compounds (or vehicle control) were added to bulk cells 
at 70% confluence and left for one hour before the addition of 20 ng/ml TRAIL.  After 18 
hours, viability was measured using the Cell Titre Blue assay.   
 Eight of the 19 inhibitors selected demonstrated an ability to significantly 
sensitise MCF-7 cells to TRAIL (p-value<0.05) at more than 2 concentrations of 
compound, whilst causing no change in viability when administered alone, in at least 
two of these concentrations (Figure 4.2 A, C, L, N, O, P, R, S).  The TRAIL-sensitisation of 
these compounds was at a similar level, approximately 20%, to that previously observed 
using siRNA c-FLIP (Piggott et al., 2011).  These compounds were therefore of most 
interest due to their efficacy at multiple concentrations, in combination with their lack 
of significant cytotoxicity, thus demonstrating a seemingly synergistic effect.  Although 
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an additional compound increased TRAIL sensitivity at more than 2 concentrations, it 
also exhibited general cytotoxicity at several molarities (Figure 4.2Q) 
 Four of the compounds were able to significantly sensitise to TRAIL at two of the 
five concentrations evaluated yet there was no correlation with dose of agent as they 
exhibited a low therapeutic index (Figure 4.2 B, E, M, G) and thus were of less interest.  
Four compounds evaluated showed no significant ability to sensitise to TRAIL in this cell 
line (Figure 4.2 D, F, H, I).  Furthermore, two compounds, OH10 and OH11, exhibited the 
opposite effect to our hypothesis and in fact increased viability when treated in 
combination with TRAIL (Figure 4.2 J and K).  Compounds OH10 and OH11 were 
therefore discounted for any further evaluation studies. 
 Three compounds increased cell number at several concentrations tested (Figure 
4.2 I, J, L), whereas others (Figure 4.2 B, C, H, K) were cytotoxic at several 
concentrations, and caused reductions in viability to below 50%, thus, any TRAIL 
sensitisation obtained in these cases was additive, rather than synergistic.  It is possible 
on the basis of molecular homology that one or more of these cytotoxic agents could 
represent specific inhibitors of caspase-8. 
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Figure 4.2: Initial viability dose response of OH1-OH19 inhibitor panel on the bulk 
population of TRAIL resistant MCF-7 cells. 
MCF-7 cells were treated in adherent conditions at 70% confluence with a dose range of 
inhibitor or vehicle control for one hour, before the addition of 20 ng/ml TRAIL (or vehicle 
control) for 18 hours.  Cell Titre blue was then performed to assay for cell viability. Results 
represent 3 experiments with 4 wells per condition per experiment. Blue and red dashed lines 
(~90 and 70% respectively) represent the effect of c-FLIP knock out by siRNA and the 
combination of c-FLIP siRNA with TRAIL treatment respectively (Piggott et al., 2011). *=p-
value<0.05, t-test TRAIL vs compound plus TRAIL.   Control of media alone and compound within 
media were included. 
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4.2.2.2 c-FLIP Inhibitors Sensitise TRAIL-resistant BT474 Bulk Cells to TRAIL  
 BT474 cells, which are a TRAIL-resistant HER2+ve, ER+ve, PR-ve cell line were 
treated with 14 of the 19 initial inhibitors.  Compounds 10, 11, 15, 17 and 18 were not 
included for analysis on this cell line due to their lack of efficacy and large flucuations in 
response, or alterations to cell viability when administerd alone on MCF-7 cells (Figure 
4.2), in addition to their lack of solubility in DMSO (Table 4.1).   
 As before, compounds (or vehicle control) were added to bulk cells at 70% 
confluence and left for one hour before the addition of 20 ng/ml TRAIL.  After 18 hours, 
viability was measured using the Cell Titre Blue assay.  The compounds performed in a 
similar manner on the bulk population of BT474 cells compared with the MCF-7 cell line 
(Figure 4.3), with some showing a synergistic ability to sensitise to TRAIL, and others 
demonstrating no effect.  Overall, the effect of the combination therapy was reduced in 
BT474 cells compared to MCF-7 cells.  
 Six compounds significantly sensitised to TRAIL at more than two concentrations 
tested, with little or no effects on viability alone at at least two of these concentrations 
(Figure 4.3 A, B, D, F, M, L).  One additional compound exhibited a modest ability to 
sensitise to TRAIL, with efficacy only demonstrated at two concentrations (Figure 4.3N).  
Two compounds showed significant abililty to sensitise to TRAIL, yet also had alterations 
to cell viability when administered alone, thus likely demonstrating a potential lack of 
specificity and therefore, off-target effects (Figure 4.3 E, G). Three compounds were 
cytotoxic at 100 µM (Figure 4.3 B, C, H), whilst one compound demonstrated no effects 
alone or in combination with TRAIL (Figure 4.3 I).  Two compounds increased viability in 
combination with TRAIL at several concentrations tested and had little ability to 
increase TRAIL sensitivity (Figure 4.3 J, K). 
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Figure 4.3: Initial dose response of 'OH' inhibitor compound panel on the bulk 
population of TRAIL resistant BT474 cells.  
BT474 cells were treated in adherent conditions at 70% confluence with a dose range of 
inhibitor or vehicle control for one hour, before the addition of 20 ng/ml TRAIL (or vehicle 
control) for 18 hours.  Cell Titre blue was then performed to assay for cell viability. Results 
represent 2 experiments with 4 wells per condition. Blue and red dashed lines (~90 and 50% 
respectively) represent the effect of c-FLIP knock out by siRNA and the combination of c-FLIP 
siRNA with TRAIL treatment respectively (Piggott et al., 2011).  *=p-value<0.05, t-test TRAIL vs 
compound plus TRAIL.   Control of media alone and compound within media were included. 
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4.2.2.3 c-FLIP Inhibitor Bulk Cell Summary and Lead Compound Selection  
 To confirm the compounds which had the greatest ability to sensitise to TRAIL 
and thus select several potential lead compounds for analysis in additional assays, we 
organised the data by selecting the lowest concentration at which a significant TRAIL-
sensitising effect was observed and plotted these on one graph.  By this means of 
analysis, we can see more clearly that, in the MCF-7 bulk population, OH14 decreased 
viability by the greatest amount, at a low concentration (Figure 4.4A) and as such, in 
addition to the fact that there were no solubility issues and the effect appeared 
synergistic rather than additive, is the lead compound from this assay in MCF-7 cells.  
Although the effect of OH14 is reduced in BT474 cells, it still remained active at a low 
concentration (Figure 4.4B).  These results, with the lack of observed toxicity and 
solubility issues deemed OH14 as our first lead compound to be analysed in further 
assays. 
 Compound OH19 also showed activity at a low concentration in MCF-7 cells, 
significantly sensitising to TRAIL in a seemingly synergistic manner by 30%.  The activity 
of OH19 was diminished in BT474 cells by comparison, with only a modest sensitisation 
observed at 100 nM.  However, since no solubility or toxicity issues were seen with this 
compound, and the due to its effect in MCF-7 cells, which represent around 60% of 
clinical patients, we decided to include OH19 as a secondary lead compound for further 
analysis. 
 OH16 showed TRAIL-sensitisation efficacy in both the MCF-7 and BT474 cell lines 
which appeared partially synergistic, as a modest reduction in viability was seen with 
compound alone at some concentrations.  Although OH16 performed best at 100 µM in 
MCF-7 cells, its effect, although modest, was in fact best at the lowest concentration, of 
10 nM in BT474 cells.  The abilty of the compound to sensitise to TRAIL at a range of 
concentrations in both cell lines, in addition to the lack of toxicity and solubility issues 
led OH16 to be selected as our third lead compound for the next assay. 
 Other compounds which appeared nearest to the top left of the summary 
efficacy plots, such as OH8 on BT474 cells and OH1 on MCF-7 cells, were discounted as 
lead compounds at this stage based on their large alterations to cell viability when 
administerd alone, low efficacy over several concentrations (i.e. only affective at two or 
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less concentations), or the solubility issues observed at several concentrations 
previously (Table 4.2).   
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Figure 4.4: Summary of 'OH' compounds on the ability to sensitise MCF-7 and BT474 
bulk cells to TRAIL. 
The data from A) Figures 4.2 (MCF-7) and B) 4.3 (BT474) is re-presented to compare the lowest 
concentration at which a significant TRAIL-sensitisation was observed.  The concentration of 
each c-FLIP inhibitor that gave a significant (p-value<0.05) decrease in cell viability, compared 
with TRAIL, is plotted as a percentage compared to experimental agent alone.  On this graph, 
compounds that appear nearest to the top left of the plot exhibit greatest efficacy. 
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Table 4.2: Initial Lead Compound selection. 
Soluble:  = Insoluble at more than two concentrations in aqueous media or initial DMSO.   
Viability:  = no deviation below c-FLIP siRNA (blue line ~90%) or above 100%.   
Efficacy:  = significant TRAIL sensitisation at more than two concentrations, with at least one 
of these concentrations altering viability alone. NA indicates untested compound 
Compound Soluble Viability 
MCF-7  
Viability 
BT474  
Efficacy 
MCF-7  
Efficacy 
BT474  
1      
2      
3      
4      
5      
6      
7      
8      
9      
10   NA  NA 
11   NA  NA 
12      
13      
14      
15   NA  NA 
16      
17   NA  NA 
18   NA  NA 
19      
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4.2.3 Small Molecule Inhibitors of c-FLIP Increase Sensitivity of Breast CSCs to 
TRAIL 
 Our observations that some of the initial 19 inhibitors did indeed show an ability 
to at least partially sensitise the bulk cell population of two previously resistant cell lines 
to TRAIL, in effect, representing a phenocopy of the results obtained using siRNA c-FLIP, 
led to the desire to explore their effect on assays representing different aspects of 
breast cancer development and progression.  The most profound in vitro effect of c-FLIP 
siRNA in combination with TRAIL treatment was observed when cells were analysed in 
the tumoursphere assay, which assesses properties of CSCs (Section 1.1.7.3).  We 
observed that knocking down c-FLIP using siRNA, in adherent conditions, and treating 
with TRAIL prevented several breast cancer cell lines from being able to form 
tumourspheres (Piggott et al., 2011).  In the same study, it was shown that suppression 
of c-FLIP alone had little effect on tumoursphere size, formation, or number whilst 
TRAIL treatment alone exhibited a modest effect on the morphology and number of 
spheres in MDA-MB-231 and MCF-7.  We therefore hypothesised that a similar effect on 
tumoursphere size and number would be obtained using small molecule inhibitors of c-
FLIP in combination with TRAIL.  Due to the complexity of the assay, only the three lead 
compounds, OH14, OH16 and OH19, selected previously based on MCF-7 and BT474 cell 
viability assays (Section 4.2.2.3), were chosen to be assessed.  MCF-7 cells were pre-
treated in adherent conditions, with one of the three lead inhibitors (or appropriate 
DMSO control), for one hour, after which TRAIL was added at 20 ng/ml and left for 18h, 
as previously described (Piggott et al., 2011). After 18 h, the remaining viable cells were 
subjected to the tumoursphere assay.   
 Two of the three lead compounds, OH14 and OH16, resulted in an increase in 
the sensitivity of MCF-7 tumoursphere forming cells to TRAIL (Figure 4.5A).  One of 
these, OH14, had no significant effect on tumoursphere formation when administered 
alone, but had a profound effect in increasing TRAIL sensitivity when administered in 
combination, within 90% of the level of c-FLIP siRNA when administered at 100 µM 
(Figure 4.5A).  Compound OH16 in combination with TRAIL demonstrated a significant 
decrease in tumoursphere number, compared with TRAIL alone, at both concentrations 
tested. An overall increase in tumoursphere number was observed with OH16 alone, 
however, at 10 µM. Similarly, OH19 demonstrated a significant increase in 
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tumourspheres at 10 µM, although this was only observed when administered to the 
cells in combination with TRAIL.  Only when cells were treated at 100 µM, did OH19 
demonstrate a significant ability to increase tumoursphere sensitivity to TRAIL. 
 When treating cells with a larger dose-range of OH14 or OH16 in combination 
with TRAIL, before plating into tumoursphere conditions, we observed OH14 to retain a 
significant ability to sensitise to TRAIL at all 3 concentrations tested.  OH16, however, 
gave inconsistent results at the 3 molarities tested.  At 100 and 1 µM, a significant 
TRAIL-sensitisation was observed, however, at 10 µM, no significant sensitisation was 
observed. 
 OH14 had no significant impact on tumoursphere morphology or number when 
administered alone, when compared with untreated or TRAIL treated cells (Figure 4.5C, 
D and E), only when treated in combination with TRAIL was there a significant impact of 
OH14 on tumourspheres (Figure 4.5F). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4: Evaluation of c-FLIP Small Molecule Inhibitors 
 
 O A Hayward   130 
 
                 
 
 
 
 
 
 
 
A 
B 
Chapter 4: Evaluation of c-FLIP Small Molecule Inhibitors 
 
 O A Hayward   131 
 
 
Figure 4.5: 3 Three Initial Inhibitors Demonstrate some Efficacy in Increasing 
Sensitivity of MCF-7 Tumoursphere Forming Cells to TRAIL. 
MCF-7 cells were cultured for 24 h in a 96 well plate, before being treated with vehicle control 
or compound for 1 h.  20 ng/ml TRAIL (or control) was added after 1 h and the cells were left for 
18 h.  The following day, cells were subjected to the tumoursphere assay, with no additional 
drug added.  A) One of 3 lead inhibitors (14, 16 and 19) at two concentrations alone and in 
combination with TRAIL.  B) OH14 or OH16 at a range of concentrations in combination with 20 
ng/ml TRAIL (no compound alone).  Results represent passage 1 of 3 replicates, with error bars 
displaying standard error of the mean.  * = p<0.05, t-test.  Representative images of 
tumourspheres from C) Vehicle control D) 100 µM OH14 E) 20 ng/ml TRAIL and F) 100 µM OH14 
plus 20 ng/ml TRAIL. Scale bar = 100 µm. 
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4.2.3.1 OH14 Sensitises Tumoursphere-Forming Cells to TRAIL in a Dose-Dependent 
Manner 
 The tumoursphere assay, in combination with the cell titre blue assay 
demonstrated that, of the three lead compounds, compound OH14 demonstrated the 
most significant and consistent ability to sensitise MCF-7 bulk cells and tumoursphere 
forming cells to TRAIL whilst having little effect when administered alone.   
 In order to fully establish the effect of this compound on increasing TRAIL 
sensitivity, a dose range was tested on the tumoursphere forming population of MCF-7 
cells.  Breast cancer cell lines contain a sub-population of around 3% of tumoursphere 
forming cells (Dontu et al., 2003).  The overall levels of spheres generated by the MCF-7 
cells used in the previous experiments (Section 4.2.3), around 6% were slightly above 
the average obtained in many of our other investigations.  Cell lines can vary between 
batches and laboratories, and repeating the experiment here with OH14, using a 
different batch of cells confirmed the initial result with OH14, but demonstrated a 
control tumoursphere potential more consistent with the norm.  
 OH14 significantly sensitised tumoursphere forming cells to TRAIL at a dose 
range of 100 µM to 100 nM (Figure 4.6A) which was particularly evident following 
passage of the primary tumourspheres (Figure 4.6B).  Confirming the initial OH14 test 
(Figure 4.5), tumoursphere forming cells were almost entirely eliminated by treatment 
with 100 µM OH14 in combination 20 ng/ml (Figure 4.6C).  In order to establish whether 
pre-treatment of adherent cells in bulk conditions was required for sensitising 
tumoursphere forming cells to TRAIL, we performed a treatment with OH14 after plating 
into anoikis conditions.  Under these conditions, OH14 exhibited a similar dose-
dependent ability to sensitise to TRAIL (Figure 4.6D). 
 Although the effects of the combination therapy on BT474 bulk cell viability 
were less significant than those observed in MCF-7 cells (Section 4.2.2.3), we have 
previously demonstrated siRNA mediated knockdown of c-FLIP acutely sensitised BT474 
tumourspheres to TRAIL (Piggott et al., 2011).  Thus, the lead compound was assessed 
for its ability to affect tumoursphere formation in this cell line (Figure 4.7).  OH14 
significantly sensitised to TRAIL at a dose range of 100 µM to 1 µM in a dose-dependent 
manner in both primary tumourspheres (Figure 4.7A) and after passaging, without the 
addition of fresh compound (Figure 4.6B). 
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Figure 4.6:  Compound OH14 significantly sensitises MCF-7 tumoursphere forming 
cells to TRAIL in a dose dependent manner. 
MCF-7 cells were cultured for 24 hours before being treated with a dose range of compound 
OH14 (or vehicle control) for 1 hour, followed by TRAIL (or vehicle control) treatment at 20 
ng/ml and 18 h incubation.  Cells were then subjected to the tumoursphere assay, with no 
additional drug added. A) Passage 1: MCF-7 dose dependent decrease in the ability of cells to 
form tumourspheres when treated with OH14 in combination with TRAIL. B)  Passage 2: MCF-7 
dose dependent decrease in the ability of cells to form tumourspheres when treated with OH14 
in combination with TRAIL. C) Representative images of MCF-7 tumourspheres under different 
treatment conditions. Scale bars = 100 µm. D) Passage 2 of MCF-7 tumourspheres treated after 
plating Passage 1 (in anoikis conditions) with vehicle control (DMSO) or a dose range of OH14 
alone or in combination with 20 ng/ml TRAIL.  Error bars represent 3 internal replicates. *=p-
value<0.05, t-test - TRAIL vs OH14 plus TRAIL. 
D 
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Figure 4.7:  Compound OH14 sensitises BT474 tumoursphere forming cells to TRAIL in 
a dose dependent manner.  
BT474 cells were cultured in adherent conditions for 24 hours before being treated with a dose 
range of OH14 (or vehicle control) for 1 hour, followed by TRAIL (or vehicle control) treatment 
at 20 ng/ml and 18 h incubation.  Cells were then subjected to the tumoursphere assay, with no 
additional drug added. A) Tumoursphere Assay Passage One: Treatment with 20 ng/ml TRAIL in 
combination with OH14 reduced significantly the number of primary tumourspheres formed in 
BT474 cells in a dose dependent manner (*=p-value< 0.05, t-test TRAIL vs OH14 + TRAIL) B) 
Tumoursphere Assay Passage 2: Treatment of primary spheres with 20 ng/ml TRAIL in 
combination with OH14 significantly reduced the number of secondary tumourspheres formed 
in BT474 cells in a dose dependent manner (*=p-value< 0.05, t-test TRAIL vs OH14 plus TRAIL).   
B 
A 
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4.2.4 TRAIL Sensitivity in Clonogenic Colony Forming Assay 
 The clonogenic assay, an assay established for over 50 years, is an additional in 
vitro assay which tests one of the functional characteristics of stem cells, that is, the 
ability to propogate colonies from single cells through an enhanced proliferative 
potential.  The assay is not as selective for CSCs as the tumoursphere assay, as 
demonstrated by the fact that between 10% and 70% of any given cell line population 
are able to form colonies, however, the assay is an informative accompaniment to the 
tumoursphere assay, which itself is partially restricted in that it only selects for stem-
like cells which exhibit the property of anoikis resistance, a property which is not an 
absolute requirement for all breast CSCs (Liu et al., 2013).  Essentially, the assay 
evaluates the ability of single cells plated at low density to form colonies of greater than 
32 cells (Grenman et al., 1989), thus having undergone five or more divisions, over a 
period of 10 days in adherent culture conditions (Harrison et al., 2013; Locke et al., 
2005) (Section 1.1.7.3).  The assay is often thought of as a progenitor or proliferation 
assay rather than a stem cell assay per se as it enables evaluation of the variabilities in 
replicative viability between cells treated in different conditions.  
 The overall TRAIL sensitivity of four relevant breast cancer cell lines, which 
represent different subtypes of the disease, was analysed using the CFA.  Cells were 
plated at a low density of 50 cells per square centimetre, allowed to attach, before 
being treated with TRAIL at 20 ng/ml.  Colonies were left to form for 10 days, after 
which, colonies of over 32 cells were counted. TRAIL was able to significantly reduce 
colony formation in the four breast cancer cell lines tested (Figure 4.8A and B), although 
it did not completely prevent the formation of colonies in any of these lines.   
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Figure 4.8: Colony Forming Cells are Sensitive to TRAIL 
Cells were seeded at 50 cells/ cm2 and treated with TRAIL at 20 ng/ml before being left for 10 
days to grow.  A) Representative images of colonies from 4 breast cancer cell lines. B) % Colony 
forming units in 4 cell lines. * = p<0.05, t-test between control and 20 ng/ml TRAIL treated 
colonies. Error bars represent standard error of the mean. 
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4.2.4.1 Compound  OH14 Increases TRAIL Sensitivity of Colony Forming Cells 
 Although we have demonstrated, in section 4.2.3.1, that our main TRAIL-
resistant cell line models are significantly TRAIL sensitive in the clonogenic assay, there 
was still a remaining population of cells, thus, we wished to establish whether we could 
further sensitise these cells to the effects of TRAIL.   
 To assay the ability of OH14 to target colony forming cells, we cultured MCF-7 
and BT474 at low density as in Section 4.2.4 and treated as before, with the addition of 
OH14 1 hour before treatment with TRAIL.  Our lead compound did indeed show an 
ability to significantly increase sensitivity to TRAIL and thus reduce ability of colony 
forming units to form in both MCF-7 and BT474 cell lines, to a similar level as that 
observed using the tumoursphere assay (Figure 4.9). TRAIL significantly reduced colony 
formation in both MCF-7 (A) and BT474 (C) cell lines (p<0.05), however, TRAIL sensitivity 
was significantly increased (p<0.05) by pre-treatment with OH14 at 100 µM, whilst the 
compound alone was found to be non-toxic.   
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Figure 4.9: Colony forming cells are TRAIL sensitive and can be further sensitised by 
treatment with OH14. 
A-B) MCF-7 and C-D) BT474 cell were plated at a low density of 50 cells per cm2 for the CFA 
assay. After cells had attached, 100 µM OH14 (or 0.1% DMSO vehicle control) was added for 1 h 
before the addition of 20 ng/ml TRAIL .  Results represent at least 3 independent experiments, 
with errors caluclated as standard error of the mean. *=p-value<0.05, t-test. 
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4.2.5 Compounds Appear Less effective in Triple Negative and HER2+ve Breast 
Cancer Cell Lines 
 Our initial assays were performed on the two luminal-like, TRAIL-resistant, ER+ve 
cell lines, MCF-7 and BT474.  Previous studies have demonstrated that breast cancer 
cells of a mesenchynmal-like phenotype, such as MDA-MB-231 cells, are TRAIL-sensitive 
(Rahman et al., 2009).  Indeed, our lab have previously demonstrated the triple negative 
cell line, MDA-MB-231 to be around 60% sensitive to TRAIL when assayed for cell 
viability in the bulk population (Piggott et al, 2011), while MDA-MB-231 tumoursphere 
populations were similarly sensitive (French et al., 2015 in press). We wished to 
evaluate whether these already TRAIL-sensitive bulk- and tumoursphere- forming cells 
could be further sensitised by treatment with OH14.   
 Although we have previously observed that MDA-MB-231 tumoursphere 
forming cells are partially TRAIL sensitive, to around 60% (French et al., 2015 in press), 
here, only in passage 2 was a modest TRAIL sensitivity evident (Figure 4.10B). Passage 1 
shows contradictory results to our previous observations, with OH14 in fact increasing 
tumoursphere number when combined with TRAIL (Figure 4.10A).  Upon passaging, 
however, which ultimately tests the key feature of CSCs; self-renewal, we did observe a 
modest TRAIL-sensitivity of MDA-MB-231 tumoursphere-forming cells, and observed 
that OH14 exhibited a modest yet significant (p<0.05) ability to further sensitise to 
TRAIL at 100 µM (Figure 4.10B). 
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Figure 4.10: OH14 has a modest ability to sensitise MDA-MB-231 Tumoursphere 
Forming Cells to TRAIL only after Passaging 
MDA-MB-231 Cells were treated in adherent conditions with vehicle control, OH14 at two 
concentrations and cells were left or treated with 20 ng/ml TRAIL after 1 h. 18 h later, cells were 
transferred to tumoursphere forming conditions.  A) Passage 1: Treatment with 20 ng/ml TRAIL 
in this case did not significantly reduce primary tumoursphere forming ability alone or 
combined with OH14.  B) Passage 2:  After passaging, a significant effect of TRAIL alone, and in 
combination with 100 µM OH14 could be observed (*=p<0.05, t-test).  Results represent three 
technical replicates with errors caluclated as standard error of the mean. 
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 The HER2 positive, SKBR3 cell line has been previously observed to be TRAIL 
resistant in both bulk cell and tumoursphere forming conditions (Piggott et al., 2011). 
Given that these cells are TRAIL resistant, we wished to evaluate whether OH14 could 
sensitise the tumoursphere forming and bulk cells to TRAIL.   
 Cells were treated in adherent conditions before being plated into the 
tumoursphere assay.  Passage 1 (Figure 4.11A) and 2 (Figure 4.11B) data demonstrated 
that indeed SKBR3 tumoursphere forming cells do not respond to TRAIL.  Initially, it 
appeared that OH14, at all concentrations tested, slightly increased the formation of 
primary tumourspheres (Figure 4.11 A), however, upon passaging and thus, when 
evaluating self-renewal, this was not the case.  Passage 2 tumorsphere forming cells had 
a modest response to OH14, with OH14 sensitising to TRAIL at the two highest 
concentrations, 100 µM and 10 µM, although this was only significant (p<0.05) at 10 
µM, where OH14 alone reduced sphere number, thus deeming the effect likely to be 
additive rather than synergistic.  At lower concentrations, the combination of OH14 and 
TRAIL resulted in a slight increase in spheres, as previously observed in passage 1, 
although this effect was not observed at 100 nM, where sphere number was reduced 
(although not significantly) in the combination-treated tumourspheres. 
 An additive TRAIL sensitising effect was observed when OH14 was evaluated 
using Cell Titre blue to measure cell viability of SKBR3 cells (Figure 4.11C). 
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Figure 4.11: OH14 does not Sensitise SKBR3 Bulk or Tumoursphere Forming Cells to 
TRAIL 
SKBR3 cells were treated with OH14 at several concentrations, with or without TRAIL at 20ng/ml 
and left for 18 h before being transferred to tumoursphere condition (A & B) or assayed for cell 
viability (C). Tumourspheres were counted after 7 days (A) or passaged and cultured for a 
further 7 days (B) to determine self-renewal capacity.  Viability of the initial treated adherent 
cell population was measured using Cell Titre blue viability assay (C). Data represent three 
technical replicates, with error presented as the standard error of the mean. *=p<0.05, t-test 
TRAIL vs OH14 plus TRAIL. 
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4.2.6 Repeated Treatment with OH14 Slows Proliferation but does not 
Significantly Reduce Viability 
 The data above lead us to conclude that OH14 was the most efficacious c-FLIP 
inhibitor, which exhibited the least non-specific toxicity.  It was therefore considered 
our primary pre-clinical lead compound. 
 In order to determine the long-term effects of OH14 on cell viability, we set up a 
7 day daily treatment experiment with OH14 at 100 µM, with two different cell 
confluences of MCF-7 cells, in order to ensure full cell confluence was not reached at 
too early a stage in the experiment.  After 3 days of treatment, no significant difference 
was observed between OH14 and vehicle control (DMSO) treated cells at either cell 
density, this suggested that the cells proliferated at the same rate (Figure 4.12A, Day 1).  
By day 4, however, the proliferation rate of cells treated with OH14 appeared lower 
than those treated with control at both cell densities (Figure 4.12A, Day 4).   At 7 days, a 
significant visual difference was observed, where untreated cells had formed a fully 
confluent monolayer, in contrast with OH14 treated cells which appeared to be around 
70 and 80% confluent for 25000 and 50000 cells respectively (Figure 4.12A, Day 7).  No 
significant decrease in viability was detected using the Cell Titre Blue assay (Figure 
4.12B), although, this may have been due to the fact that the untreated cell population 
had reached 100% confluence and had become partially quiescent.  
 Cells from Day 7 of this experiment were plated into tumoursphere assay 
conditions to evaluate the effect of repeated treatment on stem and progenitor like 
cells.  Prolonged treatment of MCF-7 cells in adherent culture conditions with OH14 at 
100 µM slightly, but significantly, reduced tumoursphere forming ability (Figure 4.13A).  
In contrast, however, when untreated cells (i.e. those which had recieved daily 
treatment with DMSO vehicle control) were plated into the same conditions, and 100 
µM OH14 was added when cells were plated out, no significant effect on tumoursphere 
forming ability was observed (Figure 4.13 B).  OH14 appeared only to impare 
tumoursphere formation when a long term treatment had been performed on the bulk 
population, thus, this observation, in combination with the fact that overall cell viability 
was not significantly reduced, suggested that OH14 alone either affected cell viability 
more gradually than the rapid TRAIL mediated activation of apoptosis, or that cells 
underwent a delayed stochastic apoptosis in response to the single agent.   
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Figure 4.12: Daily Treatment with OH14 Slows Proliferation but does not Significantly 
Reduce Viability 
MCF-7 cells were plated at two different cell densities (25000 cells per well and 50000 cells per 
well) in a 6 well plate.  Media was refreshed daily with either 0.1% DMSO (vehicle control) or 
100 µM OH14. A) Cells were assessed daily under microscope.  Scale bar = 100 µM.  B) Cell titre 
blue viability assay was performed after the 7 day daily treatment regime (assay was performed 
on one well of a 6 well plate per condition). 
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Figure 4.13: 7 Day Daily Treatment with OH14 Partially Reduces Tumoursphere 
Forming Ability 
A) Two cell densitites of MCF-7 cells which had been subjected to 7 days daily treatment with 
OH14 at 100 µM or 0.1% DMSO vehicle control were plated into tumoursphere conditions and 
left for 7 days before tumourspheres were counted. 7 day treatment with OH14 significantly 
reduced tumoursphere-forming cells at both cell densities (*=p-value<0.05, t-test between 
untreated and OH14 (blue) or TRAIL and OH14 + TRAIL (red). B) Cell density 50000 cells which 
had not previously been subjected to the 7 day OH14 treatment were subjected to 
tumoursphere conditions and either 0.1% DMSO or 100 µM OH14 was added at the beginning 
of the assay, before being left for 7 days and tumourspheres counted. Errors caluclated as 
standard error of the mean 
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4.2.7 Lead Compound OH14 is Non-Toxic to Non-Tumourgenic Cells 
 Part of the interest in TRAIL as a therapeutic is its ability to target cancer cells 
specifically, leaving non-cancerous cells viable.  This is a desirable attribute for any novel 
cancer therapeutic and we wished to determine if this was also true for OH14.   
 To determine the cytotoxicity of OH14 on non-tumourgenic cells, we evaluated 
the compound using the Cell Titre Blue viability assay on MCF-10A cells.  MCF-10A cells 
were derived from mammary tissue of a 36 year old healthy woman and have been 
cultured as immortalised but non-tumourgenic mammary epithelial cell line, and 
exhibits a stable karyotype (Soule et al., 1990).  These cells have few genetic alterations 
which are common in cultured breast epithelial cells, express normal p53 (Merlo et al., 
1995) and are ultimately used to represent non-tumourgenic mammary epithelial cells.   
 The lead compound, OH14, was assessed at a range of concentrations for its 
toxicity on the bulk population of MCF-10A cells, which show modest TRAIL-sensitivity 
(Piggott et al., 2011), using the Cell Titre Blue viability assay over a 24 h period.  The 
combined effect of OH14 and TRAIL was also analysed, since the treatment regime 
would consist of both TRAIL and OH14, thus it is important to fully establish the effect of 
the combination treatment in this cell line.  Although a small, and non-significant, 
reduction in cell viability was seen, very little toxicity was observed in MCF-10A cells 
over this time period, with the IC50 value clearly not being reached even at the highest 
concentration of OH14 tested, 100 µM (Figure 4.16). There was a modest, yet significant 
reduction in viability when cells were treated with TRAIL in combination with OH14, 
however, viability did not fall below 80% at all concentrations tested, thus, although 
significant, this decrease does not suggest a high level of toxicity. 
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Figure 4.14:  Lead Compound OH 14 is Non-Toxic to Non-Tumourgenic MCF-10A Cells 
Alone but partially decrease viability in combination with TRAIL  
Nontransformed TRAIL resistant (Piggott et aI., 2011) human breast cell line MCF-10A cells 
cultured in adherent conditions and were treated at 70% confluence with vehicle control or 
OH14 at several concentrations for 1 h, before either adding 20 ng/ml or leaving with OH14 
alone for 18 h.  Cell viability was measured the next day using the CellTiter blue MTS assay of 
cell metabolism. *=p-value<0.05 between control and OH14 alone (blue) and TRAIL and OH14 + 
TRAIL (red). Results represent three individual experiments performed with four internal 
technical replicates with errors caluclated as standard error of the mean. 
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4.3 Discussion  
 In this chapter, we have used multiple in vitro assays to evaluate 19 small 
molecules, identified in Chapter 3, for their ability to sensitise TRAIL-resistant breast 
cancer cells and stem-like cells, to TRAIL.  Here, we identify several small molecules 
which demonstrate an ability to significantly sensitise the adherent, bulk population of 
TRAIL-resistant MCF-7 and BT474 cells to TRAIL.  The compounds analysed had varied 
effects, from no effect on TRAIL sensitivity; increasing sensitivity; or even decreasing 
sensitivity and increasing viability in some cases.  Several compounds, although able to 
sensitise to TRAIL at low concentrations, also significantly increased viability at high 
concentrations which may simply have been due to the fact that several of the 
compounds were not in solution and so particles were physically preventing cell 
proliferation.  Alternatively, however, it may be that the compounds were binding to 
the site of FADD interaction on procaspase-8, due to the homology between c-FLIP and 
procaspase-8, and thus causing the effect of caspase-8 inhibition, and therefore 
potentiating an anti-apoptotic effect.  Of the 19 small molecule inhibitors evaluated on 
MCF-7 and BT474 bulk cell viability, we selected 3 lead compounds OH14, OH16 and 
OH19, which demonstrated an ability to siginificantly sensitise TRAIL-resistant MCF-7 
and BT474 cells to TRAIL to a similar level as that obtained using siRNA targetted to c-
FLIP, whilst exhibiting little viability effects alone and demonstrating good solubility 
properties, to evaluate in the tumoursphere assay.   
 The most profound result obtained from our previous work on c-FLIP siRNA and 
TRAIL treatment was observed in the tumoursphere assay, where 100% of 
tumourspheres from 4 breast cancer cell lines tested were eliminated (Piggott et al, 
2011).  Here, we show that one of the three lead compounds, OH14, significantly 
reduced the tumorsphere-forming ability of cells from two TRAIL-resistant breast cancer 
cell lines at multiple concentrations, when administered in combination with TRAIL, 
whereas the other two initial lead inhibitors did not show such efficacy.  Almost a total 
elimination of tumoursphere-forming cells generated from both MCF-7 and BT474 cells 
was observed when treated with 100 µM OH14 in combination with TRAIL.   
 In addition, we have evaluated our compounds in the colony-forming assay - a 
proliferation or progenitor like assay.  Initially, we noted that MCF-7 and BT474 
colonies, which are TRAIL resistant in bulk and tumoursphere assays, were more 
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sensitive to TRAIL in these assay conditions.  Colonies are varied in size and morphology, 
thus, this increased sensitivity may be due to the specificity of TRAIL for more 
mesenchymal-like cells (Rahman et al., 2009).  Regardless of this, however, TRAIL-
sensitivity of BT474 and MCF-7 colonies was still significantly increased by treatment 
with our lead compound, OH14.  Since 50% of cells plated form colonies, the assay is 
not representative of the minority stem cell population in the same way as the 
tumoursphere assay.  However, this assay did provide further support to the cell 
viability and tumoursphere assays as the drug efficacy data follows a similar overal 
trend in each case. 
 The initial compound screens performed here were on two TRAIL-resistant 
ER+ve cell lines, as these were hypothesised to have the greatest response to our 
combination therapy, based on previous data, however, we explored the effects of our 
lead compound on two additional cell lines, which represent different subtypes of 
breast cancer.  c-FLIP has been associated with TRAIL resistance in HER2 +ve breast 
cancer (Zang et al., 2011) and we have previously shown the bulk and tumoursphere 
forming population of SKBR3 cells to be sensitive to siRNA c-FLIP suppression and TRAIL 
treatment (Piggott et al., 2011).  SKBR3 cells were not selected for high-throughput 
compound screening primarily due to the integrity of their tumoursphere-forming cells 
being sub-optimal, in addition to their reduced ability to form colonies in the CFA.  
When treated with OH14, primary SKBR3 tumourspheres were not sensitised to TRAIL, 
however, a modest, yet significant sensitisation was observed at 10 µM upon passaging.  
This sensitisation, however, was likely to be additive rather than synergistic since OH14 
itself reduced sphere number at this concentration.  Similarly, OH14 did sensitise SKBR3 
bulk cells, assessed using the viability assay, to TRAIL, although impacting on viability 
alone.  Previously, knocking out c-FLIP using siRNA reduced SKBR3 viability by around 
15%, whilst the combination led to a 45% increase in cell death (Piggott et al., 2011), 
thus, OH14 was unable to phenocopy siRNA to such an extent on these cells. 
  The bulk population of triple-negative breast cancers are mostly TRAIL sensitive 
(Rahman et al., 2009), thus, using a TN cell line in order to study our inhibitors would 
not have been optimal for the initial viability assay.  However, as we have observed here 
using the CFA, our inhibitors can further increase the sensitivity of TRAIL-sensitive cells 
and so it may be possible to further sensitise these cells, although our previous work 
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using c-FLIP siRNA did not further sensitise the bulk population of the TN cell line, MDA-
MB-231 to TRAIL (Piggott et al., 2011).  Previous work has, however, demonstrated the 
tumoursphere-forming population of this cell line to be highly sensitive to the 
combination of siRNA c-FLIP and TRAIL treatment (Piggott et al., 2011) and so it was 
hypothesised that we may obtain a similar result with our lead compound.  We did not 
observe a significant effect of OH14 on MDA-MB-231 primary tumoursphere forming 
cells, although, similar to SKBR3 tumoursphere-forming cells, a modest, yet significant 
effect was observed at 100 µM upon passaging.  Although we, and others, have shown 
that genetic suppression of c-FLIP can sensitise MDA-MB-231 and SKBR3 cells to TRAIL 
(Piggott et al., 2011; Zang et al., 2014), it may be that inhibition of the FADD-c-FLIP 
interaction using our inhibitors is not potent enough to exert this same effect.  
 One of the primary reasons that TRAIL is such a desirable therapeutic agent is 
the specificity it exhibits for targeting cancerous cells, whilst sparing non-cancerous 
cells, thus, retaining this lack of general cytotoxicity is an important feature of a TRAIL-
sensitising agent.  Since TRAIL resistance in these cells is thought to be largely due to 
the expression of decoy receptors, with anti-apoptotic proteins such as c-FLIP only 
playing a part when activated in combination with each other (Gura, 1997; Ashkenazi et 
al., 1999; Lemke et al., 2014; Griffith and Lynch, 1998) we hypothesised that our small 
molecule c-FLIP inhibitors would be non-toxic to these cells when administerd alone, in 
accordance with published data using siRNA to c-FLIP on these cells (Piggott et al., 
2011).  In accordance with this, we hypothesised that a partial induction of apoptosis 
may be observed when administered in combination with TRAIL, due to the potential 
role of anti-apoptotic proteins in normal cell TRAIL resistance, in additoin to our 
published observations of 20% increase in cell death using c-FLIP siRNA and TRAIL in 
MCF-10A cells (Piggott et al., 2011).  Here, we have demonstrated, using the non-
cancerous MCF-10A mammary cell line, that our lead compound was indeed not 
significantly toxic to this non-transformed cell line when administered alone.  We 
observed a modest increase in cell death when treated in combination with TRAIL, 
similar to the level we have previously observed using siRNA (Piggott et al, 2011).  To 
ascertain further information regarding the long-term cytotoxicity of OH14, we 
performed daily treatment on the bulk population of MCF-7 cells at 100 µM which 
demonstrated OH14 to be non-cytotoxic.  Treatment with OH14 did, however, slow 
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proliferation after 4 days which may be due to the role c-FLIP has on stem-like cells, that 
is, inhibiting c-FLIP may be preventing growth of progenitor or stem-like cells, which 
help maintain the cell population. This data is preliminary and these experiments will be 
repeated with the use of stable c-FLIP deficient cell line (using shRNA or TALEN, for 
example) aswell as a more efficacious analogue of OH14 in the future.   
 In conclusion, we have confirmed using several in vitro assays, that, of the 19 
compounds initially selected using in silico protein modelling in Chapter 3, we have 
successfully identifed one lead c-FLIP small molecule inhibitor, OH14, which shows an 
ability to significantly increase sensitivity of previously resistant breast cancer cells to 
TRAIL induced apoptosis in a number of different assays.  The following chapters 
explore the mechanism of action of our lead compound, OH14 (Chapter 5), in addition 
to analysing analogues of OH14 to provide initial structural activity information for 
future compound generation (Chapter 6).   
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Chapter 5: Exploring the Mechanism of Action of OH14 
 
5.1 Introduction 
 The design of our inhibitors, using molecular modelling, aimed to generate small 
molecules which enter and bind within a pocket on the surface of c-FLIP L DED1 in order 
to block its interaction with the FL motif of FADD.  Data presented in Chapter 4 
demonstrated that a proportion of the candidate inhibitors do indeed function as 
intended, by sensitising previously resistant or partially resistant breast cancer cells to 
TRAIL, in several different cell-based assays.  These cellular outcomes are consistent 
with the proposed mechanism of action of our inhibitors, however, it is important that 
this is confirmed in vitro by demonstrating that the interaction between FADD and c-
FLIP is indeed impaired.  
 Many important cellular processes are reliant on protein:protein interactions 
(PPIs) and thus pharmacological inhibition of these interactions are an attractive target 
of small molecule drug design.  Developing efficient pharmacological PPIs and indeed 
studying protein interactions in vitro can be quite a challenge, due to the dynamic 
nature of such processes, and despite the many potential techniques available, there 
are many drawbacks to each.  A full understanding of the mechanism of such inhibitors, 
i.e. proving their ability to interfere with their target interactions is vital in order to 
progress such therapeutics.  Through a collaboration with the Institute of Molecular 
Genetics, Prague, we had the opportunity to utilise FRET as a technique to study these 
interactions, through advice provided by Dr David Stanek.  Additionally, Dr Ladislav 
Andera provided expertise for us to attempt to use the technique of TALEN in order to 
attempt to generate a stable c-FLIP negative cell line which would be used for 
performing mutational studies on c-FLIP key residues.   
 In addition to exploring the mechanism of action of OH14, we wished to 
evaluate its effects on additional cell lines, as well as evaluating its potential effect in 
CSC plasticity, i.e. the ability for non-cancer-stem cells to reacquire stem-like properties.  
Clinically, CSC-plasticity is a process of high importance since it implies that, even if all 
CSCs were eliminated from a tumour, any remaining bulk cells would be able to de-
differentiate to a CSC-like state and thus, re-seed resulting in new tumour growth.  A 
clinical strategy involving a combination treatment which eliminates CSCs and prevents 
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plasticity is therefore a highly desirable way of eliminating a tumour and preventing 
relapse.  Studying plasticity in vitro is a complex task since observing an increase in CSCs 
alone does not demonstrate the process as it may be occurring by increased CSC self-
renewal.  It is necessary to eliminate all CSCs from a cell population before plasticity can 
be observed with some confidence.  Our recent demonstrations that TRAIL in 
combination with siRNA c-FLIP can eliminate tumoursphere-forming cells from a panel 
of breast cancer cell lines in vitro has provided us with a tool for studying plasticity 
(Piggott et al., 2011).  We have recently optimised an in vitro assay, using our previous 
findings, which can be used as an in vitro model of plasticity (French, R., PhD Thesis 
2014).  This assay relies on the fact that, although all tumoursphere-forming ability is 
eliminated after treatment with TRAIL in c-FLIP suppressed cells, some viable cells 
remain which are able to re-acquire tumoursphere-forming ability (Piggott et al., 2011).  
Using this optimised assay, we wished to analyse whether OH14 could impair CSC 
plasticity, which would enhance the clinical potential of this small molecule c-FLIP 
inhibitor. 
 
5.1.1 FRET Acceptor Photobleaching 
 Fluorescence or Förster, after the scientist who originally discovered FRET, 
Resonance Energy Transfer (FRET) is a distance-dependent transfer of energy between 
an electronically excited fluorophore to a second, non-excited fluorophore.  FRET 
efficiency depends on the donor and acceptor molecules being within 1-10 nm of one 
another and for the absorption spectrum of the acceptor to overlap with the emission 
spectrum of the donor (Jares-Erijman and Jovin, 2003).   
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Figure 5.1: Representation of the FRET spectral overlap requirement of donor and 
acceptor. 
Donor and acceptor emission and absorption spectra, respectively, must overlap in order to 
achieve successful FRET.  Acceptor photobleaching FRET involves loss of the acceptor (e.g. in 
this case, YFP) signal, and an increase in the donor (e.g. in this case, CFP) signal. 
 
 FRET can be measured using a variety of methodologies; sensitized emission (SE-
FRET); acceptor photobleach (AP-FRET); or fluorescence lifetime imaging (FLIM-FRET).  
AP-FRET, which is used in this study, is a method of measuring protein interactions using 
the exchange of energy between a donor and acceptor.  The intensity of the donor will 
be measured before and after irreversible eradication of the acceptor by ‘bleaching’ 
using a high intensity light source. (Figure 5.2)  Successful FRET interactions will prevent 
full emission of the donor, thus, the increase in donor intensity after acceptor bleaching 
demonstrates the presence of absence of FRET. 
 
Figure 5.2: Schematic of FRET Acceptor Photobleaching using CFP Donor and YFP 
Acceptor 
A) When donor is excited at its wavelength, in a case where donor and acceptor fluorophores 
are in close proximity, energy will be transferred from donor to acceptor which will cause the 
acceptor to emit. B) In this same case, if the acceptor is bleached by exciting at a very high laser 
power, the donor emissions will not be transferred and instead will be emitted as light.  In both 
cases, if acceptor and donor are not in close proximity, then no transfer of energy will occur 
between the two fluorophores and so all donor emissions will be detectable, regardless of 
whether the acceptor is bleached or not. 
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5.1.2 TALEN Gene Manipulation 
 In February 2011, Nature Biotechnology released two articles on targeted 
genomic modification using Transcription activator-like effector nucleases (TALENs) 
(Miller et al, 2011; Zhang et al., 2011).  TALENs have since been used to modify the 
endogenous genes present in a variety of species from viruses, plants and yeast to 
insects, frogs and mammals, including mice (Kim and Kim, 2014). 
 TALEN technology was utilised in this chapter in order to attempt to eliminate c-
FLIP from MCF-7 cells, and, ultimately generate a stable c-FLIP knock-out cell line, which 
we have not been able to successfully achieve using shRNA.  If generated, this cell line 
could then be utilised for overexpression studies using SDM to analyse the importance 
of residues on c-FLIP we have identified in Chapter 3.   
 In this chapter, we explore the mechanism of action of our lead compound, 
OH14. We analyse the interactions between c-FLIP, procaspase-8 and FADD in TRAIL-
sensitive and -resistant lines and demonstrate the ability of OH14 to interfere with the 
c-FLIP:FADD interaction.  TALEN technology was utilised in order to attempt to generate 
a c-FLIP knock-out cell line, however, this was not successful and requires further work.  
Therefore additional mutagenesis studies c-FLIP:FADD interactions were not achievable 
at this time.  We also explored the effect of our lead inhibitor on additional cell lines 
and on the CSC theory of plasticity, and demonstrated it to have potential therapeutic 
efficacy in targeting this important process. 
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5.2 Results 
5.2.1 Procaspase-8 Cleavage Increases Over Time after TRAIL Treatment  
 Co-immunoprecipitation (co-IP) and Western blot were optimised in order to 
evaluate the relevant protein:protein interactions and caspase-8 activity, represented 
by procaspase-8 cleavage in TRAIL resistant and sensitive cells.   In brief, optimisation 
involved evaluating differing pairs of antibodies against FADD and caspase-8 in order to 
achieve the best combination for use in co-IP. 
 Several groups have reported the presence of interactions between caspase-8 
and FADD in TRAIL sensitive cell lines, and the lack of this interaction in TRAIL resistant 
lines (Day et al., 2008; Dickens et al., 2012; Safa and Pollok, 2011).  We therefore 
wanted to establish whether this was the case in our cell lines.  The levels of cleaved 
caspase-8 (p43 and p18 C8) was initially evaluated upon treatment with TRAIL after 
varying treatment times.  Initial Western blot on TRAIL-sensitive MDA-MB-231s 
demonstrated an increase in the cleaved and therefore, active, forms of caspase-8 as 
the duration of TRAIL treatment increased up to 2 hours (Figure 5.3A).  In contrast, 
TRAIL-resistant MCF-7 cells exhibited a barely detectable level of cleaved caspase-8 at 2 
hours (Figure 5.3A).   This Western should ideally be repeated with replicate samples 
and higher concentrations of protein to confirm these findings, particularly, since 
GAPDH confirms that the gel was not equally loaded.  Comparing band intensity, by 
normalisation to GAPDH, confirmed however the increase in cleaved caspase-8 in MDA-
MB-231 cells, while no marked differences were observed in total protein levels of c-
FLIP or FADD between the MDA-MB-231 and MCF-7 cells.   
 After TRAIL-sensitive MDA-MB-231 cells were treated at time intervals with 100 
ng/ml TRAIL  no interaction between FADD and  c-FLIP was evident, as no c-FLIP band 
was present (Figure 5.3B).  Western blot confirmed an increase in the cleaved, p43/41 
and p18 forms of caspase-8 over the duration of 2 hours.  Additionally, FADD levels 
were confirmed to stay constant throughout the treatment duration.  An interaction 
between FADD and caspase-8 was observed, although the band was faint, whilst an 
increasing interaction with FADD and the p43/41 was observed over time 
demonstrating cleavage of the pro-form of caspase-8 (procaspase-8) to its active 
cleaved form, whilst in complex with FADD (Figure 5.3B).  Stable total levels of FADD 
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confirmed that this increase did not simply correlate with increasing protein levels of 
FADD.   
 In the future, this data needs to be compared in the TRAIL resistant MCF-7 cell 
line to establish if the immunoprecipitation of FADD and c-FLIP is achievable in resistant 
cells. 
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Figure 5.3: Caspase-8 Cleavage and Interaction with FADD Increases over Time in 
TRAIL Sensitive Cells. 
 A) Total protein extracts from MCF-7 and MDA-MB-231 cells, treated with 100 ng/ml TRAIL for 
the indicated timepoints, were probed for Caspase-8, FADD and c-FLIP protein levels. GAPDH is 
provided as loading control.  B) Total protein input prior to co-IP (C) was probed for caspase-8 
and FADD protein levels, with GAPDH as loading control. C) Total protein extracts from MDA-
MB-231 cells, treated with TRAIL, were immunoprecipitated with anti-FADD antibodies. 
Immunoprecipitates were blotted with antibodies to FADD, Caspase- 8 and c-FLIP. 
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5.2.3 TRAIL Increases Caspase-8 Activity in Sensitive Cell Lines 
 TRAIL acts by inducing apoptosis mediated by the extrinsic, caspase-8 pathway.  
In the bulk population of TRAIL resistant MCF-7 cells, this pathway is blocked by the 
action of c-FLIP (Safa and Pollok, 2011; Day et al., 2009; Piggott et al., 2011), and thus, 
little caspase-8 activity will be observed when cells are treated with TRAIL.  We 
therefore expected our lead compounds, which have demonstrable ability to sensitise 
to TRAIL, to cause an increase in caspase-8 activity when treated with TRAIL in these 
cells.  In addition, we have previously observed that TRAIL does exert an effect on the 
colony forming activity of TRAIL resistant MCF-7 cells (Section 4.2.4), which is consistent 
with a recent study from our laboratory (French et al., 2015 in press) thus, we wished to 
elucidate whether this occured through the normal pathway of TRAIL activity.   
 To determine caspase-8 activity in this assay, the enzymatic Caspase-Glo 8 assay 
(Promega) was used.  An initial evaluation of this assay was performed on the trail 
sensitive MDA-MB-231 cells compared with TRAIL resistant MCF-7 cells (Figure 5.4 A-D) 
in order to confirm that this would indeed be a suitable assay for compound evaluation.  
Bulk cells from a TRAIL-resistant (MCF-7) and TRAIL-sensitive (MDA-MB-231) cell line 
were treated with either 20 ng/ml or 100 ng/ml TRAIL and left for around 2 hours, 
allowing for a significant induction of caspase-8 activity as observed in previous studies 
(MacFarlane et al., 2000; Sharp et al., 2005).  Overall caspase-8 activity was higher in 
the TRAIL sensitive line, regardless of whether TRAIL had been added.  Upon treatment 
with TRAIL at 20 ng/ml, caspase-8 activity was not altered in the TRAIL-resistant MCF-7 
cells, however, a slight, although non-significant in this case, increase was observed in 
the TRAIL-sensitive line.  When the concentration of TRAIL was raised to 100 ng/ml, an 
increase was detected in MDA-MB-231 cells, although this was not significant, however, 
no increase in caspase-8 activity was observed in MCF-7 cells (Figure 5.4E). 
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Figure 5.4: Caspase-8 Activity Increases upon TRAIL addition in TRAIL sensitive Cell 
Lines 
Representative images of untreated A) TRAIL-resistant MCF-7 and C) TRAIL-sensitive MDA-MB-
231.  Representative images of 20 ng/ml TRAIL treatment for 18 h on B) MCF-7 and D) MDA-MB-
231. Scale bars = 100 µm.  E) TRAIL-sensitive MDA-MB-231  and TRAIL-resistant MCF-7 cells 
were plated in adherent conditions and left to attach overnight. After 24 h, vehicle control, 20 
ng/ml or 100 ng/ml TRAIL was added and cells were left for around 2 h to allow the induction of 
caspase-8.  Caspase-Glo 8 was performed according to manufacturers instructions and 
luminsecence was read using a plate reader.  Results represent 3 replicates. 
E 
Chapter 5: Exploring the MOA of OH14 
 
 O A Hayward   163 
 
5.2.3 c-FLIP Inhibitors Increase Caspase-8 Activity upon TRAIL Treatment 
 To evaluate the effect of our 3 initial compounds, OH14, 16 and 19 on caspase-8 
activity in the bulk population of TRAIL resistant MCF-7 cells, we used caspase-glo 8 
luminescence assay. The compounds alone did not significantly effect caspase-8 activity, 
when treated in combination with TRAIL, however, a significant increase in caspase-8 
activity was observed (Figure 5.5A). This suggested our compounds are indeed specific 
in their ability to sensitise to TRAIL via the extrinsic, caspase-mediated pathway of 
apoptosis.  One other compound was selected (OH12) which we previously observed to 
exhibit a modest TRAIL sensisising effect at some concentrations, but increased viability 
at several higher concentrations in the initial viability evaluation (Section 4.2.2).  OH12 
did not significantly increase caspase-8 activity, as hypothesised by its lack of efficacy in 
initial assays.  OH14, 16 and 19 did show a modest, although non-significant, reduction 
in caspase-8 activity when treated alone which may be due to a suppression of baseline 
caspase-8 activation in the system, or alternatively an off-target effect of caspase-8 
inhibition when the TRAIL pathway is not stimulated.   
 In addition to the caspase-glo assay, the idea that CFA cells are TRAIL sensitive 
due to the induction of caspase-mediated apoptosis was tested using a commercially 
avaialable pan-caspase inhibitor (Z-Vad-FMK).  This was performed in BT474 cells which 
are TRAIL resistant, however, like MCF-7 cells, their CFA cells are partially TRAIL 
sensitive (Section 4.2.4).  The sensitivity of BT474 colony forming cells to TRAIL was 
rescued to 78%, by the addition of a pan-caspase inhibitor (Figure 5.5 B).  When 
combined with OH14, BT474 CFA TRAIL-sensitivity was increased, as previously 
observed which was restored to a similar level as TRAIL alone by pre-treatment with the 
pan-caspase inhibitor, with a rescue to an average of 73%.  Furthermore, we show here 
that the caspase inhibitor was able to rescue the MCF-7 CFA TRAIL-sensitivity 
significantly (p-value<0.001) (Figure 5.5 C) and demonstrated therefore that TRAIL is 
acting through the extrinsic pathway of apoptosis in the partially-sensitive MCF-7 colony 
forming cells.  Evaluation of OH14 in combination with a caspase-inhibitor has not yet 
been performed on MCF-7 colony forming cells. 
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Figure 5.5: Small Molecule c-FLIP Inhibitors Sensitise to TRAIL via Caspase-mediated 
Pathway. 
A) Caspase-8 (C8) Activity Assay (Caspase-Glo 8) performed on 70% confluent adherent MCF-7 
cells after treatment with the 3 initial lead compounds (OH14, 16 and 19) and another, less 
active, compound (OH12) at 100 µM alone or in combination with 20 ng/ml TRAIL. *=p-
value<0.05, t-test TRAIL vs compound plus TRAIL (red) and untreated 231 vs TRAIL treated 
(green).  B) CFA: BT474 cells plated at 50 cells per cm2, treated after attachment with OH14 
(both 14.2 and 14 represent OH14) at 100 µM alone or in the presence of a pan-caspase 
inhibitor (CI) at 10 µM with or without 20 ng/ml TRAIL and left for 10 days to form colonies. C) 
CFA: MCF-7 cells were plated at 50 cells per cm2 and left to attach before treatment with 20 
ng/ml TRAIL in the presence of absence of the pan-caspase inhibitor at 0.1 µM (CI) and left to 
form colonies. Results represent averages of 4 technical replicates over 2 experiments, error 
bars presented represent standard error of the mean. *=p-value<0.05, **=p-value<0.001, t-test. 
 
 
 
A 
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5.2.2 FRET Acceptor Photobleaching 
 In our experiments, eCFP and eYFP serve as the donor-acceptor pair for AP-FRET.   
 
5.2.2.1 FRET Optimisation: Plasmid Ratios 
 FRET constructs e-CFP-C1 and e-YFP-C1 were used to generate fusion constructs 
of FADD, c-FLIP and procaspase-8.  We have successfully generated e-CFP-C1-FADD and 
e-YFP-c1-c-FLIP plasmids, however, cloning is ongoing for the procaspase-8 FRET 
constructs.  Ultimately we wish to be able to use FRET to study the interactions of c-
FLIP:FADD, c-FLIP:caspase-8 and caspase-8:FADD in the presence of our lead compound 
and ultimately in order to evaluate our c-FLIP mutants via mutagenesis of the FRET 
constructs. 
  In order for AP-FRET to be successful, it is optimal for both donor and acceptor 
to be expressed to relatively similar levels, thus, a considerable amount of optimisation 
was required.  MCF-7 cells were initially chosen since these are the key TRAIL resistant 
model used in the previous inhibitor evaluations, however, HeLa cells, which are also 
TRAIL resistant are reported to be an easier cell line to transfect (Crowder and El-Deiry, 
2012), thus we decided to use these cells for the initial FRET optimisation and inhibitor 
testing.  We initially observed that it was difficult to obtain a strong fluorescent signal 
for CFP transfected cells in comparison to YFP expression, thus, we tested the 
expression obtained using several different ratios of CFP and YFP plasmid DNA to each 
other in order to achieve the optimum ratios for our system (Methods, Table 2.1).  
Fluorescence was observed using a confocal microscope to further confirm whether 
successful transfection of cells had taken place.  
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5.2.2.2 FRET Optimisation: Overexpression of FADD and c-FLIP FRET Constructs 
Induces Caspase-Mediated Apoptosis 
 In the process of plasmid optimisation we observed that when cells were 
transfected with either c-FLIP or FADD FRET constructs, a significant amount of cell 
death was present in comparison to when empty CFP and YFP constructs were 
transfected.  We hypothesised that transfection with FADD-CFP is an overexpression of 
one of the key signalling components of the apoptotic pathway, therefore, this may 
cause cells to undergo apoptosis, due simply to the abundance of a key apoptotic 
protein.  Although, it is not clear why c-FLIP:YFP expression induced cell death. 
 To determine whether the cell death was simply due to the overexpression of 
apoptotic proteins, and, in an attempt to optimise conditions for FRET experiments to 
take place, we pre-treated cells to be transfected with a pan-caspase inhibitor.  The pan 
caspase inhibitor, Z-VAD-FMK, blocks the active form of caspases and thus would not 
block the uncleaved form of procaspase-8 (or -10), which would still be able to compete 
with c-FLIP for FADD if no c-FLIP inhibitor was present.   
 HeLa cells were treated with the pan-caspase inhibitor Z-VAD-FMK at 10 µM 1 
hour before transfection with c-FLIP-YFP or FADD-CFP FRET constructs.  After 
transfection, cells were left for 24 h before being visualised using a confocal microscope 
to check both viability and uptake of the plasmids.  Transfection with both c-FLIP and 
FADD FRET constructs (either tagged to YFP or CFP) induced death in HeLa cells (Figure 
5.6 A and C) and in MCF-7 cells (data not shown).  Treatment of the cells with the pan-
caspase inhibitor Z-VAD-FMK prior to transfection prevented this cell death, as cells 
appeared more viable, and showed increased expression of FRET constructs (Figure 5.6 
B and D).  This rescue was also observed in MCF-7 cells (data not shown). 
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Figure 5.6: Pan-caspase Inhibitor Z-VAD-FMK Prevents Cell Death Induced by 
Overexpression of c-FLIP and FADD FRET Constructs 
Hela cells were plated on 24 well glass bottom plates (Mattek), left to attach overnight and 
treated with vehicle control or pan-caspase inhibitor at 10 µM Z-VAD-FMK for 1 hour before 
being transfected with either FADD-CFP or c-FLIP-YFP FRET constucts.  Phase constrast 
microscopy was performed 24h after transfection. A) FADD-CFP treated with vehicle control B) 
FADD-CFP with caspase-inhibitor C) c-FLIP-YFP treated with vehicle control D) c-FLIP-YFP treated 
with with caspase-inhibitor. White arrows highlight cells which have rounded up and detached.  
Scale bars = 100 µm. 
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5.2.2.2 CFP-YFP Construct Demonstrates FRET in HeLa Cells 
 To test the validity of FRET in our biological system, and ensure that successful 
FRET could be measured in our cells, we obtained a CFP-YFP fusion protein, to be used 
as a positive control.  Since CFP and YFP are fused together, when transfected with the 
construct, cells should show an interaction between the proteins, i.e. an increase in CFP 
when YFP is bleached.  Due to the fact that the proteins are fused, the level of FRET 
obtained is likely to be maximal, compared to when testing the FRET between two 
unfused proteins. 
 HeLa cells transfected with the fusion protein were analysed.  A region of 
interest (ROI) was selected based on the ratio of CFP to YFP fluorescence, that is, the 
fluorescence intensity of CFP and YFP was relatively similar and was adjusted using the 
digital gain to ensure this was the case (Figure 5.7A).  The average intensity within the 
ROI was plotted as a function of time (Figure 5.7B).  The positive control showed a 
significant increase in donor (CFP) fluorescence intensity after the acceptor (YFP) was 
bleached and bleaching was continued, thus confirming the ability of FRET to be 
recorded using our system. 
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Figure 5.7: Fluorescence image of HeLa cells expressing CFP-YFP fusion construct. 
A) Representative image of HeLa cells transfected with CFP-YFP fusion protein, before bleaching 
took place.  Scale bar = 50 µm. B) Fluorescence of donor (CFP) and acceptor (YFP) were 
measured as a function of time during acceptor photobleaching (bleaching occurred at each 
time point). Intensities within the region of interest (red square (A)) from an average of 4 cells 
over 3 experiments were analysed and plotted.  
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5.2.2.3 OH14 Reduces the Number of Detectable FADD:c-FLIP Interactions in TRAIL 
Treated Cells 
 Our observation that the pan-caspase inhibitor prevented apoptosis induced by 
expression of our c-FLIP and FADD FRET constructs was such that in subsequent FRET 
experiments, cells were always treated with caspase-inhibitor before transfection, in 
order to ensure that they remained viable for FRET measurements to take place 24 
hours later.  Pan-caspase inhibitors act by binding to the active site on caspases (R and 
D systems), and therefore do not interfere directly with FADD complexes. 
 To determine whether our lead compound, OH14, could indeed inhibit the 
interaction between c-FLIP and FADD, HeLa cells were left untreated (vehicle control), 
treated with TRAIL alone, treated with 100 µM OH14 alone or pre-treated with 100 µM 
OH14 before TRAIL addition at 20 ng/ml.  Untreated cells showed an increase of up to 
approximately 7% in CFP intensity upon YFP bleaching (Figure 5.8A, blue), suggesting 
that FRET was occurring to a small degree, that is, in unstimulated cells, c-FLIP and FADD 
do interact, but not to a great extent.  When cells were first treated with OH14 at 100 
µM, FRET appeared to be slightly, although not significantly, reduced, compared with 
untreated cells (Figure 5.8A).  Upon treatment with TRAIL, a significant increase in CFP 
intensity, of up to an average of approximately 35%, was observed at every time point 
after bleaching (Figure 5.8B, red), which suggested that stimulation of the apoptotic 
pathway in these TRAIL resistant cells has occurred, and that c-FLIP and FADD are 
indeed interacting.  When the cells were pre-treated with OH14, however, the CFP 
intensity increased to only 5% compared with unstimulated cells (before bleaching) 
(Figure 5.8B, green), and overall was significantly lower than TRAIL alone, which 
suggested that OH14 successfully inhibited the interaction between c-FLIP and FADD.   
 The same FRET experiments were performed in MCF-7 cells, which initially 
showed a great deal of cytotoxicity when cells were transfected with the constructs, 
and so were not selected as our primary line for performing FRET experiments. When 
treated with TRAIL alone, we did, however observe an increase in FRET, which was 
reduced when TRAIL was treated in combination with OH14, although this experiment 
needs to be repeated in order to demonstrate the significance of this reduction (Figure 
5.8C). 
 In any live cell, protein interactions will be dynamic, with the kinetics varying 
with protein expression and affinity between the proteins involved.  By using a box-
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scatter plot we have explored this variability in greater detail by looking at the 
responses at certain time points after bleaching: at the beginning; a third of the way in; 
and two thirds into reading.  The mean bars demonstrate the overall trend, however, 
individual points clearly demonstrate that whilst there were many detectable 
interactions in one cell, there were few in another (Figure 5.8D).   
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Figure 5.8: OH14 Reduces FADD:c-FLIP Interactions in TRAIL Treated TRAIL-resistant 
HeLa and MCF-7 Cells 
HeLa cells were transfected with c-FLIP and FADD FRET plasmids, treated with caspase-inhibitor 
at the time of transfection were left for 24 h before treatments. Cells were then treated with A) 
vehicle control (0.1% DMSO, blue), 100 µM OH14 alone or B) 100 µM OH14 for 1 hour before 20 
ng/ml TRAIL for 2 hours (Green), or 20 ng/ml TRAIL alone for 2 hours (Red).  Multiple cells were 
recorded, results displayed are CFP fluorescence from the average of at least 7 cells on 3 
independent experiments. There is a significant difference 4 seconds after bleaching between 
TRAIL and OH14 plus TRAIL (t-test for each time point). C) MCF-7 cells transfected and treated in 
same way as HeLa cells with either 20 ng/ml TRAIL alone for 2 h (Red) or 100 µM OH14 for 1 h 
followed by 20 ng/ml TRAIL for 2 h (blue).  Results represent the average of 10 cells on 1 
experiment. Error bars in A-C represent standard error of the mean. D) Each data point 
represents a recording made on an individual HeLa cell. Bleaching occurred at each time point. 
C 
D 
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5.2.2.4 OH14 does not act by Reducing Overall c-FLIP Levels 
 To further confirm that our inhibitors act by interfering with protein interactions 
rather than overall protein levels, we wished to assess the levels of c-FLIP protein 
present during different treatment conditions.  MCF-7 cells were cultured with vehicle 
control or OH14 at 100 µM for 1 h before the addition of 20 ng/ml TRAIL or vehicle 
control for a further 2 h.  Protein was extracted from MCF-7 cells post-treatment before 
being subjected to Western blotting (Figure 5.9A).  No significant differences were 
observed between c-FLIP protein levels between treatments when normalised to 
GAPDH (Figure 5.9 B).  Thus OH14 does not appear to alter c-FLIP expression or 
stabilisation of the protein. 
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Figure 5.9: OH14 does not decrease c-FLIP protein levels 
A) Western Blot: Total proteins were extracted from MCF-7 cells which had been subjected to 
various treatment conditions: Ctrl - 0.1% DMSO, TR - 20 ng/ml TRAIL for 2 h, 14 - 100 µM OH14 
for 3 h, 14+TR - 100 µM OH14 for 1 h before the addition of 20 ng/ml TRAIL for a further 2 h. B) 
Densitometry analysis of total c-FLIP protein expression between MCF-7 cells treated conditions 
in A).  
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5.2.3 Generation of a c-FLIP TALEN Cell Line  
 In order to generate a stable c-FLIP knockout cell line, we transfected MCF-7 
cells with TALEN constructs targetted to c-FLIP.  Transfected cells were grown as single 
cell clones until enough cells were obtained for DNA extraction and PCR analysis.  
Following PCR evaluation, we used restriction digestion to analyse the potential clones 
(Figure 5.10A).  We determined that the inital round of TALEN transfection successfully 
generated 4 potential c-FLIP heterozygote MCF-7 cell lines (Figure 5.10B) which 
required a second round of transfection with the TALEN constructs in order to attempt 
to generate a fully c-FLIP eliminated stable cell line. 
 Western blotting was performed on 4 of the potential heterozygotes as an 
additional confirmation of their reduced levels of c-FLIP (Figure 5.11A and B).  
Densitometry analysis of Western blots showed that clone 41 had the most reduced 
expression of c-FLIP and was therefore the clone of choice to undergo further 
evaluation and, subsequently, a second round of transfection (Figure 5.11C and D). 
 We have previously observed that overall c-FLIP levels within cells are not the 
reason for differences in sensitivity to TRAIL, rather it is possible that the subcellular 
localisation determines susceptibility (French et al., 2015 in press) and thus, although 
our heterozygotes are likely to express a lower level of c-FLIP than wildtype cells, we did 
not expect to see a significant increase in TRAIL sensitivity in these cells until an 
elimination of c-FLIP was obtained.  TRAIL sensitivity was tested using the Cell Titre Blue 
assay in the bulk population of untransfected MCF-7 and our TALEN cell clone 41.  As 
hypothesised, no significant increase in TRAIL sensitivity was observed between the two 
cell lines using Cell Titre blue to measure cell viability (Figure 5.12). 
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Figure 5.10: Analysis of clones from Initial round of MCF-7 TALEN transfection 
revealed potential c-FLIP heterozygotes. 
A) TALENs were targeted to flanking sequences surrounding a unique restriction enzyme site to 
aid screening via BsrI restriction enzyme digest. Genomic DNA was extracted from transfected 
cells grown up from single cell clones.  cFLIP was amplified (Methods 2.8.3.2) and the resulting 
DNA was amplified using BsrI restriction digestion.  Samples successful for TALEN showed only 1 
band, around 300 bp due to a lack of restriction digestion cleavage by BsrI within the TALEN 
spacer. Unsuccessful TALEN samples showed 2 bands, around 200 and 100 bp in size, due to 
cleavage by BsrI within the TALEN spacer site. Should TALEN be successful, two products will 
form, but if unsuccessful, DNA will be cut only at one site. B) Following genomic DNA extraction, 
71 clones of MCF-7 cells transfected once with TALEN constructs were analysed by 2% agarose 
gel electrophoresis by BsrI cleavage.  Arrows point to potential heterozygote clones. 
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Figure 5.11: Western Blotting Confirms Reduced c-FLIP Protein in TALEN Transfected 
Cells 
Western Blot: Total proteins were extracted from WT MCF-7 cells and our 4 TALEN 
heterozygote clones, and one non-heterozygote (49) as an additional negative control. 
A and B are repeats of the same cell samples. C & D) Densitometry was performed on 
the blots from A) and B) respectively, protein levels are relative to GAPDH. 
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Figure 5.12: TRAIL sensitivity is not significantly increased after initial round of TALEN 
transfection in MCF-7 cells. 
Untransfected MCF-7 cells (WT) and those subjected to one round of transfection with our 
TALEN c-FLIP constructs, and demonstrated to be the most well knocked down (TALEN - clone 
41) were grown in adherent conditions to 70% confluence before being treated with 20 ng/ml 
TRAIL or vehicle control. Results represent a single experiment performed with 6 internal 
technical replicates.  Error bars represent standard error of the mean. 
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5.2.3.1 Evaluation of Second Round of TALEN Transfected Cells 
 We performed a second round of transfection with the TALEN constructs on the 
clone identified to have the lowest c-FLIP levels in Section 5.2.3, clone 41.  Transfection 
of TALEN constructs was performed in combination with mRFP for use in FACS sorting of 
transfected cells, in order to attempt to generate cells, and ultimately, a stable cell line, 
which were homozygous for the deletion of c-FLIP gene.   
 Clones from this second round were monitored during their growth and many 
were noted to have morphologies different to that of untransfected MCF-7 cells (Figure 
5.13A and B).  In addition, many of the clones had different proliferation rates to that of 
untransfected cells, with a few of the clones growing predominantly in colonies (Figure 
5.13C and D).  This may be due to the impact of removing c-FLIP from the cells, it may 
be as a by-product of the TALEN process overall, or may be as a result of using 
subclones of MCF-7 cells .   
 We analysed expression of successfully expanded clones using qPCR.  qPCR 
analysis identified several clones with lower expression levels of c-FLIP relative to 
control, although none were identified with complete removal of the gene (Figure 
5.14A).  We then treated adherent cells of clone 40, which appeared to have the 
greatest c-FLIP reduction, with TRAIL, TALEN, however, no increase in TRAIL sensitivity 
was observed using the Cell Titre blue to assay cell viability (Figure 5.14B).   
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Figure 5.13: MCF-7 TALEN Double Transfected Cell Morphology and Growth 
Assessments. 
The morphologies and growth rates of the TALEN clones varied considerably.  A) Untransfected 
MCF-7 cells B) TALEN Clone 20 - mesenchymal-like morphology. C) TALEN Clone 13 - slow 
growth rate: small colonies with large amounts of cell death and resulting debris.  D) TALEN 
clone 10 - cells grew in colonies with morphology similar to that of untransfected MCF-7s. Scale 
bar = 50 µm. 
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Figure 5.14: qPCR and Cell Viability Analysis of MCF-7 TALEN transfected cells from 
second round of transfection. 
A) qPCR analysis of second round of transfection TALEN MCF-7 cells. B): TRAIL sensitivity of cells 
which had undergone the complete two rounds of TALEN transfection and selection. Clone 40 
cells were cultured in a 96 wp for 24 h before the addition of 20 ng/ml TRAIL for 18 h.  Cell Titre 
Blue was performed to measure cell viability. Results represent 3 technical replicates, error is 
presented as standard error of the mean. 
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5.2.4 Selection of Mutations for c-FLIP Mutational Studies 
 Currently, there are only two mutational studies performed on the DEDs of c-
FLIP, which were published after the majority of the work in this project had been 
carried out (Hwang et al., 2014; Majkut et al., 2014), with studies involving mutations 
carried out on the structure of FADD being far more abundant (Section 1.3.7).  We 
wished to further confirm the importance of the site on c-FLIPs DED1, which our 
inhibitors were designed to target.  Analysis of this binding site identified several 
residues which play a key role in the interaction with FADD, based on our model 
(Chapter 3), these include; Methionine (Met) 1, Alanine (Ala) 3, Isoleucine (Ile) 6, 
Histidine (His) 7, Glutamic Acid (Glu) 10, Arginine (Arg) 38 and Arg 45 (Figure 5.15A). 
 We designed primers to target Ile 6, His 7, Arg 38 and Arg 45, initially, as these  
residues were identified to be important on our in silico model.  Successful generation 
of constructs using these SDM primers has taken place (Figure 5.15B).  We hypothesise 
that overexpression of wildtype c-FLIP in a c-FLIP knockout, and thus, TRAIL-sensitive 
cell line would confer a significant amount of protection to TRAIL induced apoptosis 
and, in contrast, overexpression of our mutants would not protect in the same way 
since they are designed to impede the c-FLIP:FADD anti-apoptotic interaction.  
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Figure 5.15: Interacting Residues in the c-FLIP DED1 Pocket and Generation of SDM 
Constructs. 
A) Analysis of the interactive surface between c-FLIP and FADD, based on our interaction model, 
identify 7 residues which appear to have an integral role (Met 1, Ala 3, Ile 6, His 7, Glu 10, Arg 38 
and Arg 45). B) Successful generation of c-FLIP mutants (representative sequencing result). 
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5.2.5 In Vitro Assay of CSC Plasticity 
 Studies have demonstrated the ability of non-stem cancer cells to de-
differentiate into a stem cell-like state in what we and others have referred to as CSC 
plasticity (Section 1.1.7) (Gupta et al., 2011; Chaffer et al., 2011; French and Clarkson, 
2012).  Plasticity describes a state of flux between stem-like and non-stem-like sub-
populations within a cancer cell field.  Clinically, plasticity means that, even if all CSCs 
were eliminated from a cancerous population, any remaining bulk cells may have the 
ability to de-differentiate and therefore to become CSCs, thus enabling new tumour 
growth to occur.  Therapeutic strategies should therefore take into account the need to 
either eliminate both stem-like and non-stem-like pools simultaneously, or to prevent 
the ability of cells to transition between these states. 
 The data from our lab, demonstrates that when combined with TRAIL, siRNA 
inhibition of c-FLIP, can completely eliminate tumoursphere-forming cells from breast 
cancer cell lines and that under these conditions, between 5% and 20% of the total cell 
population remains viable (Piggott et al., 2011).  This gives us the ability to study 
plasticity, since we have a viable population of non-CSCs with which to study the 
reacquisition of CSC-like activity. 
 We have previously reported that BT474 breast cancer cells treated with TRAIL 
and siRNA targeted to c-FLIP to eliminate tumoursphere forming cells, if allowed to 
recover in the absence of TRAIL in adherent conditions for 7 days regain the ability to 
form tumourspheres (Piggott et al., 2011).  We have re-capitulated this in MCF-7 cells, 
showing the kinetics of tumoursphere recovery over 7 days (Figure 5.16). 
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Figure 5.16: In Vitro Model of breast CSC Plasticity 
MCF-7 cells were subjected to siRNA to c-FLIP for 48 h, after which TRAIL was administered at 
20 ng/ml and cells were left for 18 h.  Subsequently, cells were subjected to the tumoursphere 
assay to confirm complete elimination of tumourspheres (day 1). Remaining cells were seeded 
in adherent culture conditions and left to recover over 9 days, with tumoursphere forming 
ability being assayed each day by plating in tumoursphere conditions and counting after 7 days. 
A) Passage 1: siRNA c-FLIP successfully eliminated all tumourspheres initially, however, surviving 
cells regained the ability to form tumourspheres by day 2, with full tumoursphere forming 
ability restored after 9 days.  B) Passage 2: Tumourspheres from passage 1 could be successfully 
passaged, however, formation did not reach the level of untreated spheres by day 9.  Results 
are averages of three independent experiments, performed with three internal technical 
replicates (*=p<0.05, t-test). 
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5.2.5 OH14 Impacts on MCF-7 Cell Plasticity after siRNA c-FLIP Treatment 
 The previous data (Figure 5.16) was generated using siRNA to c-FLIP thus, during 
the reacquisition of tumoursphere activity, c-FLIP mRNA levels would be no longer 
repressed due to the transient nature of siRNA knockdown. We wished to determine 
whether long term suppression of c-FLIP may impede the ability of cells to reacquire 
tumoursphere-forming ability in our assay of plasticity. 
 To test this we used our lead compound to retain the suppression of c-FLIP.  
Although the compound itself targets the c-FLIP:FADD interactive surface, it is possible 
that this inhibition is relevant to the role of c-FLIP in plasticity, in addition to the fact 
that binding of the compound itself may impact on the other functions of c-FLIP. 
 Following the elimination of tumourspheres using FLIPi and TRAIL, the surviving 
cells were plated in adherent conditions and treated with OH14 at 10 µM for 7 days; 
replacing culture media and drug daily.  Treatment of the surviving population with 
OH14 prevented the formation of tumourspheres after the 7 day 'recovery' period in 
comparison with cells which were left untreated, which recovered to around 50% on 
passage 1 (Figure 5.17).  OH14 profoundly inhibited the clonal expansion of these 
residual viable cells in adherent culture (Figure 5.16).  It is possible therefore that the 
lack of tumoursphere formation could be due to the inability of the cells to proliferate 
to form floating colonies. 
 In parallel work carried out by Luke Piggott, c-FLIP has been suppressed 
permanently by shRNA, which demonstrated the same inhibition of tumoursphere 
reacquisition (Piggott, L, personal communication).  This confirms the c-FLIP specificity 
of this effect on plasticity. 
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Figure 5.17: Treatment with Lead Compound OH14 Impairs Ability of Cells to reacquire 
Tumoursphere Forming Ability following FLIPi + TRAIL 
MCF-7 cells which had been treated with c-FLIP siRNA for 48 h were treated with TRAIL for 18 h 
and then subjected to tumoursphere conditions to demonstrate complete loss of tumoursphere 
forming ability (A - Day 1).  B) The remaining cell population were re-seeded in adherent 
conditions and left to recover for around 7 days with daily 0.1% DMSO or 100 µM OH14 
treatment, after which tumoursphere forming potential was reassessed. C) Daily visual 
inspection of the cells in adherent culture prior to re-plating into the tumoursphere assay 
demonstrated that OH14 appeared to prevent the re-expansion of the cell population. Scale 
bars = 50 µm. 
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5.3 Discussion 
 Many studies have demonstrated the interaction between c-FLIP and FADD, in 
addition to the interaction between c-FLIP and procaspase-8,  to play an integral role in 
TRAIL resistance (Irmler et al.¸1997; Safa and Pollok, 2011; Safa et al., 2012; Dickens et 
al., 2012).  In the previous chapters, we identified one lead small molecule, OH14, which 
can sensitise previously resistant breast cancer bulk; progenitor-like or colony-forming; 
and stem-like or tumoursphere-forming cells to TRAIL induced apoptosis.  OH14 was 
initially selected in silico based on its ability to specifically bind to c-FLIP and prevent 
interaction with FADD.  In this chapter, we performed evaluation of the biological 
interactions of c-FLIP and validated the mechanism of action of OH14 in vitro.  In 
addition, we explored the effects of the lead inhibitor on another important process of 
cancer biology that c-FLIP may have a role in: cancer stem cell plasticity (Piggott et al, 
2011; French, 2014 unpublished). 
 Previous data has shown the presence of an interaction between c-FLIP and 
FADD, and of procaspase-8 and FADD in TRAIL-resistant and TRAIL-sensitive lines 
respectively (Safa and Pollok, 2011; Zhang and Fang, 2005; Sprick et al., 2000; Medema 
et al., 1997.  Here, we confirm the presence of the latter interaction, in our biological 
system using co-immunoprecipitation in TRAIL-sensitive MDA-MB-231 cells and the lack 
of an interaction between c-FLIP and FADD, suggesting that this interaction is indeed 
important for TRAIL sensitivity, although these results will need to be compared with a 
TRAIL-resistant line, in addition to utilising our lead inhibitor within the experiment.  
Treatment with TRAIL over a four point timecourse on TRAIL sensitive MDA-MB-231 
demonstrated an increase in cleaved (p43 and p18), and therefore active, caspase-8 
over time, up to 2 h, after treatment with 100 ng/ml TRAIL.  This is in accordance with 
previous studies which have demonstrated a similar increase caspase-8 cleavage upon 
treatment with TRAIL over time (Suliman et al., 2001; Wang et al., 2008).  In contrast, no 
increase in p43 caspase-8 was observed in the TRAIL-resistant MCF-7s, suggesting TRAIL 
induced caspase-8 activation was indeed prevented.  Previous studies have 
demonstrated similar findings in TRAIL-resistant cell lines, including in colon cancer, 
whereby TRAIL treatment in a TRAIL-resistant line showed significantly less caspase-8 
cleavage than in a TRAIL-sensitive line (Zhang et al., 2005). FADD and c-FLIP protein 
levels were confirmed to be similar between the two lines, despite their differing TRAIL 
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sensitivities, thus, sensitivity may instead be due to differential localisation of c-FLIP in 
sensitive versus resistant cells.  Our lab has recently demonstrated the importance of 
subcellular localisation, rather than overall protein levels, of c-FLIP to be most 
important for its anti-apoptotic role.  These recent results demonstrated that TRAIL-
resistant cell lines express c-FLIP predominantly in the cytoplasm, whereas c-FLIP is 
confined to the nucleus in those which are TRAIL-sensitive.  Furthermore, when c-FLIP 
localisation was assessed in the tumoursphere forming cells of these same cell lines, the 
partially sensitive tumoursphere-forming cells of the MCF-7 cell line expressed c-FLIP in 
the nucleus, in contrast to the bulk cells, which showed nuclear expression of c-FLIP 
(French et al., 2015 in press).   
 Our hypothesised mechanism of action, based on in silico drug design, was that 
OH14 directly inhibited the interaction between c-FLIP and FADD.  Here we have shown, 
using acceptor-photobleaching FRET-based confocal microscopy, that our lead inhibitor, 
OH14 did indeed significantly reduce interactions between c-FLIP and FADD in TRAIL 
stimulated TRAIL-resistant HeLa and MCF-7 cells.  The constructs themselves induced 
cell death, which was prevented by use of a caspase-inhibitor. Indeed, several studies 
have shown similar results, demonstrating that transient expression with FADD leads to 
increased activation of apoptotic pathways, even in the absence of TRAIL, which can be 
blocked by a pan-caspase inhibitor (Siegel et al., 1998; Grunert et al., 2012; Matsumura 
et al., 2000; Gomez-Angelats and Cidlowski, 2003), although the reason that expression 
of c-FLIP:YFP induced caspase-dependent cell death is unclear.  As our FRET 
experiments were based on live cells, we did obtain a large degree of variation in 
responses which is in accordance with the fact that interactions in a biological system 
are dynamic: they may be transient and frequently altering with fluctuations in protein 
interaction kinetics (Li et al., 2011).  Despite this, we have been able to observe an 
overall trend in our data, although it is unlikely to be true for 100% of the cells in a 
population.  In future, our FRET constructs may be used to perform mutational studies 
in order to elucidate the importance of our identified interacting residues using FRET.   
 Since TRAIL acts via the extrinsic caspase-mediated pathway of apoptosis, 
leading to the activation of caspase-8 (Section 1.2), we hypothesised that a specific 
inhibitor which sensitises to TRAIL would therefore, increase caspase-8 activity, and, 
thus blocking caspase activity would inhibit this effect.  Our data suggest that our 
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inhibitors are indeed specifically acting in this manner, as we have shown that pre-
treatment with a pan-caspase inhibitor significantly impaired the ability of our 
compounds to sensitise to TRAIL.  In addition, we have observed a modest, yet 
significant, increase in caspase-8 activity upon treatment of our lead compound in 
combination with TRAIL, further confirming this mechanism of action.   
 We have identified, using our in silico interaction models, several residues on the 
interactive pocket of c-FLIP which appear important for the anti-apoptotic interaction 
with FADD, and, as such, were targeted with our small molecule inhibitors.  Here, we 
have attempted to generate a stable c-FLIP knock-out cell line, using TALEN technology, 
to analyse our identified residues.  Cell clones which had reduced c-FLIP levels and 
survived the second transfection had significantly altered morphology and proliferation 
rate, and many did not survive passaging.  Those clones which did survive the second 
transfection did indeed exhibit reduced c-FLIP levels, as measured by qPCR, but did not 
show an increased sensitivity to TRAIL using an assay of cell viability.  It may be that 
despite the reduction in c-FLIP levels induced by this double transfection, the 
phenotype of the cells was further altered, either by inhibition of c-FLIP or subclonal 
expansion, which prevented any significant change in TRAIL sensitivity being observed.  
Furthermore, as c-FLIP was not completely eliminated from these cells, the remaining c-
FLIP may have been sufficient to retain their TRAIL resistance, as we have recently 
demonstrated that c-FLIP mediated TRAIL-sensitivity may be due to c-FLIP localisation 
rather than expression levels (French et al., 2015 in press), thus, only a total elimination 
of c-FLIP would be likely to cause a significant sensitisation to TRAIL.  Additionally, it is 
possible that use of TALEN to modify the genes itself has compromised cell viability, 
since TALEN does not release the ends it has bound to immediately after cleavage, DNA 
repair may be interfered with thus potentially inducing cell death (Beumer et al., 2013; 
Mali et al., 2013).  Furthermore, our TALEN constructs targetted an area within exon 4 
of c-FLIP (nucleotides 935-946, approximately amino acids 148-151), toward the middle 
of DED2 on c-FLIP (Methods, Figure 2.9).  It is possible that targetting this site, around 
30% into the sequence of c-FLIP, may not be sufficient to knock down the whole 
protein, especially since it is DED1 and 2 that are important for TRAIL resistance, thus, it 
may be that these domains remain intact and available to retain the anti-apoptotic role 
of c-FLIP.  Since c-FLIP was not completely eliminated, it would have been more relevant 
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to assess the clones using FRET to evaluate whether there was a reduction in 
interactions, however, the since the proliferation of the transfected cells was altered, 
the majority of cells did not survive additional transfection and plating on FRET assay 
plates, and would not have survived laser bleaching.  Further work is required to 
ascertain an appropriate assay or optimum clone for performing mutagenesis studies. 
 The ability of a cancer therapy to prevent CSC plasticity is clinically desirable, as, 
when combined with a treatment to eliminate bulk tumour cells, a CSC and 
chemotherapy combination therapeutic regime may have the potential to destroy the 
original tumour whilst also preventing relapse (Vinogradov and Wei, 2012; Han et al., 
2013; Frank et al., 2010).  Although OH14 was designed to target the c-FLIP:FADD 
interaction, long-term treatment with the compound may abrogate additional functions 
of c-FLIP, perhaps due to compound binding at one site inducing conformational 
changes at other protein domains.  We have observed here, that OH14 may have 
potential efficacy for targeting CSC plasticity in our in vitro model of the process.  After 
elimination of tumoursphere-forming cells using siRNA c-FLIP, we observed that daily 
OH14 treatment of the remaining viable cells, replated in adherent conditions 
prevented growth compared with vehicle control treated cells.  Prolonged treatment of 
OH14 does not affect overall cell viability (Chapter 4), however, it does result in a 
modest, yet significant reduction in tumoursphere forming ability, in contrast to a single 
overnight treatment, which did not significantly alter tumourspheres (Chapter 4).  
Section 4.2.6 explored the effect of long-term treatment with OH14, which 
demonstrated a lack of overall cytotoxicity, although a slowing of proliferation was 
observed, it is possible, therefore, that treatment with OH14 effects a more gradual 
process, such as plasticity, and prevents reacquisition of breast CSCs or progenitor cells, 
thus leading to the ultimate death of the surviving population, which require breast 
CSCs to propagate and proliferate.  A repeat of our plasticity study using stable c-FLIP 
inhibition, for example, using shRNA is required as an appropriate control to make more 
definite conclusions about the actions of OH14 in plasticity.  Since c-FLIP in combination 
with TRAIL induces the extrinsic pathway of apoptosis, it is likely that bCSCs are lost by 
cell death.  We will address this in future using the pan-caspase inhibitor Z-VAD-FMK, to 
determine whether treatment with the caspase-inhibitor can rescue tumoursphere 
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ablation.  Alternatively, it is possible that cells which survive FLIPi/TRAIL are quiescent, 
which may be assessed using flow cytometry of pyronin γ and hoescht (Shapiro 1981). 
 In conclusion, we have demonstrated that our lead compound OH14 was able to 
sensitise to TRAIL through direct interference with the c-FLIP:FADD interaction and 
therefore, facilitated TRAIL-induced apoptosis through a caspase-mediated pathway, 
leading to activation of caspase-8.  We have observed that the effects of our inhibitor 
may be even more clinically important than initially evaluated, as the inhibitor appeared 
to prevent CSC plasticity, in our in vitro model.  
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Chapter 6: Biological Evaluation of OH14 Analogues 
 
6.1 Introduction 
 Agents which have been demonstrated to have an ability to sensitise to TRAIL, 
via effects, albeit non-specific, on c-FLIP are often seen to be working at relatively high, 
micromolar, concentrations (Chen et al., 2010, Rao-Bindal et al., 2014; Li et al., 2013) 
(Section 1.3.6), and exhibiting a high IC50, i.e.  the concentration required to achieve 
50% inhibition of a specific target.  Reducing the dose of c-FLIP inhibitor required to 
achieve such effects is beneficial in terms of improving any potential safety and 
tolerability issues that may result from treatment. 
 We selected compound OH14 as our lead compound after thorough biological 
evaluation using assays of cell viability, proliferation, and stem cell functionality 
performed in Chapter 4 and evaluation of the mechanism of action in Chapter 5.  
Subsequently, in this Chapter, we both obtained (from SPECS database) and generated 
(in house at Cardiff School of Pharmacy) analogues of OH14 to be tested in relevant, 
high-throughput assays, with the aim of identifying compounds which have similar 
efficacy to OH14 but exhibited lower effective working concentrations, as we have 
previously observed OH14 to function best at >10 micromolar concentrations.  Due to 
the fact we will evaluate multiple compounds, we wanted to select an assay that was 
both relatively high-throughput and representative of the TRAIL-sensitising ability of our 
compounds.  The clonogenic or colony forming assay was selected for this purpose, as it 
was demonstrated, in Chapter 4, to produce results which correlated well with both 
bulk cell viability and tumoursphere forming ability in both MCF-7 and BT474 cell line 
models.  This fits in with the output of the assay being a progenitor-like proliferation 
assay, thus encompassing two of the features of cell viability and tumoursphere forming 
assays.  Analogues of OH14 will help us to establish an initial structure-activity 
relationship for our compounds which will help us to further refine analogue generation 
in the future.   
 Here, we have tested a series of 39 analogues of OH14 for their ability to 
increase the sensitivity of breast cancer colony forming cells to TRAIL.  We have 
successfully identified around 7 analogues which exhibit a similar or improved efficacy 
as OH14. 
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6.2 Results 
 We obtained 8 analogues of OH14 from Specs database and 29 analogues of 
OH14 were synthesised in house at Cardiff School of Pharmacy, by Gilda Giancotti, in 
order to identify potential analogues with similar or improved efficacy than OH14.  
6.2.1 SPECS Based Analogues 
 Initially, 8 analogues of OH14 (Termed 14.1-14.9, 14.2 is the same as compound 
OH14) were identified and obtained from Specs (Table A6.1, appendix).  These 
compounds were selected as they were 90% idential to OH14 and retained the 
important sulphonamide group but had alterations in the aromatic rings and side 
groups. 
 
6.2.2 OH14 Synthesis and Analogue Design 
 After identifying OH14 as our lead compound, in-house synthesis of the 
compound was begun at Cardiff School of Pharmacy (performed primarily by Gilda 
Giancotti).  The method of synthesis (appendix section A6.1) followed a previously 
described method of synthesis for similar chemical structural compounds (Peifer et al., 
2007). 
 The lead compound, OH14, was predicted to form hydrogen bonds with several 
key amino acid residues on c-FLIP, including Glu 10, Lys 18, Arg 38 and Arg 45, amongst 
others (Figure 6.1).  Analogues of OH14 were therefore selected and designed to so that 
these or similar bonds were formed, as evaluated by entering in the structure of 
analogues on the in silico structure of c-FLIP and assessing the compounds affinity to 
these residues.  
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Figure 6.1: Ligand interaction of Compound OH14 in the predicted binding pocket on 
c-FLIP 
A) Predicted binding pocket on surface of c-FLIP DED1 with lead compound OH14 docked. Part 
of c-FLIP is shown in yellow ribbon format. Compound OH14 is presented in ball and stick 
format. B) Ligand interaction diagram of OH14 in c-FLIP pocket, with relevant key. 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
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6.2.3 Analogue Modifications and Synthesis 
 The sulphonamide group on OH14 was identified as a highly important 
component of the compound for binding with the pocket on c-FLIP, and thus, this group 
was to be retained on all analogues.  Alterations to the aromatic rings were therefore 
the most logical first points of modification.  A range of hydrophobic groups were 
chosen to replace the two chlorine and methyl groups present on OH14 (R), in order to 
elucidate whether alternative hydrophobic groups at different positions on the aromatic 
ring could increase fit within the pocket and overall stability of the compound within 
solution and within the pocket.  Additionally, replacing the carboxylic acid with a methyl 
ester group on the other aromatic ring (R1) was considered (Figure 6.2).  A methyl ester 
group was considered due to its hydrophobicity, which could facilitate cell permeation 
through the lipid cell membrane in addition to the fact that, once through the 
membrane, in a more hydrophilic environment, ester hydrolysis to carboxylic acid 
would occur, thus re-enabling interactions with amino acid residues on c-FLIP.  This 
methyl ester would be synthesised to occupy varying positions on the aromatic ring to 
fully explore whether alternative reactions with other amino acids on c-FLIP may occur 
and subsequently improve the affect of the compound.   
 Twelve analogues of OH14 were initially designed which conserve the central 
sulphonamide group which connects the two aromatic rings (Previous Figure 6.3) but 
have a variety of substitutions on the aromatic rings (Table 6.2).  Synthesis of the 
analogues was similar to OH14 synthesis (appendix A6.2).  
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Figure 6.2: Central Scaffold for Pharmacy Synthesised Analogues of OH14 
R and R1 represent the two groups to be modified by the addition of either a range of 
hydrophobic groups (on R) or a methyl ester (on R1).  
 
 
Table 6.1: Aromatic Ring Substitutions for Pharmacy Synthesised Analogues of OH14 
Compound R R1 
GG1 2-methyl ester 2,4-dicholoro-5-methyl 
GG2 3-methyl ester 2,4-dicholoro-5-methyl 
GG3 4-methyl ester 2,4-dicholoro-5-methyl 
GG4 2-methyl ester 4-trifluoromethyl 
GG5 2-methyl ester 3,4-dimethyl 
GG6 2-methyl ester 3,4-dichloro 
GG7 2-methyl ester 2,4-dichloro 
GG8 2-methyl ester 2,4-dimethyl 
GG9 2-methyl ester 2,5-dimethyl 
GG10 2-methyl ester 2,5-dichloro 
GG11 2-methyl ester 4-tert-butyl 
GG12 2-methyl ester 4-methyl-3-chloro 
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6.2.3.1 Cardiff School of Pharmacy Synthesised Analogues 
 Two sets of analogues were synthesised by Gilda Giancotti at Cardiff School of 
Pharmacy. Pharmacy synthesised compounds, GG 1-12 featured modifications 
discussed in section 6.2.3 (Table A6.2, appendix). The additional 17 Pharmacy 
Synthesised analogues, termed N1-17 in the results section (Table A6.3, appendix) 
followed similar structural substitutions to those explained previously, for compounds 
GG1-12 and were produced by Mahmoud El-Hiti.   
 
6.3 Analogue Analysis 
6.3.1 Compound Solubility 
 The solubility of all the compounds in cell culture media was assessed as in 
Section 4.2.1 in order fully understand the properties and thus, the effects, of these 
compounds.  Ideally, compounds would all be soluble when dissolved at 100 mM in 
DMSO and subsequently in aqueous cell media to aid biological evaluation.  At this 
point, we also wished to establish whether OH14 was soluble directly in sterile water, as 
this would eliminate the need for DMSO and would thus allow higher concentrations to 
be tested without risking toxicity to cells due to high percentage of DMSO.  OH14, 
however, did not dissolve in water and required a minimum of 10 µl DMSO to 1 ml 
water/media in order to dissolve. 
 All of the SPECS analogues of OH14, 14.1-14.9, dissolved at 100 mM in DMSO 
and remained in solution when further diluted in cell culture media (Table 6.2).  
Analogues N1-17, synthesised by Cardiff School of Pharmacy, did not all remain in 
solution (Table 6.3).  All  but one of the GG1-12 analogues, synthesised by Cardiff School 
of Pharmacy, all dissolved at 100 mM in DMSO and in subsequent aqeous media 
diluations to make up working stock (Table 6.4). 
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Table 6.2: Solubility of SPECS Analogues of OH14  
Visual assessment of compound solubility in DMSO or after overnight incubation in media (100 
µM, 10 µM, 1 µM, 100 nM, 10 nM). '' indicates no detected problems with solubility. 
Compound 100 mM in DMSO 100 µM in Aqueous Media 
14.1   
(14.2 = OH14)   
14.3   
14.4   
14.5   
14.6   
14.7   
14.8   
14.9   
 
Table 6.3: Solubility of Pharmacy Synthesised Compounds N1-17  
Visual assessment of compound solubility in DMSO or after overnight incubation in media (100 
µM, 10 µM, 1 µM, 100 nM, 10 nM). '' indicates no detected problems with solubility. 
Compound 100 mM in DMSO 100 µM in Aqueous Media 
N1  Soluble at ≤10 µM
N2  Soluble at ≤10 µM 
N3 50 mM Soluble at ≤10 µM 
N4  Soluble at ≤10 µM 
N5  Soluble at ≤1 µM 
N6  Soluble at ≤1 µM 
N7   
N8   
N9  Soluble at ≤10 µM 
N10  Soluble at ≤10 µM 
N11   
N12 10 mM Soluble at ≤10 µM 
N13  Soluble at ≤10 µM 
N14  Soluble at ≤10 µM 
N15  Soluble at ≤1 µM 
N16  Soluble at ≤0 µM 
N17 10 mM  Soluble at ≤10 µM 
 
Table 6.4: Solubility of Pharmacy Synthesised Compounds GG1-12 
Visual assessment of compound solubility in DMSO or after overnight incubation in media (100 
µM, 10 µM, 1 µM, 100 nM, 10 nM). '' indicates no detected problems with solubility. 
Compound 100 mM in DMSO 100 µM in Aqueous Media 
GG1  Soluble at ≤10 µM
GG2   
GG3   
GG4   
GG5   
GG6   
GG7   
GG8   
GG9   
GG10   
GG11 50 mM  
GG12   
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6.3.2 Testing the Efficacy of Novel Compounds  
 Chapter 4 utilised several assays for the evaluation of inhibitor efficacy however, 
the clonogenic or colony forming assay (CFA) was chosen to evaluate the new inhibitors 
initially as it provides the most representative combined result for the compounds when 
compared with the cell viability and tumoursphere assays.  Additionally, it is easily 
replicated for testing multiple compounds and requires relatively little resources in 
comparison.  The tumoursphere assay was utilised after initial clonogenic testing, as it 
provides the most representative result for stem cell survival in vitro and was the assay 
in which the most profound effects have been previously observed for both siRNA c-FLIP 
and for our compounds. Analogues, like OH14, were considered to be efficacious if they 
significantly increased sensitivity to TRAIL, without being significantly toxic when 
administered alone. 
 
6.2.1.1 SPECS Analogues of OH14: Colony Forming Assay 
 The 8 SPECS analogues of OH14 were tested in MCF-7 and BT474 cells using the 
colony forming assay at 100 µM initially, as this was the dose of OH14 which we 
established to be the most affective in several assays (Chapter 4). 
 Overall, the analogues exhibited similar effects on MCF-7 (Figure 6.3A) and 
BT474 (Figure 6.3B) colony forming cells, with 6 compounds demonstrating similar 
efficacy to OH14 (compounds 14.3, 14.4, 14.6, 14.7 and 14.8) and compound 14.9 
demonstrating a modest improvement on the activity of OH14 in both cell lines.  
Compounds 14.3, 14.4, 14.7 were less active in BT474 cells, with only 14.8 and 14.6 
demonstrating a significant ability to sensitise to TRAIL.  In both cell lines, compounds 
14.1 and 14.5 showed no significant difference from TRAIL alone.  14.7 in both cell lines 
reduced colony-formation ability when administered alone, and yet did not significantly 
improve on the effect of TRAIL. 
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Figure 6.3: Specs Analogues 14.1-14.9 in combination with TRAIL have similar effects 
on colony growth of MCF-7 and BT474 cells. 
Specs Analogues 14.1-14.9 (14.2 = newer preparation of OH14) at 100 µM on A) MCF-7 and 
B)BT474 cells plated at 50 cells per cm2 and left to grow for 10 days before colonies were 
counted. Results represent at least 3 individual biological repeats. *=p-value<0.05, t-test 
between TRAIL and compound + TRAIL. 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
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6.2.2.2 SPECS Analogues of OH14: Tumoursphere Assay 
 The stem cell compartment of a tumour is the ultimate target of a c-FLIP 
inhibitor and TRAIL combination therapy, thus, the analogues were also analysed using 
the tumoursphere assay. 
 When plated in tumoursphere conditions, cells treated with 4 of the 8 new 
analogues did not significantly improve on the TRAIL-sensitising effect of OH14 on MCF-
7 tumoursphere forming cells.  Compounds 14.6, 14.7 and 14.8 significantly increased 
MCF-7 tumoursphere forming cell TRAIL sensitivity, although to a smaller degree than 
OH14 (Figure 6.4A).  Compound 14.9 showed a modest improvement on the TRAIL-
sensitising ability of OH14, similar to that observed in the colony forming assay (Section 
6.2.2.1).   
 The compounds were slightly more effective on BT474 tumoursphere-forming 
cells, with 6 of the 8 compounds showing an ability to sensitise to TRAIL (Figure 6.4B).  
Compounds 14.3 and 14.4, which were not efficacious in MCF-7 cells did show an ability 
to sensitise to TRAIL, although the effect with 14.4 appeared additive due to the effect 
of the compound when administered alone.  Compound 14.9 again was the most 
effective analogue, sensitising to TRAIL by approximately 50%, similar to OH14.  
Interestingly, 14.7, which previously reduced colony-forming number alone on both 
MCF-7 and BT474 cells did not exhibit this same effect but did exert a small yet 
significant ability to sensitise BT474 tumoursphere forming cells to TRAIL. 
 A modest alteration in tumoursphere forming ability was observed for some 
compounds when administered alone, particularly on BT474 tumoursphere-forming 
cells, however, the effect of the effective most effective compounds (14.6, 14.7, 14.9) in 
combination with TRAIL did appear synergistic rather than additive across both cell 
lines.  Overall, the effect of our analogues when analysed in the tumoursphere assay 
appeared to follow a similar trend to the colony-forming assay, further demonstrating 
the assay to be a good surrogate test to give an initial idea about the efficacy of 
analogues.   Across both the tumoursphere and the colony forming assays, in both cell 
lines tested, 14.9 showed consistent efficacy, with a modest improvement on the 
activity OH14. 
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Figure 6.4: Several SPECS Analogues Sensitise MCF-7 and BT474 Tumoursphere 
Forming Cells to TRAIL to a similar level as OH14. 
A) MCF-7 and B) BT474 cells were cultured for 24 h in a 96 wp, before being treated with vehicle 
control or compound at 10 µM for 1 h. 20 ng/ml TRAIL (or control) was added after 1 h and the 
cells were left for 18 h.  The following day, cells were subjected to the tumoursphere assay, with 
no additional drug added.  A) Passage 1: MCF-7 B) Passage 1: BT474. Results represent passage 
3 replicates, with error bars displaying standard error of the mean.  *=p-value<0.05, t-test 
between TRAIL and compound + TRAIL. Compound 14.2 = newer preparation of OH14. 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
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6.2.2 Pharmacy Synthesised Analogues 
6.2.2.1 Pharmacy Synthesised Analogues N1-17: Colony Forming Assay  
 To analyse the effect of OH14 analogues on MCF-7 progenitor-like cells, we 
performed the colony-forming assay, as described previously.  This assay gave an initial 
idea as to the efficacy of the compounds, as we have previously demonstrated that the 
effects observed in the CFA are representative of effects which can be obtained from 
the tumoursphere assay.   
 Initially, compounds were treated at 100 µM as this was the concentration at 
which we had previously observed the best effect with OH14.  At 100 µM, in addition to 
the previously observed solubility issues (Table 6.5), however, several of the compounds 
were highly toxic to MCF-7 colony forming cells at this concentration (Figure 6.5A).  We 
therefore decided to commence with evaluation at 10 µM in order to retain compounds 
in solution and thus not induce toxicity simply due to physical barriers to growth, as well 
as observing whether compounds which initially appeared toxic could be titrated down 
in order to uncover their actual efficacy as TRAIL sensitising agents.  
 Overall, the first series of compounds had similar efficacy to OH14, when treated 
at 10 µM (Figure 6.5B).  Compounds N10, N13 and N17 showed a modest increase in 
efficacy compared with OH14, increasing sensitivity to TRAIL by an average of 60% as 
opposed to 55%.  Five of the analogues did not improve on the efficacy of OH14 but did 
retain the ability of OH14 to significantly sensitise to TRAIL by on average 50%, whereas 
six compounds had a slightly reduced efficacy, and did not significantly enhance TRAIL-
sensitivity.  Many of the compounds, although demonstrating a consistent trend, did 
show a large variability in their ability to sensitise to TRAIL, thus producing a wide error 
range which may be due to issues with solubility, as we previously observed several of 
these compounds to be partially soluble in aqueous media or indeed, in DMSO (Table 
6.5 previously).  
 Three of this first set of pharmacy-synthesised compounds, N15, N5 and N6, 
appeared toxic to the cells at both 100 and 10 µM, even when administered without 
TRAIL.  These compounds, however, had been observed to be partially out of solution at 
100-10 µM (Table 6.5 previously), which may explain their toxicity i.e. cells were 
physically prevented from growing due to compound particles blocking their ability to 
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do so.  In order to elucidate the potential reasons for the toxicity of the two most 
significantly toxic compounds, N5 and N15, a cell viability experiment was performed 
using a dose-range of the compounds on the bulk population of MCF-7 cells.  Cell 
viability was not significantly affected by N15 at 4 of 5 concentrations tested, with a 
significant decrease in viability only observed with both analogues at 100 µM (Figure 6.6 
A and B). 
 N10, N13 and N17 were selected as compounds of interest for future evaluation, 
due to their ability to reproduce the effects of OH14, with a modest improvement 
observed in some cases. 
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Figure 6.5: Several Series 1 Analogues Sensitise MCF-7 colonies to TRAIL in a similar 
manner to OH14. 
MCF-7 cells were plated at 50 cells per cm2 and treated with vehicle control, OH14 (14) or 
analogues at A) 100 µM or B) 10 µM alone or in combination with 20 ng/ml TRAIL and left to 
grow for 10 days before colonies were counted.  Results represent 1 to 3 individual experiments 
for A and at least 3 individual biological repeats for B. *=p-value<0.05 t-test between TRAIL and 
compound + TRAIL. 
 
 
A 
B 
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Figure 6.6: Analogues are less toxic to the bulk population of MCF-7 cells than colony 
forming cells 
MCF-7 cells were plated to achieve a confluence of 70% before treatment with a dose range of 
analogues A) N5 and B) N15.  After 24 h Cell Titre Blue was performed to evaluate cell viability.  
Results represent averages from 4 technical replicates. Error bars are presented as standard 
error of the mean.  *=p-value<0.05, t-test between vehicle control (DMSO) and compound. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A                                                                    B 
*                                                                             * 
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6.2.2.2 Pharmacy Synthesised Analogues GG1-12: Colony Forming Assay 
 The second series of Pharmacy compounds, GG1-12 had more variation in their 
ability to increase the sensitivity of MCF-7 colony forming cells to TRAIL.  The majority of 
the compounds, including GG1, 2, 5, 6, 7, 9 and 11, were not as active as OH14, showing 
no significant decrease in CFU number compared with TRAIL alone. Four of the 
compounds, GG2, 6, 8 and 10 appeared to increase the number colony forming cells 
when treated alone, whilst some, including GG3 and GG11, reduced colony forming 
cells.  
 Compounds GG4 and 12 demonstrated the most similar ability to increase MCF-
7 colony forming cell sensitivity to TRAIL, as OH14, improving on TRAIL alone by up to 
80%.  GG3, 8 and 10 showed a significant TRAIL-sensitisation, although this was more 
modest than the effect of OH14 (Figure 6.7), increasing sensitivity to TRAIL by 
approximately 70%.     
 Subsequently, GG4, GG8 and GG12 were selected as compounds of interest for 
future evaluation. 
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Figure 6.7: Several Series 2 Analogues Sensitise MCF-7 colonies to TRAIL in a similar 
manner to OH14. 
MCF-7 cells were plated at 50 cells per cm2, allowed to attach and treated with vehicle control, 
OH14 (14) or Pharmacy Synthesised analogues of OH14: compounds GG1-12 at 10 µM, before 
being left to form colonies which were counted after 10 days. All results are averages of three 
or more independent experiments.  *=p-value<0.05, t-test between TRAIL and compound + 
TRAIL. Error bars represent standard error of the mean. 
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6.3 Discussion 
 In chapter 4 we used several in vitro assays to screen our 19 commercially 
available compounds and identified OH14 as our initial lead compound.  The aim of this 
chapter was to select and design novel analogues of OH14 which may improve on the 
efficacy of OH14 and provide an initial structure-activity relationship.   
 Although molecular modelling is a very useful tool for distinguishing between 
active and non-active compounds, it cannot accurately predict activity at µM 
concentration of compounds with highly similar structures.  Consequently, we obtained 
8 commercially available analogues from Specs database, which showed 90% structural 
similarity with OH14, and 29 compounds were synthesised in-house, by Gilda Giancotti 
and Mahmoud El-Hiti, at Cardiff School of Pharmacy for in vitro evaluation.  Three 
primary structural modifications on the structure of OH14 were implemented when 
designing analogues.    
 Only compounds which dissolved in the common solvent, DMSO and were 
soluble in aqueous solution were potential lead analogues.  The majority of the 
analogues we analysed here fit these criteria.  Alterations to the structure of OH14 
appeared to impact on the solubility of the compounds, with many being partially 
insoluble in DMSO, or coming out of solution when further diluted in cell media.  
Solubility of a compound is an important feature when selecting potential drug 
candidates, thus, those candidates with impaired solubility will not be carried through 
for further testing.  The presence of a carboxylic acid group on a compound aids in 
solubility due to the ability to form hydrogen bonds, thus, this feature will be retained 
on analogues in the future.   
 We selected the colony-forming assay as our initial screen for the compounds as 
it provides a repeatable result which is representative of both viability and 
tumoursphere-forming ability (as observed in Chapter 4).  Here we have evaluated a 
total of 37 analogues of OH14.  The 8 commercially available analogues were assessed 
on MCF-7 and BT474 cells in both colony-forming and tumoursphere assays.  These 
compounds, 14.1-14.9, as predicted, showed similar efficacy data when analysed in the 
CFA and tumoursphere assays.  Compound 14.9 performed with the greatest efficacy of 
all SPECS analogues tested, showing consistent and significant ability to sensitise to 
Chapter 6: Biological Evaluation of OH14 Analogues 
 
 O A Hayward   213 
 
TRAIL across both MCF-7 and BT474 tumoursphere- and colony-forming cells, in a 
seemingly synergistic manner, to the same or better level as OH14.   
 The remaining 29 Pharmacy-synthesised analogues were assayed only in MCF-7 
cells, thus, their effects in BT474, as well as other cell lines, is yet to be evaluated.  We 
observed the analogues to have varied activities, with many compounds unable to 
improve on the effect of TRAIL alone and others some showing toxicity to colony 
forming cells when administered alone (Figures 6.6-6.8).  N5 and N15, observed to be 
the most toxic analogues to colony forming cells did not demonstrate significant toxicity 
on the bulk population of MCF-7 cells until the highest concentration of 100 µM was 
administered, thus suggesting this toxicity is restricted to progenitor-like colony-forming 
cells.   
  Ultimately, we identified six pharmacy synthesised analogues: GG4, GG8, GG12, 
N10, N13, N17 and one SPECS analogues, 14.9, which increased sensitivity of MCF-7 
colony forming cells to TRAIL, by at least 80%; a similar sensitisation to that achieved 
with OH14.  Comparison of the chemical structures of compound OH14 and the 
structures of these analogues suggest that perhaps removal of one or both of the 
chlorine atoms on the aromatic ring of OH14 plays a key role in increasing efficacy of 
the compound (Figure 6.8).  The absence of these chlorine groups 6 of the 7 lead 
analogues may have increased solubility in aqueous solution, thus, perhaps the 
increased efficacy of due to the fact that a higher concentration of drug in media is 
achieved and therefore more can enter the cells.  The ability of N13 and N17 to increase 
colony-forming sensitivity to TRAIL may, however, be an additive rather than synergistic 
effect since a decrease in colony forming ability was observed when these compounds 
were treated alone.  This decrease was not seen for the other lead analogues, and so it 
is likely that their efficacy was indeed due to a synergistic effect with TRAIL. 
 These analogues will be analysed in the future on additional relevant assays to 
ascertain a lead analogue.  Further structural modifications may be able to lower the 
working concentrations of the drugs, although, if their toxicity to untransformed cells 
remains non-significant, identifying a promising drug candidate with a relatively high 
working concentration is feasible. 
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Figure 6.8: Structures of Most Efficacious Pharmacy Synthesised Analogues 
Chemical structures of OH14 and most efficacious analogues of OH14: 14.9, GG4, GG8, GG12, 
N10, N13, N17. 
 
 In conclusion, we have identified and synthesised several chemical analogues of 
OH14, which were designed to retain the important features of the compound.  Using 
primarily the colony-forming assay, we have identified 7 potential lead analogues of 
OH14 which will be evaluated in additional assays in order to attempt to identify more 
efficacious lead compound. 
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Chapter 7: General Discussion 
 TRAIL is an endogenous death ligand which exhibits cancer cell-specific 
cytotoxicity (Gura, 1997; Lempke et al., 2014) (Section 1.2). There is a large body of 
evidence for TRAIL as a therapeutic in multiple cancer types due to its cancer-specific 
ability to induced apoptosis.  Research is growing into specific apoptosis inducing 
agents, with the strive to find more cancer cell-targeted treatment options.   
 Studies have demonstrated TRAIL to be most efficacious in mesenchymal-like 
breast cancer lines (Rahman et al., 2009), with many cell lines from other subtypes of 
the disease exhibiting TRAIL resistance.  We, and others, have demonstrated c-FLIP to 
have a key role in TRAIL resistance (Piggott et al., 2011; Safa and Pollok, 2011).  c-FLIP 
directly competes with procaspase-8/-10 for interaction with FADD upon TRAIL pathway 
stimulation (Dickens et al, 2012; Safa, 2012; Scaffidi et al., 1999) (Section 1.3).  It is this 
anti-apoptotic role that, if inhibited, could facilitate a route to TRAIL sensitisation. 
 Breast cancer stem-like cells, although contributing to only around 4% of a 
tumour, are thought to have a key role in resistance to treatment and disease relapse 
(Vinogradov and Wei, 2012).  We have recently been able to successfully eliminate 
tumoursphere-forming cells, which are an in vitro model of CSC-like cells (Dontu et al., 
2003), in a panel of breast cancer cell lines using the combination of c-FLIP suppression, 
using siRNA, and treatment with TRAIL (Piggott et al., 2011).  There is therefore much 
evidence to support the therapeutic potential for TRAIL sensitising agents, and, in 
particular, agents which prevent the anti-apoptotic role of c-FLIP, however, there are 
currently no c-FLIP specific inhibitors of which we are aware. 
7.1 Targeting c-FLIP with Small Molecule Inhibitors 
 Several studies have identified agents which decrease c-FLIP expression, and 
sensitise cells to TRAIL or other chemotherapeutics (Trivedi and Mishra, 2015).  These 
agents function by interfering with c-FLIP transcription, degradation or translation (Safa 
et al., 2008; Safa and Pollok, 2011).  Furthermore, many of these agents act via inducing 
DNA damage, and will usually affect other proteins, thus reducing their target-specificity 
(Safa, 2012).  The combination of TRAIL with a c-FLIP-specific small molecule inhibitor 
that retains a cancer-specific mechanism of action is therefore highly desirable.  The 
high homology between c-FLIP and procaspase-8 (Goltsev et al., 1997) means that a 
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small molecule targeted to c-FLIP could potentially also inhibit this pro-apoptotic 
protein, however, therefore any method of c-FLIP suppression must be highly specific. 
 We have used in silico modelling to model the structure of c-FLIP and associated 
proteins and develop interaction models.  We have confirmed that the structures of the 
DEDs of procaspase-8 and c-FLIP are indeed very similar and show a great amount of 
structural homology (Goltsev et al., 1997).  Our models demonstrated, however, that 
the potential interactive surface between DED1 of procaspase-8 or c-FLIP and the DED 
of FADD shows some variation in physical and electrostatic properties. We identified a 
site on DED1 of c-FLIP which provides a specific target for small molecule inhibitors to 
bind and interfere with the interaction with FADD and potentially also affect any 
interaction between c-FLIP and procaspase-8, whilst sparing the site of FADD interaction 
on procaspase-8 itself.  A recent publication by Dickens et al. have shown a similar in 
silico model for the structure of caspase-8, modelled using different software but a 
similar homology model, based on v-FLIP, MC159 (Dickens et al., 2012) which supports 
the accuracy of our model.  Additionally, after the completion of our in silico modelling 
and initial compound testing, two publications emerged which performed similar in 
silico analyses of c-FLIP and FADD (Hwang et al., 2014; Majkut et al., 2014).  In 
particular, Majkut et al. constructed a very similar model to ours of the c-FLIP 
DED1:FADD interaction, providing further support for our own model. 
 A structure-based virtual screen was performed on c-FLIP and procaspase-8 in 
parallel.  After a multi-step in silico selection process, 19 small molecules were selected 
for their potential ability to prevent the interaction between c-FLIP and FADD, whilst 
sparing the interaction between procaspase-8 and FADD.   
 
7.2 Biological Evaluation of c-FLIP Small Molecule Inhibitors 
 We performed biological evaluation of the 19 compounds primarily on the two 
previously described TRAIL-resistant breast cancer cell lines MCF-7 and BT474 which 
demonstrated several of our 19 c-FLIP inhibitors to have an ability to partially sensitise 
these cells to TRAIL induced apoptosis.  The ability of the compounds to sensitise to 
TRAIL, with little viability alterations when administered alone was similar to that 
observed previously on MCF-7 and BT474 cells using siRNA to remove c-FLIP followed by 
treatment with TRAIL (Piggott et al., 2011), thus in effect, our lead compounds were 
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able to phenocopy c-FLIP siRNA.  Treatment with one of our lead compounds, OH14, at 
a range of concentrations, in assays which are used to represent stem-like and 
progenitor cells respectively, demonstrated a dose-dependent ability of the compound 
to significantly sensitise both MCF-7 and BT474 tumoursphere- and colony-forming cells 
to TRAIL, whilst remaining non-toxic when administered alone.  In order to fully 
differentiate between additive and synergistic effects of the compounds, ideally, the 
IC50 of the drugs would need to be reached, using a combination of cell and interaction 
assays. 
 Our initial data demonstrated OH14 in a TN breast cancer and PR -ve cell line to 
only modestly increase sensitivity to TRAIL at one concentration.  Studies have 
demonstrated HER2 status to be associated with TRAIL resistance, in that HER2 +ve 
cancers are more TRAIL resistant (Zang et al., 2014), thus, perhaps HER2 receptor status 
impacts on sensitivity to the combination therapy, with HER2 cells expressing a different 
variant of c-FLIP.   Both SKBR3 and MDA-MB-231 cells, unlike BT474 and MCF-7 cells, are 
PR -ve cell lines, thus, it may be that lack of expression of this hormone receptor 
impacts on the ability of these cells to be sensitised to TRAIL by our inhibitors, although 
this hypothesis has not yet been explored.   
 An additional explanation for the differences in sensitivity to OH14 is that both 
the MDA-MB-231 and SKBR3 cell lines may express a modified variant of c-FLIP.  Even a 
one amino acid alteration in the sequence of c-FLIP around the pocket of DED1, which 
we have selected OH14 to target, could lead to the compounds being ineffective.  
Protein sequence variation is common in cell lines, as demonstrated by around 15 
million, of reported single nucleotide polymorphisms (SNPs) present in the human 
genome.  These have been identified in a large-scale project 'The 1000 Genomes 
Project' which characterised human genome sequence variation and correlate results 
with genotype and phenotype information (1000 Genomes Project Consortium, 2010).  
In order to explore the idea that the c-FLIP sequence variation plays a role in the lack of 
OH14 sensitivity to some cell lines, sequencing of the c-FLIP gene is required in order to 
determine its primary structure in these cell lines. In addition, further evaluation into 
the effects of OH14 or lead analogues in other breast cancer cell lines, including triple 
negative, PR -ve and HER-2 positive cell lines is required.  
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 Our results thus far suggested that our lead compound was most efficacious in 
the micromolar rage, with the concentrations at which our lead compound was most 
efficacious in multiple assays from 10 to 100 µM, deeming OH14 to have a low potency.  
Although this is a relatively high concentration, many non-specific c-FLIP-inhibiting 
agents, for example the Akt Inhibitor API-1 (Li et al., 2012); the HDAC agent MS-275 
(entinostat) (Rao-Bindal et al., 2013);  also act at micromolar levels.  Furthermore, pan-
caspase inhibitors, such as Z-VAD-FMK (Promega) are reccomended for use at 
micromolar concentratons, up to 100 µM (Promega, Datasheet).  Testing of analogues 
of OH14 has begun and has provided us with an initial structure activity relationship for 
the compound, with the identifications of several compounds which exhibited different 
activity to OH14, with some showing improved efficacy.  It is hoped that we will identify 
an analogue of OH14 with improved efficacy and a lower working concentration, thus a 
larger therapeutic range. 
7.3 Mechanism of Action: c-FLIP:FADD Interactions 
 The pharmacological disruption of PPIs is an increasingly important tool in 
modern medicine.  Compounds targeted to protein-protein interactions, involving 
crucial processes in both disease and normal states, such as apoptosis, must have their 
mechanism of action validated to demonstrate that it exerts its desired effect through 
the inhibition of the target protein interaction (Roszkik et al., 2013).  Several studies 
have reported on the presence of interactions between the DEDs of FADD and c-FLIP, 
FADD and procaspase-8, and c-FLIP and procaspase-8 (Day et al., 2008; Dickens et al., 
2012; Safa and Pollok, 2011).  One of the key reasons for TRAIL resistance is the 
competition between c-FLIP and procaspase-8 for interacting and binding with the DED 
present on FADD (Safa, 2012), thus, demonstrating that our inhibitors prevent this 
interaction is of great importance.  
 In Chapter 5, we utilised co-IP and Western blot in a TRAIL-resistant line to 
demonstrate an interaction between caspase-8 and FADD, however, further 
optimisation is required for compound analysis using co-IP.  We have, however 
optimised FRET acceptor-photobleaching to evaluate the ability OH14 to interfere with 
the interaction between c-FLIP and FADD in TRAIL-resistant HeLa and MCF-7 cells.  FRET 
provides a technique for studying protein:protein interactions which does not rely on 
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antibodies, which are often are not highly sensitive and can exhibit poor target 
selectivity.  FRET has previously been utilised, in different formats, including flow 
cytometry FRET, to demonstrate FADD:caspase-8 and -10 interactions (Wang et al., 
2001; Muppidi et al., 2006), TRAIL-receptor interactions (Neumann et al., 2014) and 
FADD self-association (Muppidi et al., 2006), however, FRET has not yet been performed 
to evidence c-FLIP:FADD interactions.  Using FRET, we were able to show that our lead 
inhibitor, OH14, can prevent the interaction between c-FLIP and FADD in HeLa cells 
stimulated with TRAIL, and, although less profound, a similar effect was observed in 
MCF-7 cells.  Furthermore, using several assays to evaluate caspase activity, we have 
demonstrated that our lead compound OH14 indeed facilitates TRAIL-induced apoptosis 
through the caspase-mediated pathway, and, as such, in combination with our FRET 
studies, have demonstrated the highly specific likely mechanism of action of OH14.   
 
7.4 Residues Involved in c-FLIPs Anti-Apoptotic Role 
 Primers for site directed mutagenesis have been designed and plasmids have 
been generated to target residues I6, H7, R38 and R45 on DED1 of c-FLIP, although 
successful biological evaluation of these has not yet taken place.    
 At the time of the study, there were no mutational studies published on the 
DEDs of c-FLIP.  Much more recently, however, two studies have emerged which look 
into mutations on the relevant domains of c-FLIP and both utilise in silico modelling.  
One study utilised in silico modelling and carried out mutations on DED2 of c-FLIP.  This 
study, performed by Hwang et al., evaluated mutations of E80A, L84A, K169A and 
Y171A, all present within DED2, and, using co-IP, showed a disturbed interaction with 
FADD, in addition to lowering the overall stability of the DEDs of c-FLIP (Hwang et al., 
2014). 
 Majkut and team evaluated mutations in both DED1 and DED2 of c-FLIP, and, in 
particular the residue, H7 in DED1: one of the residues which we had selected based on 
in silico modelling.  They observed that an H7G FLIP mutant had a modest reduction in 
the ability to block apoptosis and bind to procaspase-8 when compared to wildtype 
FLIP, whilst F114A in DED2 impacted more significantly on FADD procaspase-8 binding 
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although this was not the expected outcome, since based on their own in silico model, 
they expected H7 to be of greater importance (Majkut et al., 2014).  
 Interestingly, an equivalent amino acid residue on procaspase-8, Y8, was shown 
to be important for the interaction with FADD and activation of downstream 
executioner caspases upon TRAIL stimulation, whilst mutation of F122A in DED2 did not 
have any effect.  A double mutant, F122A/Y8G however, reduced the ability of 
procaspase-8 and FADD to interact even more than Y8G alone, suggesting again, that 
both DED domains are important for these interactions, although processing of 
procaspase-8 may be impacted (Majkut et al., 2014).  Furthermore, they assessed 
mutations on FADD at F25A and H7G, demonstrating the H7G mutant to have more 
important role in FADD:c-FLIP interactions.  The group demonstrated, however, that, 
unlike murine c-FLIP R (Ueffing et al., 2008) both DED1 and DED2 are required for the 
anti-apoptotic activity of c-FLIP S (Majkut et al., 2014).  These results provide 
interesting, although non-conclusive information about some of the DED residues of 
importance in c-FLIP, FADD and procaspase-8 interactions.   
 In the future, we aim to use our mutagenesis plasmids to demonstrate residues 
on c-FLIP which are important for its ability to interact with FADD.  Confirming the 
importance of these residues will be used by using mutant c-FLIP overexpression versus 
wildtype c-FLIP overexpression in c-FLIP knock-out cell lines, such as those generated 
using TALEN.  Unfortunately, we were unable to successfully generate a c-FLIP null cell 
line using TALEN technology (Chapter 5) and our siRNA cells do not have enough of a 
long term and stable reduction of c-FLIP to perform these studies.  We hope to generate 
an shRNA c-FLIP cell line, or continue to work on generating a TALEN c-FLIP cell line in 
order to perform our own mutational studies.  In addition, we may utilise our c-FLIP:YFP 
FRET constructs as our cloning template in order to generate mutant c-FLIP FRET 
constructs which will be analysed using FRET.   
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7.5 Future Directions 
 There are many additional avenues of evaluation into the potential effects and 
efficacy of our inhibitors, and indeed, targeting c-FLIP as a therapeutic strategy that we 
wish to explore in the future. 
 Synthesis and testing of new analogues is ongoing in order to improve efficacy 
and divulge structure-activity-relationship information about the compounds.  Further 
testing of these analogues, in particular, the analogues which have demonstrated the 
greatest effects so far: GG4, GG8, GG12, N10, N13, N17 and 14.9, in additional relevant 
assays, primarily the tumoursphere assay and assays to demonstrate mechanism of 
action, will be performed in the future in order to attempt to establish a novel and more 
efficacious lead compound.  Our optimised FRET acceptor-photobleaching will be 
utilised for this, alongside additional interaction assays, such as the proximity ligation 
assay, which is a highly selective and sensitive method for detecting protein interactions 
(Leuchowius et al., 2010).   
 All work carried out in this study was performed on immortalised cell lines, as 
opposed to primary tumours.  In order to increase the clinical relevance of our findings, 
it would be of interest in future to analyse our compounds in, for example, clinical 
human breast tumour biopsy samples.  Preliminary data from our lab, analysing OH14 
plus TRAIL in such samples has shown promise for the combination therapy in this 
material (Andreia Silva, personal communications).  In addition, evaluation of our c-FLIP 
inhibitors in other cancer types would certainly be of interest.  High expression levels of 
c-FLIP occurs in many cancers, including: liver, bladder, ovarian, colon, colorectal, 
prostate and breast cancers (Safa et al., 2008) and, as such, c-FLIP has been associated 
with TRAIL resistance, and indeed to play a role in chemotherapy resistance, in many of 
these cancer types (Okano et al., 2003; Kim et al., 2002; Safa, 2012; Lee et al., 2013; 
Lempke et al., 2014, Zang et al., 2014).  It would be of great interest, therefore, to test 
OH14 and lead analogues of OH14 in alternative cancer types which show potential to 
be sensitised to TRAIL in a similar way as our breast cancer cell lines.  Through use of 
HeLa cells in our FRET studies, we have demonstrated that our inhibitors do indeed 
inhibit the c-FLIP:FADD interaction in this cervical cancer line, which supports the 
hypothesis that our inhibitors may work in other cancer types. 
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 Work in this study focussed on a dual combination of our c-FLIP inhibitors and 
TRAIL, the ultimate therapy would likely include a chemotherapeutic regime.  A triple 
therapeutic action, such as this, could allow for the targeting of both cancer stem cells, 
and the bulk tumour cells, enabling a complete coverage of the cancerous cells present 
within a tumour, and the surrounding environment.  Preliminary studies from our lab 
have shown promise for such a triple-combination therapy with OH14, TRAIL and 
chemotherapy in vitro (Timothy Robinson, Personal communications).  In addition, c-
FLIP has been demonstrated to impact on chemotherapy resistance (Safa, 2012), thus, 
future work will be carried out to establish an optimum drug combination, dose and 
treatment schedule with OH14 or a lead analogue. 
 The existence of cancer stem-like cells, in combination with CSC plasticity, the 
ability of a cancer cell to de-differentiate and become a CSC, are recently proposed 
theories often used to explain cancer relapse (Section 1.1.7) (Wicha et al., 2006; 
Flemming, 2015).  A cancer therapeutic which could eliminate CSCs and prevent 
plasticity, in combination with a treatment which can eliminate bulk cells, is highly 
clinically desirable.  Although OH14 was designed to inhibit the interaction between c-
FLIP and FADD, it may be that blocking this site on c-FLIP alters other functions of c-FLIP.  
Preliminary data using OH14 on our in vitro model of plasticity is promising.  However, 
much further investigation is required in order to elucidate whether, and how, OH14 
prevents plasticity in our model. 
 One of the primary criterion of our in vitro compound assessment was the ability 
of the compound to dissolve in the common lab reagent DMSO, in order to achieve a 
millimolar stock solution.  DMSO is a widely used solvent for dissolving hydrophobic 
drug molecules, since it is amphipathic in nature and is used in both in vitro and in vivo 
studies.  In general, DMSO is only used at low concentrations, since at higher 
concentrations undesirable side effects have been observed (Galvao et al., 2014).  
Although only low concentrations of DMSO were utilised here, at latter stages of drug 
development, we may attempt to modify the chemical structure in order to increase the 
water solubility of the drug and, thus, eliminate the reliance on DMSO for preparing 
initial stock drug solutions.  This would benefit both in vitro and in vivo studies as it 
would likely allow a higher concentration of drug to be administered, which would have 
been previously restricted due to the potential toxicity of the vehicle. 
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 Ultimately, in order to progress this potential combination therapy further, in 
vivo studies would be required to provide toxicity, pharmacodynamics and side effect 
profiles for OH14 or its analogues, in addition to evaluating the in vivo efficacy of 
combination therapy overall. 
Table 7.1: Summary of all compounds tested.  
Compound obtained from: OM = original modelling SPECS (Chapter 3), SPECS analogue 
of 14 = S14, Pharmacy analogue Mahmoud = PM, Pharmacy analogue Gilda = PG. 
Efficacy: - = lack of solubility, observed toxicity or no observed efficacy, + = some 
efficacy but potential toxicity, ++ = efficacy but below OH14, +++ = efficacy equal or 
great than OH14. 
 
Compound Obtained Efficacy 
OH1 OM + 
OH2 OM - 
OH3 OM + 
OH4 OM - 
OH5 OM - 
OH6 OM + 
OH7 OM - 
OH8 OM - 
OH9 OM - 
OH10 OM - 
OH11 OM - 
OH12 OM - 
OH13 OM - 
OH14 OM +++ 
OH15 OM - 
OH16 OM ++ 
OH17 OM - 
OH18 OM - 
OH19 OM ++ 
14.1 S14 - 
14.3 S14 + 
14.4 S14 + 
14.5 S14 - 
14.6 S14 + 
14.7 S14 + 
14.8 S14 + 
14.9 S14 +++ 
N1 PM + 
N2 PM + 
N3 PM + 
N4 PM + 
N5 PM + 
N6 PM - 
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N7 PM - 
N8 PM + 
N9 PM + 
N10 PM +++ 
N11 PM + 
N12 PM + 
N13 PM +++ 
N14 PM + 
N15 PM - 
N16 PM + 
N17 PM +++ 
GG1 PG - 
GG2 PG - 
GG3 PG + 
GG4 PG +++ 
GG5 PG - 
GG6 PG - 
GG7 PG - 
GG8 PG ++ 
GG9 PG - 
GG10 PG + 
GG11 PG + 
GG12 PG +++ 
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Appendices 
 
A6.1 OH14 Synthesis 
 Amounts equal to 2-anthranilic acid (5.78 mmol), 2,4-dichloro-5-methyl-phenyl 
sulfonyl chloride (5.78mmol) and NaOH were mixed into 50 ml of water and stirred at 
room temperature overnight. The product was filtered, washed with water, dried and 
recrystallized from EtOH.   
A6.2: Analogue Synthesis 
 P-toluenesulfonyl chloride (7.95 mmol), under an atmosphere of nitrogen, was 
added to the stirred solution of methyl anthranilate (6.62 mmol) in anhydrous pyridine 
(20 ml). The reaction mixture was stirred at room temperature for 6 hours and was then 
quenched by the addition of water. The aqueous layer was extracted using 
ethylacetate (3 x 50 ml additions) and dried over anhydrous sodium sulphate. The 
solvent was removed under vacuum, and the crude product was then chromatographed 
over silica gel (eluen: hexane/ethylacetate 9/1), to produce a compound yield of 85%. 
This method followed a previously described method of synthesis for similar chemical 
structural compounds (Mishra and Panda, 2007). 
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Table A6.1: SPECS analogues of Compound OH14 (14 and 14.2 are the same compound). 
H d = hydrogen donors, H a = hydrogen acceptors 
Cpd. MW 
(g/mol) 
Formula H d H a  
OH14 360.22 C14H11Cl2NO4S 2 5 
 
14.1 360.22 C14H11Cl2NO4S 2 5 
 
14.2 360.22 C14H11Cl2NO4S 2 5 Same structure as 14 
14.3 339.8 C15H14ClNO4S 2 5 
 
14.4 360.22 C14H11Cl2NO4S 2 5 
 
14.5 332.21 C13H11Cl2NO3S 2 4  
14.6 325.77 C14H12ClNO4S 2 5  
14.7 360.22 C14H11Cl2NO4S 2 5 
 
14.8 380.64 C13H8Cl3NO4S 2 5 
 
14.9 305.35 C15H15NO4S 2 5 
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Table A6.2: Pharmacy Synthesised Compounds – GG1-12 
Compound MW 
(g/mol) 
Structure 
 
 
GG1 
374.239 
 
 
GG2 
374.239 
 
 
GG3 
374.239 
 
 
 
 
GG4 
359.3 
 
 
 
GG5 
319.37 
 
 
 
GG6 
360.21 
 
 
 
GG7 
360.21 
 
 
 
GG8 
319.37 
 
 
 
GG9 
319.37 
 
 
 
GG10 
360.2 
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GG11 
347.4 
 
 
 
GG12 
339.8 
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Table A6.3: Pharmacy Synthesised Analogues N1-17 
Analogues were generated of OH14 in order to improve the efficacy of the compound and 
provide further information as to the most important structural features of the inhibitors. 
 
Compound MW (g/mol) Formula Structure 
N1 407.79 C16H13ClF3NO4S 
 
N2 442.24 C16H12Cl2NO4S 
 
N3 393.77 C15H11ClfNO4S 
 
N4 428.2 C15H14ClNO4S 
 
N5 431.2 C15H14INO4S 
 
 
N6 339.79 C15H14ClNO4S 
 
 
N7 393.77 C15H11ClF3NO4S 
 
 
N8 338.79  C15H14ClNO4S 
 
N9 339.75 C15H14ClNO4S 
 
N10 339.8 C15H14ClNO4S 
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N11 339.8 C15H14ClNO4S 
 
 
N12 369.8 C16H16ClNO5S 
 
 
N13 383.85 C17H13ClNO5S 
 
 
N14 353.82 C16H16ClNO4S 
 
 
N15 353.82 C16H16ClNO4S 
 
 
N16 339.8 C15H14ClNO4S 
 
 
N17 431.25 C15H14INO4S 
 
 
 
 
 
 
 
 
 
 
 
 
 
